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Abstract 
The widespread use of the organophosphorous insecticide chlorpyrifos (CPF) 
over recent decades has posed major concerns about its toxicity in humans. 
Sub-cytotoxic concentrations of CPF and its metabolite CPF-oxon (CPO) were 
known to inhibit neurite outgrowth in differentiating neural cells but little was 
known about their ability to cause neurite retraction. The main aims of this 
study were to investigate the effects of CPF and CPO on the stability of 
neurites in pre-differentiated mouse N2a neuroblastoma and human ReNcell 
CX neural stem cells, and to relate toxicity to the regulation of cytoskeletal 
proteins involved in neural differentiation.  
 
At 3 µM, both compounds reduced the numbers of axon-like processes in pre-
differentiated N2a cells, as indicated by morphometric analysis of 
carboxyfluorescein succinimidyl ester-labelled cells. Retraction of neurites was 
observed within 2 h of exposure by live cell imaging. Neurofilament disruption 
was detected in treated cells, by indirect immunofluorescence with anti-
phosphorylated neurofilament heavy chain (pNFH) monoclonal antibody 
SMI34, while the microtubule network was unaffected. Western blotting 
analysis revealed transiently increased levels of reactivity of Ta51 after 2 h 
exposure but reduced levels of reactivity following 8 h treatment with both 
compounds, whereas reactivity of anti-total NFH or anti-tubulin were 
unaffected. Altered NFH phosphorylation at 2 h exposure was associated with 
increased activation of extracellular signal-regulated protein kinase ERK 1/2. 
Increased levels of phosphatase activity were observed following 8 h treatment, 
suggesting that organophosphate-induced neurite retraction in N2a cells is 
associated with early transient increases in NFH phosphorylation and ERK1/2 
activation.    
 
High content analysis of immunofluorescently stained N2a cells showed that 
the induction of neurite retraction by both compounds was concentration-
dependent. The same concentrations of CPF and CPO also caused retraction of 
neurites in differentiating neuronal and glial populations of human ReNcells. 
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Using a cell ELISA technique changes observed in Western blot analysis were 
confirmed and found to be concentration-dependent in N2a cells. In pre-
differentiated ReNcells, reduced levels of NFH phosphorylation were 
observed, whereas total NFH, βIII-tubulin and ERK1/2 activation were 
unaffected.  Acetylcholinesterase assays suggested that inhibition was not 
required for neurite retraction but could affect the severity of such effects. 
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1 Introduction 
1.1 Basic aspects of the nervous system 
The mammalian central nervous system is composed of two common cell 
types, neuronal and glial cells. Neurons are one of the essential cells in the 
nervous system, being responsible for the perception of stimuli, responding to 
those stimuli and transmitting the cellular signals to other neighbouring 
neurons or effector cells through synaptic transmission. Neurons are known to 
be highly polarised cells in that produce axons and dendrites upon 
differentiation. The morphological features of axons play an important role in 
neurotransmission and axonal transport (Barres and Barde, 2000). Glial cells 
are the second common type of cells found in nervous system. Although glial 
cells are not involved in nervous signal transmission, nor they do not generate 
axons, these cells provide fundamental homeostatic, nutritional, structural, and 
defensive support to the neurons (Barone et al., 2000). Glial cells in the central 
nervous system are composed of a heterogeneous array of cell types of 
different origin. These include, microglia, which are derived from the immune 
system. Microglia act as specialised brain macrophages that clean up cellular 
debris and dead neurons after apoptosis (Compston et al., 1997). The other 
glial cells are known as astrocytes and oligodendrocytes, which are mainly 
developed after neurogenesis. Both cells types can be found in differentiating 
neural stem cell cultures (Compston et al., 1997, Rice and Barone, 2000).  
In the adult brain, the ultimate function of astrocytes is to maintain the ionic 
and trophic balance of the neurons and extracellular environment. Astrocytes 
also provide guidance for axons and assembly of synapses during brain 
development, and play crucial roles in neuronal proliferation, migration and 
differentiation (Aschner et al., 1999). Additionally, astrocytes help to regulate 
the formation of the blood-brain barrier and respond to neural injury by 
secreting neurotrophic factors such as glial-derived neurotrophic factor 
(GDNF), which have a protective role against neuronal damage (Barres and 
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Barde, 2000). Oligodendrocytes synthesise the myelin sheath, an insulating 
membrane around axons that provides axonal support and allows electrical 
signals to be transmitted along axons more efficiently (Compston et al., 1997). 
As a consequence, any toxicity in these cells could lead to complications in the 
development of insulated neurons in mammals (Sachana et al., 2008).  
The peripheral nervous system is also composed of two major types of glial 
cells, Schwann cells and enteric glia. Schwann cells consist of two types, 
myelinating and non-myelinating cells. The non-myelinating cells providing 
mechanical and metabolic support for neurons, while the myelinating cells, 
which have similar structure and function to those of oligodendrocytes, 
providing an insulating sheath around the axons. Enteric glia are found in the 
autonomic ganglia of the gut and have an essential role in synaptic 
transmission (Jessen, 2004). 
Development of the nervous system involves a series of sensitive and complex 
events extending from early embryonic life till adolescence. These processes 
include neuronal cell proliferation, migration, differentiation, synapse 
formation, glial cell development, and apoptosis, which are all tightly regulated 
within a specific time frame. Each developmental process has to be complete in 
a correct order. This complex structure and function of the developing brain 
increases its vulnerability and sensitivity to toxic injury by environmental 
pollutants such as organophosphorous (OPs) insecticides and others toxic insult 
(Grandjean and Landrigan, 2014). Exposure to OP toxicity can cause 
disruption in the central nervous system which may result in behavioural 
changes and neuropsychiatric disorders include learning difficulties, disrupted 
memory, confusion and fatigue (Lotti and Moretto, 2005). OP neurotoxicity 
can also have adverse effects on the peripheral nervous system such as 
weakness in the lower limbs and subsequent paralysis (Elersek and Filipic, 
2011).  
 
 
Introduction                                                                                        Chapter 1                                                   
3 
 
1.2 Organophosphorous insecticides 
Pesticides are mixtures of chemicals that are used globally, predominantly in 
agriculture to protect crops from insect damage. The consumption of pesticides 
worldwide is estimated at more than five billion kilograms (kg) annually, 
amongst which organophosphorus insecticides are the most widely used 
(Gupta, 2006, FAO, 2013). Some of these commonly used OPs include 
parathion, malathion, methyl parathion, chlorpyrifos, diazinon, dichlorvos, and 
phosmet. OPs are used in many medical, residential and industrial settings (e.g. 
lubricants, solvents and fire retardants) but their main uses are as agricultural 
insecticides (Hargreaves, 2012). Each year, four billion kg of OP insecticides, 
such as chlorpyrifos, are applied in agricultural fields in different parts of the 
world, but only small amounts of these target pests, while the remainder 
pollutes the environment (Gavrilescu et al., 2015).  
 
In Europe, several products, including baby food and processed food are 
contaminated with more than 250 different OP chemicals. In addition, 
approximately 50% fruits of European origin, as well as vegetables and cereals 
have been reported to contain residues of OP agents (EC, 2005). Another study 
from the USA has also reported that around 11 million kg of OP compounds 
(primarily chlorpyrifos, diazinon and malathion) were used in the production of 
agricultural crops in 1995 alone. Residential and commercial properties also 
consumed a large quantity of insecticidal OP compounds (6 to 9 million kg) in 
the same year (Aspelin, 1997).  
 
This widespread use of OP compounds and the underlying adverse effects are 
pose potential risks to public health. Exposure to these insecticides not only 
affects agricultural workers who deal closely with OPs, but also the general 
population. Several epidemiological studies have shown that the majority of 
consumers are repeatedly exposed to low concentrations of OP compounds 
throughout the environment and food sources, which over long-term may cause 
chronic damage to the nervous system (Mearns et al., 1994, Stephens et al., 
1995). The increased rate of acute pesticide poisoning in humans due to high 
exposure to OPs is another major public health concern. Globally, around three 
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million people endure unintentional acute pesticide poisoning and 346,000 
deaths per year are reported (WHO, 2008). The World Health Organisation 
(WHO) also reported that two million cases of intentional (suicidal) pesticide 
poisoning occurred each year and around 370,000 people each year die from 
this worldwide (Gunnell et al., 2007). According to a surveillance finding from 
the US Sentinel Event Notification System for Occupational Risks (SENSOR) 
pesticides program, OP insecticides were responsible for nearly 50% of acute 
pesticide related illnesses (Calvert et al., 2004). In the UK and other western 
countries, the incidence of acute pesticide poisoning related deaths is relatively 
low (Jamal, 1995). However, the rate in developing countries is estimated to be 
significantly higher, more than 300,000 deaths/year. This is mainly due to the 
wider use of OP pesticides, lack of strict regulations, and poor knowledge of 
safety procedures by people at risk in developing countries (Carlton et al., 
2004, WHO, 2008).  
 
The widespread use of OP compounds together with the emerging concerns 
over their potential impacts on public health has lead to the imposition of 
restrictions or bans on their uses by the regulatory authorities of some 
developed countries. For example, in 2000 the Environmental Protection 
Agency (EPA) in the USA had completely banned the domestic use of 
chlorpyrifos (CPF), which is one of the highly toxic OPs and the main focus of 
this thesis (EPA, 2000). Two years later, the United Kingdom Advisory 
Committee on Pesticides (ACP) raised concerns regarding the potential toxicity 
of CPF and its impact on food safety and public health (ACP, 2002). As a 
result of these concerns, all household uses of CPF have been stopped and the 
use of this pesticide restricted to agricultural application only in certain 
countries (Colborn, 2006). Despite these restrictions, CPF remains a popular 
pesticide and is still in use in many developing countries (Salyha, 2010).
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1.3 Chlorpyrifos 
CPF is one of the most extensively used OP pesticides worldwide. It was first 
synthesised and manufactured commercially by the Dow Elanco Company in 
1965. CPF has a potent biocide activity to control insects in agricultural fields, 
gardens and homes (Cox, 1994). Since then it has been widely distributed into 
the world market under several brand names, including Empire, Eradex, Scout, 
Brodan, Dursban, Lorsban, Reldan and others (Salyha, 2010). Around 850 
commercial CPF products were registered for use in the USA in 1997 according 
to the EPA (EPA, 1999). The use of CPF is still authorised in more than 50 
countries worldwide, such as Australia, France, Japan, US, Canada, UK, Spain, 
Italy, New Zealand and other developed countries (Salyha, 2010).  
 
CPF is used in a wide variety of applications. For example, in the home, CPF is 
used to control insect pests such as mosquitos, cockroaches, flies, fleas and lice. 
CPF products are also applied directly to sheep and turkeys, animal sites, farm 
buildings, storage bins, and on lawns and golf courses. In agricultural settings, 
CPF is used over several major crops in the world for protection. Some of these 
crops include vegetables, fruits, corn, tree nuts, soybeans, citrus fruit and wheat 
(Eaton et al., 2008, Salyha, 2010). According to the National Centre for Food 
and Agriculture Policy in the USA (2000), around 1.4 million kg of CPF were 
applied every year in the home and garden market (NCFAP, 2000). In 2011, the 
annual usage of CPF was estimated at approximately 20 million kg in China 
alone (Agronews, 2013).  
 
 
1.3.1 Chemical structure and physical properties 
Chlorpyrifos (O,O-diethyl O-3,5,6-trichloropyridin-2-yl phosphorothioate, O,O-
diethyl O-3,5,6-trichloro-2-pyridyl phosphorothionate, chlorpyrifos-ethyl) is a 
colourless to white crystalline solid with a strong mercaptan-like odour (Figure 
1.1). CPF is used as the active ingredient in many chemical formulations, which 
are available in a variety of forms, such as granules, capsules, powder, 
suspensions, emulsifiable concentrates and gel-based products (Wauchope et al., 
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1992). CPF has a lipophilic nature, which is poorly soluble in water but it can 
dissolve in most organic solvents. Thus, prior to its application into animals or 
on crops, CPF is usually mixed with solvents such as benzene, acetone, diethyl 
ether, xylene, carbon disulphide and methanol (Wauchope et al., 1992, Eaton et 
al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.2 Chlorpyrifos routes of exposure  
CPF can be rapidly absorbed through skin, oral mucosa, and airways, upon 
dermal contact, ingestion, or inhalation (Munoz-Quezada et al., 2012). Humans 
and animals are exposed to CPF through breathing polluted air, inhaling dust, 
contact during preparation or application of OPs in the workplace, and eating and 
drinking of contaminated food and water (WHO, 2001).  
 
A major route of CPF dispersion is the indoor application of pesticides and other 
types of insect treatment. In the US, poison control centres received more than 
22,000 cases of CPF exposure between 1985 and 1992 (EPA, 1994). 
Additionally, surveys of hundreds of US homes have indicated the significant 
presence of CPF residues in dust samples collected from different US states 
including Florida, Indiana and Seattle. Recently, several reports have highlighted 
the detection of CPF in indoor air, floor dust and carpets (Roinestad et al., 1993).  
 
Occupational exposure is another source of CPF poisoning. CPF exposure is 
quite common among agricultural workers and their family members, sheep 
Figure 1.1. Chemical structure of chloryrifos. 
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dippers, farmers and pesticide sprayers. However, people and children living in 
homes on or near a farm that applies OP insecticides are still at risk of exposure 
to these compounds (Gupta, 2006, Munoz-Quezada et al., 2012). Treatment of 
workplaces with insecticides for termites or other insect could expose the 
employees to lethal doses of CPF. Between 1985 and 1992, more than 1300 
cases of workplace exposure to CPF were reported to the US poison control 
centre (EPA, 1994). A recent prospective cohort study was carried out to 
evaluate the level of occupational exposure on workers involved in CPF 
manufacture. The outcome of this study showed a significant increase in the 
level of CPF metabolites in urine samples (Albers et al., 2004). These figures 
raise a major concern about the implanted guidelines regarding occupational 
exposure to CPF.  
 
Another prime route of exposure to CPF is the consumption of contaminated 
water and air. Groundwater contamination with CPF residues was reported in 
nine US states (EPA, 1992). Similarly, surface water contamination with CPF 
was measured in South Africa and Spain (Thoma and Nicholson, 1989). 
Moreover, air contamination with CPF at the application sites was noted. For 
example, assessment of air samples taken from approximately 1 meter above 
cornfield showed that one-half of the applied CPF was vaporised and 
contaminated the air for more than 25 days (Whang et al., 1992). In addition, 
CPF can be carried out and transferred into the atmosphere from the application 
site. Zabik and Seiber (1993) detected CPF contamination in air samples 
collected about 24 kilometres from the application site (Zabik and Seiber, 1993). 
 
After CPF is applied in the environment, it is rapidly absorbed via all routes of 
exposure (oral, inhalation, dermal). As CPF is a lipophilic compound, it readily 
crosses biological membranes including the placenta and the blood brain barrier. 
It enters the bloodstream and distributes into tissues at concentrations that are 
able to induce neural damage by inhibiting acetylcholinesterase (AChE), one of 
the key enzymes in the nervous system (Timchalk et al., 2002). In humans, OP 
half-lives are relatively short (minute to hours) as they undergo rapid hepatic 
metabolism (mainly through conjugation and esterase-mediated hydrolysis) and 
excretion through urine, faeces, and breath (Casarett et al., 2001). 
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1.3.3 Chlorpyrifos biotransformation 
After CPF enters the body, it is metabolically converted into its oxygen form 
chlorpyrifos oxon (CPO), in which the sulphur group is replaced by oxygen. This 
biotransformation reaction is carried out primarily by the cytochrome P450 
(CYP)-dependent monooxygenase system, which mainly exists in the liver 
(Costa, 2006). CPF can also be converted into CPO directly by brain microsomal 
CYP450, although at a 100-fold lower rate  (Chambers and Chambers, 1989). 
CPO, in turn, is well absorbed, and exerts toxic effects in animals and humans, 
as it is a much more potent AChE inhibitor than the parent compound (Lotti, 
2001). In the liver, CPO undergoes further hydrolysis to form less toxic products, 
such as diethylphosphate (DEP) and 3,5,6-trichloro-2-pyridinol (TCP) by A-
esterases such as paraoxonase PON1 (Costa, 2006). In addition to CPO 
bioactivation, CPF is oxidized via CYP450 to diethylthiophosphate (DETP) and 
TCP (Figure 1.2). These metabolites are then detoxified and filtered through the 
kidneys and excreted in the urine (Eaton et al., 2008). 
 
The biotransformation of CPF is mainly mediated by CYP450, which is present 
in humans in several isoforms. It has been shown that CYP2B6 and CYP3A4 are 
the most effective enzymes in the formation of CPO, while CYP2C19 is the most 
important isoform for TCP production (Croom et al., 2010). The polymorphic 
nature of CYPs in humans results in variation in CYP isoform expression which 
in turn explains the variation in individuals’ susceptibility to OP poisoning 
(Buratti et al., 2007). In addition to the CYP enzymes, the detoxification of CPO 
to TCP and DEP metabolites also involves plasma A-esterases such as 
paraoxonase 1 (PON1). Several in vivo studies have shown that low levels of this 
enzyme can increase the susceptibility of humans and animals to OP 
neurotoxicity (Costa et al., 2013).  
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1.3.4 Chlorpyrifos toxicity mechanism 
The principle mechanism of CPF toxicity involves its ability to interact with and 
inhibit the AChE enzyme, which is the key enzyme in the nervous system that 
terminates neurotransmission at central and peripheral cholinergic synapses 
(Campbell et al., 1997, Steevens and Benson, 1999). The persistent inhibition of 
AChE activity causes decreased degradation of neurotransmitter acetylcholine 
(ACh) into choline and acetate, and subsequent accumulation of ACh in the 
synaptic cleft. ACh binds to two types of postsynaptic receptors; the muscarinic 
and nicotinic receptors. Muscarinic receptors consist of five subtypes (M1-M5) 
G-protein coupled receptors, while nicotinic receptors are ligand-gated ion 
channels in structure (Tata et al., 2014). Details of each subtypes and location are 
summarised in table 1.1. Binding of ACh to its receptors plays an important role 
in transmitting electrical information through postsynaptic muscarinic and 
nicotinic receptors from, to and within the brain and spinal cord. Excess 
accumulation of ACh can lead consequently to cholinergic overstimulation with 
various clinical symptoms according to the site at which ACh accumulates 
(Eaton et al., 2008, Flaskos, 2012) (Figure 1.3). 
Figure 1.2. Metabolic bioactivation of chlorpyrifos. 
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Table 1.1. Acetylcholine receptors, subtypes and location. 
 
ACh receptors Subtypes Location 
Nicotinic  
receptors 
N1 or Nm Neuromuscular junction 
N2 or Nn Autonomic ganglia, central nervous system 
Muscarininc  
receptors 
M1 Cortex and hippocampus regions of the brain 
M2 Heart, brain, spinal cord, exocrine gland 
M3 Exocrine glands and smooth muscles 
M4 Central nervous system 
M5 Central nervous system 
 
 
 
 
Figure 1.3. Chlorpyrifos effect on AChE 
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At the molecular interaction level, only CPO, which has a P=O moiety is a 
potent inhibitor of AChE, whereas CPF with its P=S moiety lacks this inhibitory 
effect. For CPF to become a potent inhibitor of AChE, it undergoes bioactivation 
in the liver to form CPO, which is the main cause of acute toxicity in mammals 
(Richardson, 1995, Bjorling-Poulsen et al., 2008, Eaton et al., 2008). When CPO 
binds to the active site of AChE, a covalent bond is formed between the 
phosphate group of the OP compound and the hydroxyl group of the serine 
within the active site of AChE. This bond is stable and usually persists for hours 
or weeks depending on the OP involved (Karalliedde, 1999). The 
organophosphorylation of AChE by CPO leads to the inhibition of its normal 
function in degrading the major neurotransmitter acetylcholine (ACh) at the 
cholinergic nerve endings in the central and peripheral nervous system (Koelle, 
1992).  
After inhibition by many OP compounds, reactivation of AChE usually occurs 
by spontaneous hydrolysis of the AChE-OP bond within several hours (Abou-
Donia and Lapadula, 1990). However, when AChE is inhibited by CPO, the 
AChE-CPO complex subsequently undergoes an “ageing” mechanism where it 
loses one of the two alkoxy labile groups (R1, R2) by a non-enzymatic hydrolysis 
process. When the enzyme-inhibitor conjugate has aged, inhibition of AChE is 
considered to be irreversible as the enzyme becomes more resistant to 
reactivation, permanently inhibited and its restoration can occur only by 
synthesis of new enzyme molecules (Abou-Donia and Lapadula, 1990, 
Karalliedde, 1999). Inhibition of AChE causes a build up of ACh at cholinergic 
synapses, which presents all over the body and, consequently, hyperactivation of 
both nicotinic and muscarinic cholinergic receptors (Abou-Donia, 2003, Elersek 
and Filipic, 2011). 
 
The resultant clinical manifestations of CPF poisoning can be distinguished into 
four main categories. These include acute cholinergic syndrome, intermediate 
syndrome, delayed neuropathy and other chronic neurological disorders. The 
development of a specific neurological syndrome depends on several factors, 
including extent and time of exposure, the chemical nature of the compound, and 
the onset and clinical symptoms (Abou-Donia, 2003). 
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1.4 Chlorpyrifos associated neurotoxicity 
1.4.1 Acute cholinergic syndrome 
Excess accumulation of ACh at the synapses of the peripheral nerves after AChE 
inhibition leads to hyperstimulation of the cholinergic (nicotinic and muscarinic) 
recepetors in the central and peripheral nervous systems (Abou-Donia, 2003). 
The resulting “cholinergic syndrome” is the main mechanism underlying CPF 
intoxication, which is characterised by a variety of clinical symptoms depending 
on the site of ACh accumulation. When a toxic dose of CPF is inhaled, ingested 
or absorbed via dermal contact, excess ACh binds to muscarinic receptors. As a 
result several muscarinic effects may develop, including hypersalivation, 
increased sweating and lacrimation, bronchoconstriction, bronchorrhoea, 
hypotension, increased gastrointesinal motility, abdominal cramps, vomiting, 
diarrhoea, miosis, visual disorders and lowered heart beat (Elersek and Filipic, 
2011). 
Acute cholinergic syndrome develops very rapidly within a few minutes to 
several hours from CPF exposure although sometimes it can appear up to one 
day after (Eaton et al., 2008, Hargreaves, 2012). During this phase, the nicotinic 
receptors are stimulated causing hypertension, uncontrolled muscle contractions 
and susequent paralysis (Singh and Sharma, 2000, Elersek and Filipic, 2011). 
Clegg and van Gemert (1999) reported that severe inhibition of AChE by more 
than 70% of normal levels can lead to the well characterised symptoms of 
cholinergic crisis (Clegg and van Gemert, 1999a). In humans, severe exposure to 
such OPs results in the accumulation of excessive ACh at neuromuscular 
junctions, leading to the development of neurotoxic effects such as 
neuromuscular paralysis (i.e. neuromuscular block) throughout the body (Lauder 
and Schambra, 1999, Costa, 2006, Gupta, 2006). Death can occur within a very 
short time, and this is usually as a result of a paralysis of the respiratory muscles 
followed by respiratory failure and/or cardiac arrest (Eaton et al., 2008, Flaskos, 
2012, Hargreaves, 2012). Central nervous system symptoms may also arise 
following severe CPF intoxication. These include, headache, insomnia, spasms, 
confusion, speaking disorders, coma, ataxia, convulsion and blurred vision 
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(Clegg and van Gemert, 1999b, Lotti and Moretto, 2005, Elersek and Filipic, 
2011).  
In 1997, the EPA reported more than 17,000 cases of people affected by acute 
CPF poisoning between 1993 and 1996 (EPA, 1997). In the US alone, 2,593 
incidents of acute CPF poisoning were reported among school children between 
1998 and 2002 (Alarcon et al., 2005). According to a recent EPA report, CPF 
was found to be involved in more than 300 cases of acute toxicity between 2002 
and 2011 (EPA, 2013). 
Treatment of acute CPF toxicity has two main purposes, to block muscarinic 
receptors and to reactivate AChE activity. The first aim can be achieved by 
administering atropine, which serves as cholinergic muscarinic antagonist, and 
thus, accumulation of ACh on muscarinic receptors is prevented. In order to 
reactivate the AChE enzyme, a specific antidote, such as the oxime, pralidoxime 
is administered (Thiermann et al., 1999, Eaton et al., 2008, Eddleston et al., 
2008). However, oximes are unable to reactivate the inhibited AChE once the 
AChE-CPO complex has undergone aging (Eaton et al., 2008). Another potential 
treatment for CPF intoxication is the use of anticonvulsant drugs such as 
diazepam, which is used to relieve anxiety and convulsions caused by acute 
poisoning following CPF exposure (Thiermann et al., 1999, Eaton et al., 2008, 
Eddleston et al., 2008). 
 
 
1.4.2 Intermediate syndrome 
Another neurotoxic effect associated with CPF exposure is known as 
intermediate syndrome. Senanayake and Karalliedde (1987) defined it as an 
intermediate syndrome because it occurred after the acute cholinergic syndrome 
but before organophosphate-induced delayed neuropathy (OPIDN) (Senanayake 
and Karalliedde, 1987). In general, it was reported that approximately 20% of 
people developed manifestations of intermediate syndrome following exposure 
to OP insecticides (Karalliedde, 2006). The clinical features of intermediate 
syndrome are usually initiated by respiratory insufficiency, followed by 
weakness in respiratory, neck and proximal limb muscles (Eaton et al., 2008). 
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These symptoms usually occur within 24 to 96 h after acute CPF poisoning 
(Yang and Deng, 2007). For example, a typical case of intermediate syndrome 
was described in a 16-month old child who developed respiratory arrest and 
flaccid paralysis 27 h after CPF ingestion (Mattingly et al., 2003). 
 
Although, the precise mechanism that underlies intermediate syndrome remains 
unclear, a number of proposed mechanisms have been reported. These include, 
prolonged inhibition of AChE, damage to muscle cells (myopathy), down 
regulation of ACh receptors and failure of ACh release at neuromuscular 
junctions (Yang and Deng, 2007, Abdollahi and Karami-Mohajeri, 2012). 
 
The clinical signs of intermediate syndrome, such as severe respiratory muscle 
weakness, can be addressed by mechanical ventilation and monitoring of 
respiratory functions. Other manifestations can be treated by administration of 
oximes. In animal studies, oximes were found to prevent myopathy if 
administered immediately following CPF exposure. However, when oximes 
were not used within two hours of CPF poisoning they had no effect 
(Karalliedde, 2006).  
 
 
1.4.3 Organophosphate-induced delayed neuropathy (OPIDN) 
CPF poisoning can also cause a delayed peripheral neuropathy known as 
OPIDN. This neurological disorder is a rare neuropathic condition resulting from 
single or repeated exposure to CPF and other OP insecticides. OPIDN is well 
characterised by delayed onset of ataxia followed by degeneration in the distal 
part of long axons and large peripheral nerves with a subsequent degeneration of 
the myelin sheath in both central and peripheral nervous systems (Abou-Donia 
and Lapadula, 1990). Abou-Donia (1981) first described OPIDN as an 
irreversible demyelination syndrome, which was caused by a ‘dying back’ 
degeneration of the long myelinated nerve axons of the nervous system (Abou-
Donia, 1981). Further investigations found that this degeneration was associated 
with axonal swellings containing aggregates of cytoskeletal protein (Abou-Donia 
and Lapadula, 1990). 
Introduction                                                                                        Chapter 1                                                   
15 
 
The clinical effects of OPIDN after CPF exposure are typically manifested 
following recognised cholinergic toxicity and intermediate syndrome. However, 
there can be a latent period of 6 to 14 days between CPF exposure and the 
clinical onset of OPIDN (Abou-Donia, 2003, Eaton et al., 2008, Jokanovic et al., 
2011). In humans, the early signs of developing OPIDN following exposure to 
CPF include vomiting and diarrhoea. After the latency period, this is followed by 
the development of progressive weakness of the lower limbs leading to a 
neuropathic condition called steppage gait, which involves both foot drop and 
pointing down together with toes, which drag along the floor during walking. In 
later stages, limb weakness may also extend to the hands and arms causing 
abnormal balance and reflex deterioration of certain limbs, and eventually a 
flaccid paralysis in severe cases. After several weeks, this paralysis may progress 
into spastic paralysis in which the muscles are affected by prolonged spasms as a 
result of nerve damage (Abou-Donia, 1981, Abou-Donia and Lapadula, 1990, 
Abou-Donia, 1993a, Jokanovic et al., 2011). Patients with nerve impairment may 
recover gradually following rehabilitation. However, the effects of OPIDN 
usually persist for many years even after rehabilitation, as regeneration of 
peripheral nerve function is not always reversible (Abou-Donia, 1981, Abou-
Donia, 2003, Jokanovic et al., 2011).  
The pathology and symptoms of OPIDN have been investigated in numerous 
animal models (Richardson et al., 1993). Of all animals that have been selected 
to study OPIDN, hens are the preferred model due to their sensitivity and 
development of clinical effects that resemble to a large extent those observed in 
humans (Abou-Donia, 1981, Honorato de Oliveira et al., 2002). In addition, 
treatment of hens with OP agents via dermal or oral administration and then 
screening the clinical symptoms of OPIDN is considered to be a relatively easy 
process, with a lack of complicated tests (Abou-Donia, 1981). Experiments with 
hens demonstrated that inhibition of neuropathy target esterase (NTE), a 
membrane associated enzyme of unknown function in neurons, was the primary 
cellular target of OP mediated neuropathy, and this was the first proposed 
mechanism involved in OPIDN (Johnson, 1969, Zech and Chemnitius, 1987).  
Using hens as experimental models, it was suggested that CPF was able to 
induce OPIDN if more than 50% of NTE activity was inhibited (Johnson, 1990, 
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Lotti, 1991). The previous animal studies were in agreement with CPF-induced 
OPIDN cases in humans, which are mainly based on accidental exposure to CPF 
(Eaton et al., 2008). For instance, Osterloh et al. (1983) demonstrated low levels 
of plasma cholinesterase and NTE activity in a patient who had ingested CPF. In 
that case, the patient also showed minimal acute cholinergic syndrome, but 
coma, cardiac arrhythmia and death ensued 30 hours after poisoning (Osterloh et 
al., 1983). Moreover, Lotti and colleague (1986) followed up on a male patient 
who had been accidentally poisoned by oral CPF (< 300 mg/kg) and developed a 
mild axonal neuropathy after 43 days. In this study, the authors concluded that 
CPF was able to induce OPIDN, which was associated with a lower level of NTE 
inhibition than that required in animals (Lotti et al., 1986).  
 
Previous studies on hens also revealed that the onset of clinical symptoms of 
OPIDN occurred following two main steps. The first one involves inhibition of 
the enzymatic activity of NTE by phosphorylation, which significantly decreases 
the hydrolysis of the enzyme (Glynn, 2000). Aging of phosphorylated NTE then 
follows and OPIDN is initiated. The process of NTE aging occurs when an OP 
with a negatively charged group covalently binds to the NTE active site serine 
residue. By aging of NTE, the activity of the enzyme becomes permanently 
inhibited and OPIDN occurs (Johnson, 1990, Glynn, 2000). Johnson (1969) and 
Du Toit et al (1981) demonstrated that inhibition of NTE in the spinal cord leads 
to a spinal syndrome only, but not neuropathy. However, to develop an 
axonopathy such as OPIDN, NTE aging is required (Johnson, 1969, du Toit et 
al., 1981). NTE inhibition and aging are then followed by several alterations in 
peripheral nerves. These include degeneration of long axons, myelin sheath loss, 
proliferation of Schwann cells and accumulation of macrophage in nerves (Singh 
and Sharma, 2000). Therefore, only OPs that are able to inhibit as well as age the 
enzymatic activity of NTE can induce OPIDN.  
 
It has been found that the inhibition and ageing of NTE may not represent the 
only critical early event in the pathogenesis of OPIDN. A number of studies have 
demonstrated a series of other chemical mechanisms that may be involved in this 
delayed neurodegenerative condition. These include the disruption of protein 
kinases that mediate phosphorylation of cytoskeletal proteins of microtubule and 
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neurofilament networks (Abou-Donia, 2003). In addition, activation of calcium 
activated neutral protease (CANP) occurs, which promotes axonal degeneration 
following exposure to OP mediated neuropathy (Emerick et al., 2012). 
Furthermore, increased intracellular free calcium (Ca
2+
) levels and 
phosphorylation of calcium/calmodulin-dependent protein kinase II (Ca
2+
/CaM 
kinase II) were also found to occur prior to the onset of clinical signs of OPIDN. 
In this context, an earlier study by Suwita et al. (1986) has shown that increased 
activity of calcium/calmodulin protein kinase II was related to phosphorylation 
of microtubule and neurofilament networks in the brain and spinal cord of hens 
treated with other OPs such as tri-o-cresyl-phosphate (TOCP), which was 
administered orally in a single neuropathic dose (Suwita et al., 1986). These 
findings suggest that alterations in the phosphorylation status of cytoskeletal 
proteins, destabilisation of microtubules and subsequent axonal degeneration are 
common biochemical events associated with OPIDN development (Abou-Donia, 
1993a, Gupta and Abou-Donia, 1998, Suwita et al., 1986).   
 
The clinical effects of OPIDN can be prevented by administration of NTE 
inhibitors such as carbamates, sulphonates, and phosphinates, which can inhibit 
the NTE enzyme without causing aging (Glynn, 2000). Despite having similar 
effects on NTE activity to OPs, studies have shown that pre-dosing with such 
agents can protect against the toxic effects of CPF. The basis of this protection is 
that these agents form a complex with AChE, thus preventing its interaction with 
CPF (Johnson, 1975, Johnson, 1982). Johnson and Lauwerys (1969) showed that 
the pre-treatment of chickens with these agents protected them from developing 
OPIDN when they were subsequently exposed to a neuropathic OP (Johnson and 
Lauwerys, 1969). However, these agents could potentially initiate the 
neuropathy-inducing activity of OPs, as Lotti (2000) demonstrated several toxic 
axonopathies associated with exposure to carbamate and phosphinate compounds 
(Lotti, 2000). 
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1.4.4 Other chronic neurological conditions associated with CPF 
exposure 
In addition to the above described classical neurological syndromes, CPF and 
certain other OPs are capable of causing a number of persistent, long lasting, 
chronic neurobehavioral and neuropsychiatric disorders. These deficits are 
collectively named chronic OP induced neuropsychiatric disorder (COPIND), 
and are observed following acute single dose or repeated subchronic exposure to 
CPF (Sanchez-Santed et al., 2004). COPIND is characterised by behavioural 
changes, such as drowsiness, confusion, anorexia, lethargy, anxiety, emotional 
lability, depression, insomnia, fatigue and irritability (Salvi et al., 2003). Similar 
symptoms of COPIND have been observed in agricultural workers accidentally 
exposed to a single dose of CPF, who demonstrated impaired cognitive 
functions, abnormalities in neuropsychological tests as well as memory and 
attention deficit (Savage et al., 1988, Rosenstock et al., 1991, Steenland et al., 
1994). 
 
Previous studies have described a variety of neurological changes in adults 
following long term use of OPs. Stephens et al (1995) studied farm worker 
performance after repeated exposure to OPs. They showed relatively slow speed 
of information processing in neurobehavioural tests, impaired attention, memory 
problems and greater susceptibility to psychiatric disorders (Stephens et al., 
1995). Fiedler and colleagues (1997) found dystonic reactions and schizophrenia 
amongst people exposed to large doses of CPF for long periods (Fiedler et al., 
1997). In addition, exposure to low levels of the same compound was found to 
induce neurobehavioural effects. For instance, high levels of anxiety were 
observed in insecticide sprayers but not in farmers (Levin et al., 1976). Impaired 
cognitive function of weaning rats was also reported after their exposure to sub-
acute doses of CPF (Jett et al., 2001). 
 
The impact of CPF insecticides causing cognitive deficits was also investigated 
in children. Several epidemiological studies have demonstrated that children and 
adolescents who work as pesticide applicators in agricultural fields such as 
cotton crops, have significantly more neurological symptoms and lower 
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neurobehavioural performance compared to non-OP workers (Rohlman et al., 
2001, Rohlman et al., 2005, Abdel Rasoul et al., 2008). These findings further 
confirm the previously highlighted association between the period and duration 
of applying CPF in agriculture and the extent of cognitive and developmental 
disorders. However, the precise neurological mechanisms underlying the clinical 
symptoms of COPIND in humans remain poorly understood (Kamel et al., 2003, 
Rohlman et al., 2007).  
 
 
1.5 Developmental neurotoxicity of chlorpyrifos 
During gestational development and early childhood, CPF and its metabolite 
CPO can cause severe brain deficits, abnormalities and permanent impairment, 
even if the exposure occurs at lower concentration than those required to produce 
clinical signs of acute neurotoxicity in adults (Grandjean and Landrigan, 2006). 
In humans, exposure to CPF during early brain development has been linked to 
several neurodevelopmental disorders in children, including attention deficit 
hyperactivity disorder (ADHD), autism, learning disabilities, and other 
emotional and behavioural problems. Such deficits may have considerable 
impacts on health and the economy (Grandjean and Landrigan, 2006, Engel et 
al., 2011, Rauh et al., 2012). About one in six children are diagnosed with 
developmental disorders worldwide (Schettler, 2001). Neurobehavioral problems 
affect up to 15% of all births (Grandjean and Landrigan, 2014). Children with 
these deficits may show early onset lifelong damage or delayed effects that 
appear after a period of time. The severity of the neurodevelopmental effects is 
varied and may not be clinically obvious. For that reason it can only be assessed 
in individuals by special applications such as intelligence quotient (IQ) testing 
(Flaskos and Sachana, 2011). In animals, several in vivo studies found that 
exposure to CPF during critical periods of brain development causes a variety of 
behavioural abnormalities in developing mice and rats. The neurodevelopmental 
effects include changes in locomotor skills and cognitive performance (Icenogle 
et al., 2004, Ricceri et al., 2006).  
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Developmental neurotoxicity of CPF can occur during the prenatal or postnatal 
period. Prenatal exposure to CPF occurs through the placental barrier from the 
exposed mother to the foetus or embryo. Postnatal exposure can be direct via the 
normal routes of CPF administration, for instance dermal absorption, ingestion 
or inhalation, or through an indirect exposure such as breastfeeding (Grandjean 
and Landrigan, 2006).  
 
Previous studies have shown that the developing brain is more susceptible than 
the mature brain to injury caused by the acute toxicity of CPF (Pope et al., 1991, 
Pope and Chakraborti, 1992, Whitney et al., 1995). For example, Zheng and 
colleagues (2000) found that the LD50 of CPF in 1-week-old rats is 10-fold lower 
than that in adult rats (Zheng et al., 2000). Similar differences were also 
observed between the maximum tolerated dose of CPF in 1 day old rats and 6 to 
9 day old animals (Whitney et al., 1995).  
 
The higher susceptibility of the nervous system to toxic agents during foetal life 
or the early postnatal period compared to that of the adult is due to a number of 
reasons. Firstly, the developing brain in embryos and infants is more sensitive 
than that of the mature nervous system in adults (Grandjean and Landrigan, 
2006, Flaskos and Sachana, 2011). The second reason is related to the fact that 
the foetus is not completely protected against toxic compounds by the blood-
placenta barrier. Since CPF is a lipophilic compound with low molecular weight, 
it can easily cross through the placental barrier to the foetal circulation, thus 
affecting the developing nervous system (Andersen et al., 2000). It has been 
found that OPs can rapidly cross the placenta and accumulate in umbilical cord 
blood at higher concentrations than those normally found in maternal blood 
(Sakamoto et al., 2004). Whyatt and Barr (2000) also demonstrated high levels 
of CPF metabolites in faecal samples of newborn children of exposed mothers 
(Whyatt and Barr, 2001). 
 
Another main factor that increases the susceptibility of the foetus and young 
children to OP neurotoxicity is that the blood brain barrier is not fully developed 
until 6 months after birth, so it cannot prevent the transfer of some toxic 
chemicals from the maternal blood to the foetal or infant brain in early life 
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(Costa et al., 2004). Furthermore, exposure to CPF during prenatal and neonatal 
life was found to be capable of disrupting the stability and integrity of the blood-
brain barrier (Yang et al., 2001, Parran et al., 2005).  
 
Differences in pharmacokinetic aspects such as drug absorption and metabolism 
following OP exposure, between the young and adults could also account for the 
vulnerability of the developing brain to developmental neurotoxicity (Flaskos 
and Sachana, 2011). In this context, CPF absorption in foetal brain is higher than 
that observed in the maternal brain. This is mainly because of the late 
development of epidermis keratinization and the thinner skin layers in the human 
foetus compared to infant and adults, which leads to greater toxin absorption via 
skin, lung and intestinal mucosa (Kearns et al., 2003, Vidair, 2004). By contrast, 
biotransformation of CPF is lower in neonates compared to the adult. This is due 
to the decreased levels of detoxifying enzymes in the liver and other tissues of 
developing organisms, which leads to increased concentrations of oxon 
metabolite. For example, the activity and amounts of A-esterase PON1, which is 
the major plasma enzyme that hydrolyses CPO to less toxic metabolites in 
humans and mice, is 4-fold lower in developing organisms than in adults 
(Karanth and Pope, 2000, Vidair, 2004). Karanth and Pope (2000) demonstrated 
that A-esterase PON1 activity is lower in neonatal rats than in adult rats (12-, 5-, 
8-fold lower in plasma, liver, and lung A-esterase PON1, respectively) treated 
with 1 mM CPO (Karanth and Pope, 2000). Moser et al. (1998) provided more 
evidence of the age-related differences in the activity of A-esterase PON1 in 
animals. In that study, it has been found that the activity of plasma PON1 in 1 
day old rat is 20-fold lower than that in adult rat following 1 mM CPO exposure 
(Moser et al., 1998). In humans, a 13-fold variability in PON1 status has been 
observed (Davies et al., 1996). Furlong et al. (2006) predicted a range of 131 to 
164-fold variability in CPO sensitivity among 130 pregnant women farmworkers 
and their newborns in the Latina cohort based on their PON1 status (Furlong et 
al., 2006). Therefore, the variation in PON1 level explains the higher susceptibly 
observed among mothers and newborns to CPO exposure. This finding clarifies 
the observation of severe CPO effects in some cases where mother and her 
newborn share a low level of PON1 (Furlong et al., 2006). 
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Brain developmental processes involve a sequence of events including neural 
cell proliferation, migration, differentiation, axonogenesis/neurite outgrowth, 
synaptogenesis, gliogenesis and apoptosis, which start from embryonic life and 
continue to late adolescence. Animals and humans share the same developmental 
order. However, the developmental stage at which each of these processes occurs 
is different between humans and animals (Flaskos and Sachana, 2011, Grandjean 
and Landrigan, 2014). For example, synaptogenesis and gliogenesis occur during 
pregnancy in humans, whereas these neurodevelopmental processes start after 
birth in rats. Disruption at each event of neurodevelopment provides a window of 
susceptibility to CPF toxicity (Rice and Barone, 2000). Therefore, CPF mediated 
developmental neurotoxicity is mainly dependent on the developmental stage at 
which the exposure occurs. The timing at which the exposure to CPF occurs has 
greater impact in determining the affected regions and function (Flaskos and 
Sachana, 2011).  
A number of experimental reports have demonstrated the ability of CPF and 
CPO to interfere with the normal development of the nervous system, which may 
in turn lead to developmental neurotoxicity. Interference by CPF and CPO in the 
developmental process of neurite outgrowth in neuronal and glial cells and the 
involved cytoskeletal proteins are the main focus of this thesis, which will 
discussed in the following part of this chapter. 
 
 
 
1.5.1 Neurite outgrowth as a morphological target of CPF-
induced developmental neurotoxicity 
Neurite outgrowth is an in vitro morphological marker of neural cell 
differentiation. It involves a series of complex events that occur during brain 
development, including differentiation of precursor cells into a terminal 
phenotype of neuronal cells, initiation and growth of sheet-like extensions 
(lamellipodia) and their condensation into minor processes, development of short 
dendrites and long axons with the guidance of the growth cone, and finally 
formation of the synapse (Craig and Banker, 1994b). Normal outgrowth of 
neurites is a critical process in the developing brain and nervous system as it 
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forms the basis of neuronal connectivity (Radio and Mundy, 2008). Disruption at 
any stage of this developmental pattern by a toxic agent would impair the 
neuronal differentiation process leading to developmental neurotoxicity, which 
has been linked to several neurobehavioral and neurodevelopmental disorders in 
humans (Webb et al., 2001, Ramakers, 2002).  
The ability of CPF and CPO to induce developmental neurotoxicity by 
interfering with neurite outgrowth in the developing nervous system has been 
studied in a number of animal and cellular models. For instance, Slotkin et al. 
(2006) have shown that treatment of neonatal rats with CPF at 1 mg/kg daily 
dose (subcutaneously injected for four days) inhibits neurite outgrowth as 
indicated by decreased levels of choline acetyltransferase (ChAT) activity, a 
cholinergic neuronal marker. The previous study also reported that the effect of 
CPF towards neurite outgrowth was not associated with an impact on animal 
survival and caused only 20% reduction in the activity of AChE, which is below 
the 70% inhibition level that have been shown to induce acute cholinergic 
symptoms (Slotkin et al., 2006). In this in vivo study, neurite outgrowth was 
evaluated biochemically by measuring the activity of ChAT (membrane protein) 
and its ratio to total cell protein. As the neural cell contains a single nucleus, 
measurement of DNA content reflect the numbers of cells. Thus, cell packaging 
density was assessed by measuring DNA concentration. As the neurites expand 
and developed into axon and dendrites, it requires contribution of membrane 
proteins and other cellular proteins. Therefore, the amount of total protein in 
response to cell differentiation was measured (Slotkin et al., 2006).   
The impact of CPF and CPO on neurite outgrowth has also been investigated in 
in vitro studies using different glial and neuronal cell culture models. In most of 
these reports, OP-induced effects on neurite outgrowth have been evaluated 
morphometrically by microscopy, following histological or immunostaining 
techniques, using high-resolution cameras and either manual counting or specific 
neurite outgrowth analysis software. For instance, a significant inhibition (by 
38%) in neurite outgrowth, but not cell viability, in differentiated rat PC12 
pheochromocytoma cells was detected after 24 h exposure to 3 µM CPF and 3 
nM CPO. The observed CPF-induced effect on neurite outgrowth was detected 
in the absence of AChE inhibition. However, the CPO effect on neurite 
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outgrowth was associated with 90% inhibition of AChE activity (Das and 
Barone, 1999). In addition, CPF, at a non-cytotoxic concentration of 3 µM, 
impaired neurite outgrowth significantly in cultures of differentiating mouse N2a 
neuroblastoma cells after 4 or 8 h treatment with a lack of observed effect on 
AChE activity (Sachana et al., 2001). In the same cell line, CPO, at non-
cytotoxic concentrations of 5 and 10 µM was found to impair axon outgrowth in 
differentiating N2a cells after 4 and 24 h exposure, although in this study there 
was an acute level of inhibition of AChE (˃70% of control levels) which 
persisted for 24 h (Flaskos et al., 2011). The ability of CPF and CPO to alter the 
neuronal morphogenesis in the previous in vitro studies was seen at relatively 
high doses of CPF or at CPO concentrations causing acute levels of AChE 
inhibition. However, a number of studies demonstrated that both compounds are 
also able to inhibit neurite outgrowth at much lower concentrations without 
AChE inhibition (Howard et al., 2005, Yang et al., 2008). 
 Howard et al. (2005) showed that CPF and CPO at lower doses (0.001 µM and 
0.01 nM, respectively) than those required to reduce the enzymatic activity of 
AChE or cell viability, inhibited the axonal and dendritic outgrowth in primary 
cultures of superior cervical ganglia (SCG) rat embryonic neurons after 24 h 
treatment (Howard et al., 2005). Under the same exposure conditions, CPF and 
CPO also interfered with axon outgrowth in embryonic cultures of dorsal root 
ganglia (Yang et al., 2008). At sub-cytotoxic concentrations (1-10 µM) CPF and 
CPO were also found to inhibit the extensions outgrowth in rat C6 glioma cells 
after 24 h of inducing cell differentiation and this effect was not associated with 
reduced AChE activity (Sachana et al., 2008). These findings demonstrated that 
neurite outgrowth can be more sensitive than the enzymatic activity of AChE to 
the toxic effects of CPF and CPO in these cell models. Since the reported 
alterations in neuronal morphogenesis occurred in both the absence and presence 
of changes in AChE activity, it is likely that inhibition of AChE is not in the 
main cause of the inhibition of neurite outgrowth by CPF and CPO. These 
findings suggest that additional non-cholinergic targets are involved in the 
developmental toxicity of CPF and CPO. These targets will be discussed in the 
next section to provide a better understanding as to how their disruption might 
inhibit neurite outgrowth.  
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1.5.2  Cellular proteins as molecular target of CPF-induced 
developmental neurotoxicity 
Although CPF exerts poisoning effects due to the CPO mediated inhibition of 
AChE activity, several other cellular proteins have been proposed as targets for 
the neurotoxicity of CPF and CPO, including those involved in cytoskeletal 
architecture, cell signalling pathways and growth associated protein. 
 
1.5.2.1 Cytoskeleton 
The neuronal cytoskeleton plays fundamental roles in controlling the 
developmental processes of the nervous system. These include cell proliferation, 
migration, differentiation, morphogenesis, neurite outgrowth, elongation of 
axons, branching of dendrites, steering of growth cones and apoptosis 
(Hargreaves, 1997, Flaskos, 2014). Disruption of cytoskeletal proteins results in 
serious damage in these phases of neurodevelopment (Flaskos, 2014). The 
neuronal cytoskeleton is fibrous network of proteins, which is composed of three 
main classes of filamentous proteins, microtubules (MTs), intermediate filaments 
(IFs) and microfilaments (MFs). These components of cytoskeletal proteins have 
an important role in the regulation of axon growth and stability and thus, they 
represent potential neurotoxicity targets (Hargreaves, 1997). 
 
1.5.2.1.1 Microtubules 
Microtubules (MTs) have important roles in neuron growth and physiology, 
being implicated in the regulation of neuronal morphology, intracellular 
transport, and outgrowth of axons and dendrites (Cambray-Deakin, 1991a, 
Ginzburg, 1991, Lodish et al., 2000a). MTs are straight, hollow cylinders formed 
by a ring of thirteen protofilaments that are built by the assembly of two tubulin 
heterodimers, α- and β-tubulin subunits, and MT associated proteins (MAPs) 
(Cleveland, 1993a, Hargreaves, 1997).  
MTs represent the largest type of cytoskeletal structure, with an average external 
diameter of ~ 25 nm and an internal diameter of ~ 14 nm (Figure 1.4) (Tilney et 
al., 1973). In mammalian cells, MTs originate from a specific regions called the 
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+ - 
centrosomes or microtubule organising centres (MTOCs). MTs are organised in 
a polar fashion, where the centrosome-attached end is the “minus end”, while the 
other is called the “plus end” (Figure 1.4). Each end has its own growth rate, for 
example, the plus end grows fast, unlike the minus end which known as the slow 
growing end (Heidemann et al., 1981b). During cell division and movement, 
MTs undergo several rearrangements (polymerisation - depolymerisation) that 
are fuelled by the enzymatic hydrolysis of guanosine triphosphate (GTP), with 
the plus end extending towards the extremities of the cell (Lodish et al., 2000a). 
The development of elongating neurons largely depends on the orientation of 
MTs (Bamburg et al., 1986, Julien and Mushynski, 1998). For instance, in neural 
cells, the plus end of MTs extends towards the axon tip and the minus end is 
oriented at the MTOC of the axon. In contrast, in dendrites, the polarity of MTs 
is mixed, with both ends being distal to the cell body. In non neuronal cells such 
as glia, the minus end is associated with MTOCs. Each MTOC has the ability to 
nucleate and organise MTs by polymerising the tubulin subunits (Lodish et al., 
2000a).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Microtubule structure and composition. A schematic diagram of a MT 
showing the structure of 13 protofilaments packed together to form the cylindrical wall in 
cross section and a side view of a short section of a microtubule with the tubulin 
polypeptides aligned into rows (Lodish, 2000). 
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The main component of MTs is tubulin, which has α- and β- subunits. However, 
there are other subunits of tubulin such as ϒ-tubulin, which is not present in MTs 
but has an important role in MT nucleation and polar orientation (Martin et al., 
1997). Each α- and β-tubulin subunit has a molecular weight of approximately 
50 kDa. They consist of several isoforms encoded by a number of genes 
(Tischfield and Engle, 2010). Both α- and β-tubulin isoforms have an important 
role during nervous system development. For instance, class III β-tubulin isotype 
(βIII-tubulin) is almost exclusively distributed in neuronal cells and has an 
essential role in cell differentiation and neurite outgrowth. In addition, βIII-
tubulin is one of earliest cytoskeletal protein to be expressed during 
neurodevelopment (Easter et al., 1993).  
Tubulin binds a variety of MAPs due to its strongly acidic carboxyl terminal 
domain (Cleveland, 1993a, Hargreaves, 1997). The carboxyl terminal of tubulin 
subunits contains an acidic region of 40 amino acids. This peptide sequence is 
believed to harbour the target region of calcium binding, phosphorylation sites 
(serine residues) and binding sites of MT-stabilising proteins, such as MAPs 
(Table 1. 2) (Luduena, 1993). Several post-translational modifications are also 
involved in the regulation of tubulin polymer formation. The most common 
modifications include acetylation of α-tubulin at lysine at position 40 (Lys40), 
detyrosination/tyrosination of α-subunits by the removal/addition of tyrosine 
(Tyr) residues at the C-terminal. Other post-translational modifications include 
phosphorylation of β-subunits at a serine residue at position 172 (Ser172) and 
polyglutamylation of β-tubulin subunits at multiple glutamate residues (Luduena, 
1993, Fourest-Lieuvin et al., 2006) (Table 1.2). Such modifications may affect 
MT stability and locations (Janke and Kneussel, 2010). 
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Table 1.2. Major microtubule cytoskeletal proteins of the nervous system (adapted 
from (Kirkpatric and Brady, 1999) . 
 
Protein Expression pattern and distribution 
Post-translational 
modification 
α-tubulin 
In all cells, but some isoforms preferentially 
expressed in brain 
Acetylation, 
Tyrosination, 
Polyglutamylation 
β-tubulin 
In all cells, but some isoforms preferentially 
expressed in brain 
Phosphorylation, 
Polyglutamylation 
γ-tubulin In MTOC of all cells  Phosphorylation 
MAP 1a Appears late, widely distributed Phosphorylation 
MAP 1b Appears early, then declines; enriched in axons Phosphorylation 
MAP 2a 
High molecular weight; expressed in dendrites 
in mature neurons 
Phosphorylation 
MAP 2b High molecular weight; expressed in dendrites Phosphorylation 
MAP 2c 
Low molecular weight; expressed in dendrites 
in developing neurons 
Phosphorylation 
Tau Enriched in axons Phosphorylation 
 
The assembly and stability of MTs is strongly dependent upon MAPs, which 
regulate the dynamics of tubulin heterodimers (Lodish et al., 2000b, Lodish et 
al., 2000a). For instance MAPs stimulate MT assembly and are involved in the 
interaction with IF and actin filaments (Cleveland, 1993b). The main MAPs 
family members that are known to be important during central nervous system 
development include MAP 1, MAP 2, tau and stathmin. Their main function 
during neuronal development is to maintain the stabilisation of the growth cones, 
and the dynamics of axonal and dendritic MTs (Schoenfeld and Obar, 1994). 
Other groups of MAPs such as, kinesin and dynein can also function as motor 
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proteins (ATPases) by driving the intracellular transport of organelles and 
proteins from the cell body to the extending axons and synapses (Vallee and 
Bloom, 1991).  
MAPs 1 and 2 are composed of three different phosphoproteins each (MAP 1a, 
1b, 1c, MAP 2a, 2b, 2c), which can be distinguished according to their molecular 
weights (Olmsted, 1986). While MAP 1 and MAP 2 are expressed in neuronal 
cell bodies and dendrites, tau is found primarily in axons (Table 1.2). Tau is also 
considered as an axonal marker and tau abnormalities are strongly related to the 
pathophysiology of neurodegenerative diseases, such as Alzheimer’s disease 
(Kolarova et al., 2012).  
The role of MTs in organising axonal growth and development is well 
established. As developing neurites extend, MTs begin to be assembled and to be 
modulated by posttranslational modifications of tubulin (Cambray-Deakin, 
1991a). In this process, MAPs play essential roles, helping to maintain structure, 
orientation, and function of MTs (Heidemann et al., 1981a, Mandell and Banker, 
1995, Craig and Banker, 1994a). Given the important roles of MTs in neuron 
growth and functions, it is not surprising that MT alterations or disruption of MT 
protein phosphorylation by toxic agents lead to interference with brain 
development and may be involved in the pathophysiological mechanisms of 
several neurodegenerative diseases (Millecamps and Julien, 2013).  
The ability of CPF and CPO to cause developmental neurotoxicity via disruption 
of the microtubule cytoskeleton has been demonstrated in a number of previous 
studies. For instance, exposure of differentiating rat C6 glioma cells to sub-
cytotoxic neurite inhibitory doses (1-10 µM) of CPF and CPO were found to be 
associated with reduced protein levels of MAP 1b and α-tubulin (Sachana et al., 
2008). Furthermore, Abou-Donia (1993) demonstrated that hens exposed to OP 
exhibited increased phosphorylation of tubulin and MAPs (Abou-Donia, 1993b). 
In addition, CPO at doses range from 0.1 to 10 µM was shown to induce 
alterations in MT and MAP ultrastructure in cultured rat brain slices (Prendergast 
et al., 2007). Therefore, MTs may serve as useful biomarkers of CPF-induced 
neurodegeneration. 
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1.5.2.1.2  Intermediate filaments 
Intermediate filaments (IFs) are an important component of the eukaryotic 
cytoskeleton, and are usually identified in cellular studies as markers for neural 
cell differentiation. IFs are slightly smaller and more biochemically stable than 
MTs. Thus, they provide structural support for many different cell types 
including neurons (Omary et al., 2006). All IF proteins contain a conserved α-
helical rod domain, flanked by a hypervariable amino-terminal head domain and 
a carboxy-terminal tail (Figure 1.5). Since the central rod domain contains 310 
amino acid residues, which are highly homologous amongst the main IF types, 
the variations in amino acid sequence of the two end domains determine the 
difference in the molecular weight and molecular interactions of all IF subunits 
(Cooper, 2000). IFs are initially constructed from two polypeptide chains wound 
together in a parallel fashion to form a coiled-coil dimer, two of which then form 
a staggered tetramer (consisting of two antiparallel dimers), leading to the 
subsequent formation of octamers, protofilaments and eventually large complex 
IFs that contain 16 to 32 polypeptides (Figure 1.6) (Lodish et al., 2000b).  
 
 
 
 
 
 Figure 1.5. Structure of intermediate filament protein subunits. The 
diagram shows the generalized structure of an IF protein monomer, which contains 
an α-helical rod domain composed of around 310 amino acid residues, an amino-
terminal head domain and the carboxy-terminal domain at the tail. 
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Although there are more than 50 different IF proteins, which have been classified 
into six main groups based on their amino acid sequence homology, two classes 
of IFs that are specific to the nervous system are the focus of this dissertation. 
These include neurofilament (NF) proteins and glial fibrillary acidic protein 
(GFAP), which are mainly expressed in neuronal and astroglial cells, 
respectively (Cooper and Hausman, 2000).  
NFs are composed of three polypeptides chains termed neurofilament heavy 
(NFH), medium (NFM) and light (NFL) chains, which are categorised according 
to their molecular weights of approximately 200, 145 and 70 kDa, respectively 
(Ackerley et al., 2003). In mammals, these triplet proteins are found in mature 
neurons but are highly expressed in axons. NFs provide support during axon 
Figure 1.6. Assembly of intermediate filaments. A schematic diagram 
showing that IFs are assembled from two polypeptide chains wound together to 
form a parallel coiled-coil dimer. Dimers are staggered in an antiparallel fashion 
to form tetramers, octamers, protofilaments and eventually large complex IFs that 
contain 16 to 32 polypeptides. 
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extension and also play major roles in the complex series of interactions that 
regulate axonal growth and development (Lee and Cleveland, 1996). NFs share a 
similar structure to all other IF proteins in which each NF subunits contain head, 
central rod and tail domains. The central rod domain that comprises 310 amino 
acids plays an important role in NF polymerisation, whereas the tail domains of 
NFH and NFM are important in the formation of fine lateral projections (Yuan et 
al., 2012). The central rod domain of each NF is co-assembled with other NF 
subtypes to form a filament with 10 nm in diameter. NFL forms the central core 
of this filament, while NFM and NFH subunits are situated on its surface 
forming radial projections that interconnect NFs with other cytoskeletal elements 
(Rao et al., 2003). Therefore, cross bridges between NF extensions of the tail 
domains and other organelles in the cytoplasm stabilise the axonal outgrowth 
(Hirokawa et al., 1984). 
The axonal cytoskeleton contains MTs, NFs and microfilaments (MFs) that are 
assembled in ordered networks of filaments interconnected by cross-bridges. 
Newly synthesised NFs are transported into the axonal space in a slow non-
diffuse manner and then rapidly incorporated into the axonal cytoskeleton. The 
process of NF assembly and transport is launched within the neuronal cell body 
and continues as they are transported into and along the axons by axonal 
transport (Black and Lasek, 1980).  
During NF assembly, NFs undergo several post translational modifications 
which involve phosphorylation of the carboxyl terminal domains. 
Phosphorylation of NFs is crucial for the regulation of their axonal stability and 
transport, assembly and disassembly in the cell (Williamson et al., 1996). 
Additionally, it plays an important role in regulating the interactions between 
NFs themselves and the interaction of NFs with MTs (Hisanaga and Hirokawa, 
1989, Hisanaga et al., 1991). It has been demonstrated that increased NFH 
phosphorylation is directly related to an increase in the spacing between NF 
subunits and axonal diameter (Hirokawa et al., 1984). Moreover, aberrantly 
phosphorylated NFs accumulate in neuronal cell bodies and can be found in axon 
from patients with neurodegenerative diseases such as Alzheimer’s and 
Parkinson’s disease (Rudrabhatla et al., 2011). Abnormal NF aggregation is also 
a common histological hallmark of OP poisoning (Jensen et al., 1992).  
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Phosphorylation of NF subunits can occur at the carboxyl terminal domains, 
which contain multiple Lysine-Serine-Proline (KSP) region or phosphorylation 
sites. NFH and NFM are known to have the highest number of phosphorylatable 
sites compared to NFL, which is less phosphorylated (Perrot and Eyer, 2009). 
This is due to the extreme length of the tail domain of NFH and NFM and the 
presence of large numbers of KSP repeats compared to NFL (Yuan et al., 2012). 
It has been demonstrated that NFs can also be phosphorylated at the amino head 
domain. However, the phosphorylation sites in the latter are less abundant than 
those at the carboxyl domains (Sihag et al., 2007). Phosphoarylation of NFH and 
NFM begins after their synthesis in the cell body and continues along their 
transport into the axon towards the synapses (Nixon et al., 1982). 
Phosphorylation of the tail domain of NFH and NFM is regulated by different 
protein kinases and phosphatases. Protein kinases are sets of several enzymes 
that have the ability to phosphorylate proteins by adding a phosphate group to 
them, such as mitogen activated protein kinases/extracellular-signal-regulated 
kinase 1/2 (MAPKs/ERK1/2) (further details in section 1.4.2.2) (Veeranna et al., 
1998).  Phosphatases are a group of enzymes that removes a phosphate group 
from a protein such as protein phosphatase 1 and 2A (PP2A and PP1) (Strack et 
al., 1997). In patients with Alzheimer’s disease, NF phosphorylation was 
associated with activation status of ERK1/2 and decreased levels of PP1 and 
PP2A (Gong et al., 1993, Veeranna et al., 2004). The mechanisms underlying the 
NF phosphorylation mediated by kinases and phosphatases are not completely 
understood. 
Data from previous studies showed that exposure of differentiating N2a cells to 
sub-cytotoxic neurite outgrowth inhibitory levels of CPF (3 µM) caused a 
significant reduction in the level of total NFH (Sachana et al., 2001). In addition, 
the densitometric analysis of western blots in a study by Flaskos et al. (2011) 
reported that neurite inhibitory effects of CPO were associated with reduced 
levels of total NFH in a concentration dependent manner in N2a cells (Flaskos et 
al., 2011). However, phosphorylated levels of NFH were unaffected by CPO. 
The observed alteration of NFH was further confirmed by the aggregation 
localised in cell bodies (Flaskos et al., 2011). Other OPs have been also shown to 
affect the NF network in different ways. Hargreaves et al. (2006) showed that 
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sub-cytotoxic neurite inhibitory concentration of phenyl saligenin phosphate 
(PSP) were associated with reduced levels of total NFH following 4 and 24 h 
exposure in differentiating N2a cells. A transient increase in NFH 
phosphorylation after 4 h exposure and a subsequent decrease after 24 h were 
also seen together with aggregates in the cell bodies in PSP-treated cells 
(Hargreaves et al., 2006). In the same cell line, inhibition of axon outgrowth was 
found to be accompanied with reduced levels of total and phosphorylated NFH 
in cells treated with trio-ortho-cresyl phosphate (TOCP) for 24 h (Fowler et al., 
2001). However, increased expression of NFH phosphorylation without 
significant changes in total NFH were detected in differentiating N2a cells 
exposed to sub-cytotoxic concentrations of diazinon oxon (DZO) for 24 h 
(Sidiropoulou et al., 2009a). In an animal study, increased phosphorylation status 
of NFH has been found in the spinal cord of hens treated with TOCP (Suwita et 
al., 1986) and PSP (Jortner et al., 1999). This alteration in NFH suggests that 
these OP compounds including CPF and CPO have the ability of to interfere with 
molecular expression of axonal cytoskeleton proteins and the arrangement of 
cytoskeletal networks within the cell (Flaskos et al., 2007, Harris et al., 2009a).  
GFAP is the major IF protein found in mature astrocytes of the nervous system. 
GFAP can also be found in other types of cells such as the glial cell of the 
digestive system, and the non-myelinating Schwann cells in the peripheral 
nervous system, which have similar function to those of astrocytes (Yang and 
Wang, 2015). GFAP has an important role in modulating the shape and motility 
of astrocytes by providing structural support for their processes (Eng et al., 
2000). Astrocytes can be activated in response to neuronal damage, brain injury, 
genetic disorder or neuronal toxicity in a process called reactive astrocytosis or 
astrogliosis. Increased astro-glial cells number and levels of GFAP expression 
were found to be the main characteristics of astrocytesʼ reaction to OP 
intoxication (O'Callaghan, 1988). During reactive astrogliosis, GFAP is 
responsible for the formation and extension of astrocytic processes. Earlier 
studies showed that generation of GFAP-deficient-mice was associated with 
neurological or behavioural abnormalities, abnormal myelination, and reduced 
myelin thickness in the spinal cord (Gomi et al., 1995, Liedtke et al., 1996). 
Other studies detected increased levels of GFAP in brains of humans suffering 
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from neurodegenerative conditions such as Alzheimer and Parkinson’s disease 
(Zhang et al., 2014). These data suggest that GFAP could be a useful protein 
marker of neurological pathophysiology (Liu et al., 2012).   
During brain development, increased expression of GFAP is an indication of 
glial differentiation from neural precursor cells into astrocytes, which usually 
reaches a peak at the second and third postnatal week. Thus, GFAP has also been 
recognised as a biomarker for astrocyte differentiation (Bramanti et al., 2010). 
Since glial development continues into adolescence, effects on developing glia 
during postnatal development due to CPF and CPO exposure could contribute to 
developmental neurotoxicity. Garcia et al. (2002) showed that subcutaneous 
administration of CPF for 4 days to developing rats at the peak of gliogenesis 
and glial differentiation results in decreased GFAP levels (Garcia et al., 2002). 
Similar findings were also observed in cultures of differentiating rat C6 glioma 
cells, when treated with sub-cytotoxic concentrations (1-10 µM) of DZO for 24 
h. The decreased GFAP expression level obtained in the previous study is 
indicative of OP direct injury on astro-glial cells (Sidiropoulou et al., 2009b). 
 
1.5.2.1.3  Microfilaments 
Microfilaments (MFs) are another class of cytoskeletal network; they are 
composed of actin protein with a molecular weight of approximately 43 kDa. 
MFs are formed by polymerisation of two globular strands of actin monomers 
(G-actin) twisted around each other like strings of pearls to form F-actin, through 
the binding of adenosine triphosphate (ATP) (Theriot, 1994, Hargreaves, 1997). 
Thus, F-actin is formed by the addition of G-actin monomers at the positive end 
of F-actin (Hargreaves, 1997). Actin is found in all glial and neuronal cells and 
enriched in presynaptic terminals, dendritic processes and growth cones 
(Kuczmarski and Rosenbaum, 1979). Actin filaments are relatively thin and 
short in length in all regions of the neuron. However, MFs are more prominent 
and much longer in the axonal branching lamellipodia and particularly in the 
filopodia of the growth cone (Pak et al., 2008, Lowery and Van Vactor, 2009). 
The growth cone is a highly motile structure that explores the extracellular 
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environment, determines the direction of growth, and then guides the extension 
of the axon in that direction. The main morphological elements of growth cones 
are lamellipodia and filopodia, which are sheet-like and finger-like protrusions, 
respectively. They are rapidly formed and later disappear from the terminal tip. 
Such movements reflect rapid, controlled rearrangement of MFs, which is 
thought to be involved in the control of axonal path finding (Cooper, 2011).  
During neuronal development, actin filaments are dynamic and undergo rapid 
assembly-disassembly cycles that enable the filopodia to extend towards and 
retract from the growth direction (Cooper and Hausman, 2000). The bundles of 
MFs in growth cone projections together with the associated actin network are 
thought to be involved in growth cone movement, myelination and cell migration 
(Sobue, 1993). MF dynamics occur through the incorporation and release of (i.e. 
the exchange) of actin monomers (G-actin) at the ends of the polymer (Zhang et 
al., 2005). This process is regulated by ATP hydrolysis and the interaction with 
actin binding protein such as growth associated protein-43 (GAP-43) and actin 
depolymerizing factor (ADF)/cofilin (McGough and Chiu, 1999). It has been 
proposed that disturbing MF regulation may be one additional target of OPs. In 
this context, Harris et al. (2009) found increased levels of cofilin in N2a cells 
induced to differentiate for 24 h in the presence of 10 µM diazinon (DZ). The 
observed alterations in the levels of cofilin might suggest a disruption in the MF 
dynamic and polymerization as well as organization of MF network (Harris et 
al., 2009b). Changes in this actin-binding protein could also disrupt the ability of 
cofilin to regulate growth cone motility and neurite outgrowth (Endo et al., 
2003).  
Other studies hypothesised that GAP-43 is another protein that plays an 
important role in the regulation of neurite outgrowth (Skene, 1989, Pekiner et al., 
1996). GAP-43 is found prominently in the growth cones and elongating axons 
in the neurons (Das et al., 2004). During neurodevelopment, GAP-43 regulates 
the formation of growth cones, interferes with the development of axons, and is 
involved in the plasticity of the synapse (Benowitz and Routtenberg, 1997). It 
has been demonstrated that GAP-43 synthesis is elevated during axonal 
outgrowth (Skene, 1989, Pekiner et al., 1996), and thus, inhibition of neurite 
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outgrowth could be reflected by altered expression level of GAP-43 (Das et al., 
2004).  
Exposure of differentiating N2a cells to neurite inhibitory concentrtaions of CPF, 
CPO and other OPs have been associated with reduced levels of GAP-43 
(Fowler et al., 2001, Sachana et al., 2001, Sachana et al., 2003, Sachana et al., 
2005, Sidiropoulou et al., 2009a, Flaskos et al., 2011). The findings of the 
previous studies indicated that disturbance in the levels of GAP-43 synthesis 
might possibly affect the transport of this protein to axon and dendrites from the 
cell body. Thus, GAP-43 could be a common molecular marker of OPs-induced 
neurite outgrowth inhibition (Sachana et al., 2005).  
 
1.5.2.2 Cell signalling pathway involved in neurite outgrowth 
The complex developmental processes of the nervous system are dependent on 
precisely controlled activation or inactivation of several signal transduction 
pathways (Bertrand et al., 2002). Mitogen activated protein kinases (MAPKs) are 
key signalling pathways that functionally regulate neural cell proliferation, 
differentiation, mitosis, survival and apoptosis (Perron and Bixby, 1999). 
MAPKs are serine/threonine kinases, which activated by extracellular stimuli 
such as OP exposure, osmotic stress or heat shock (Widmann et al., 1999). 
MAPK activation is dependent on a series of phosphorylation events at both 
threonine and tyrosine residues, whereas MAPK inactivation is mediated by a 
number of phosphatases that have the ability to hydrolyse the phosphate group 
and reduce the MAPK activity (Shaw and Filbert, 2009).  
In mammals, MAPK pathway is consists of three main signalling modules 
include the extracellular-signal regulated kinases (ERK1/2), the stress-activated 
protein kinases p38, and the JUN N-terminal kinases (JNK) (Chang and Karin, 
2001). Each MAPK signalling group is composed of three acting kinases: a 
MAPK, a MAPK kinase (MAPKK) and a MAPK kinase kinase (MAPKKK). 
MAPKKKs are phosphorylated and activated by MAPKK, which in turn 
phosphorylate and activate MAPKs (Figure 1.7). MAPKKKs activation occurs 
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through phosphorylation of Ser/Thr residues and/or interaction with small G-
protein such as Ras in response to extracellular stimuli (Cargnello and Roux, 
2011).  
The two MAPK pathways p38 and JNK activation have been linked to apoptotic 
cell death (Wang et al., 1998). They are responsive to cellular stress that could be 
induced by stress stimuli such as, inflammatory cytokines or heat shock. In the 
signalling cascades of JNK and p38, each MAPKK can be activated by multiple 
MAPKKKs for instance, MEK3 and MEK6 activates the p38 pathway whereas 
MEK4 and MEK7 activate the JNK pathway (Figure 1.7) (Robinson and Cobb, 
1997). 
ERK1/2 are among the most extensively studied kinases of the MAPK pathway 
and the MAPKs of interest in this thesis. ERK1 was first cloned in 1990s and 
consider one of the well characterised MAPK in mammals (Boulton et al., 1991). 
It was initially found to be phosphorylated at tyrosine and threonine residues in 
response to growth factors (Cooper et al., 1982). ERK1/2 have similar amino 
acid identity and are highly expressed in neurons in the mature nervous system 
(Boulton et al., 1990). The ERK pathway is controlled by mitogen activated 
extracellular receptors and growth factors that stimulate neural cell proliferation 
and differentiation, and is suppressed in many events leading to apoptosis (Jin et 
al., 2002).  
ERK1/2 are activated by several growth factors such as nerve growth factor 
(NGF), and epidermal growth factor (EGF) (Boulton et al., 1991). Additionally, 
ERK1/2 are activated by cytokine receptors, osmotic stress, microtubule 
disorganisation, and G protein-coupled receptors such as kinase suppressor of 
Ras (KSR) (Raman et al., 2007). However, the main route of activation of 
ERK1/2 mainly occurs by cell surface receptor, such as tyrosine kinase 
receptors. In the ERK1/2 signalling cascade, the growth factor receptor-bound 
protein (Grb) links the tyrosine kinase receptor to guanine nucleotide exchange 
factors, such as son of sevenless (SOS), which are proteins that can activate the 
small GTPases. Then, the signal is transduced to the small GTP binding protein 
(Ras), activating Raf, which then acts as a MAPKKK. This, in turn, activates 
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MEK1/2 which acts as MAPKK, which finally activates the terminal ERK1/2 as 
MAPK (Figure 1.7) (Johnson and Lapadat, 2002). 
ERK1/2 can phosphorylate many neuronal proteins, such as NFH and other 
substrates (Shaul and Seger, 2007). In a previous study by Veeranna et al. (1998) 
it has been found ERK1/2 are capable of phosphorylating all types of KSP 
repeats in the C-terminal tail domains of NFH and NFM in rat brain. In the same 
study, it has also been demonstrated that inhibition of the ERK1/2 by MEK 
inhibitor (PD98059) caused a decrease in neurite length in primary culture of rat 
hippocampal cells (Veeranna et al., 1998). This implies that ERK1/2 may 
regulate the axonal cytoskeletal proteins involved in neurite outgrowth.   
Numerous in vitro studies have demonstrated the effect of CPF exposure on cell 
signalling cascades. Caughlan and colleagues (2004) showed that CPF at sub-
cholinergic levels induced apoptosis in rat cortical neurons by the activation of 
ERK1/2, JNK and p38 MAPK pathways. The authors also found that embryonic 
neuronal cells were more sensitive than postnatal cells, which indicate that CPF 
is able to disrupt the activities of MAPK families involved in neuronal cell 
development and survival (Caughlan et al., 2004). Consistent with this finding, 
increased activation of ERK1/2 was also observed in primary cultures of human 
astrocytes following CPF exposure (Mense et al., 2006). Moreover, in human 
neuroblastoma SH-SY5Y cells, CPF caused induction of JNK and p38 MAPK 
activation (Ki et al., 2013).   
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Figure 1.7. Schematic diagram of the MAPK signalling pathways. The general 
mitogen-activated protein kinase (MAPK) signalling cascade includes the activation of a 
MAPK kinase kinase (MAPKKK), which then activates a MAPK kinase (MAPKK), 
which activates the terminal MAPK. MAPK pathways consists of three main signalling 
modules include the extracellular-signal regulated kinases (ERK1/2), the stress-activated 
protein kinases p38, and the JUN N-terminal kinases (JNK). In the MAPK/ERK 
pathway, the exposure to CPF and the binding of ACh to muscarinic and nicotinic ACh 
receptors activates the small GTP binding proteins Ras activates Raf, which acts as a 
MAPKKK. This in turn, activates MEK1/2, which acts as a MAPKK, which finally 
activates the terminal ERK1/2 as MAPK. ERK1/2 are linked to cell development, while 
activation of p38 and JNK has been linked to cell apoptosis. In the signalling cascades of 
JNK and p38, each MAPKK can be activated by multiple MAPKKKs; for instance, 
MEK3/6 activates p38 pathway, whereas MEK4/7 activates the JNK pathway. 
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1.6 The use of in vitro mammalian cell models for 
assessment of CPF neurotoxicity 
The high ethical and economic impact, together with complex and time 
consuming processes associated with animal experiments for neurological 
purposes have prompted investigators to identify alternative methods that could 
be used for assessing both physiological and pathological processes. Hence, in 
vitro models provide invaluable assets and a simplified tool for studying the 
neurotoxicity of OP pesticides at both cellular and molecular levels (Silva et al., 
2006). The use of in vitro cell culture models for neurotoxicity assessment has 
some intrinsic limitations, such as diminished metabolic capability, lack of cell 
to cell interaction (e.g. between neurons and glial cells), and partial involvement 
of pharmacokinetic factors, which may not accurately determine the effective in 
vivo levels (Rice and Barone, 2000, Flaskos, 2012). However, these culture 
systems have many important advantages that make them appropriate approach 
in this project.  
First, mammalian cell lines have the ability to reproduce large numbers of 
homogenous cells by simple preparation. Second, they are easy to grow, store 
and maintain for an extended periods of time (Radio and Mundy, 2008, Flaskos, 
2012). Additionally, they enable the testing of CPF and CPO at different 
concentrations on neuronal and glial cells, separately. Moreover, they also permit 
the detection of cellular alterations as well as characterisation of molecular 
changes during a specific neurodevelopmental phase, such as neurite outgrowth. 
Furthermore, the differentiated neuronal cells that express the main 
morphological features of neurites including axons and dendrites make it 
possible to control the timing and onset of development and adjust the research 
method to the needs of the study (Banker and Goslin, 1998). This advantage has 
made numerous cell lines suitable models for high throughput screening. Neural 
stem cells derived from humans also provide the potential benefit of predicting 
the neurotoxicity of CPF and CPO in a more physiologically relevant cellular 
system. However, there is a lack of published work to show that stem cells 
derived from humans are able to predict human developmental neurotoxicity any 
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better than cell lines derived from rodents (Radio and Mundy, 2008). The two 
mammalian cell lines used in this thesis to investigate the developmental 
neurotoxicity of CPF and CPO are further described below.  
 
1.6.1 Mouse N2a neuroblastoma cell line 
The N2a cell line has been widely used as a model for the study of OP toxicity 
on neuronal differentiation and neurite outgrowth (Henschler et al., 1992, 
Flaskos et al., 1998, Sachana et al., 2001, Sachana et al., 2003, Sachana et al., 
2005, Hargreaves et al., 2006, Sidiropoulou et al., 2009a, Flaskos et al., 2011, 
Sachana et al., 2014). N2a cells were derived from the mouse C1300 tumor 
(neuroblastoma) and can differentiate into a neuron-like morphology that 
expresses AChE and many neuronal markers, including adrenergic and 
cholinergic markers (Klebe and Ruddle, 1969). In mitotic conditions, N2a cells 
grow as round neuroblasts. N2a cells are differentiated by removal of serum and 
the addition of dibutyryl cyclic 3', 5'-monophosphate (dbcAMP) in serum free 
medium. Serum withdrawal results in non-dividing differentiating cells that 
extend neurites with morphological characteristics of neurons, while dbcAMP 
promotes N2a cell differentiation by mimicking the action of cAMP. Once N2a 
cells are differentiated, they undergo several morphological changes. The most 
prominent change involves the formation of axon-like processes and dendrites, 
which is accompanied by the increased perikaryon and nucleus size (Haffke and 
Seeds, 1975). The neurites produced by N2a cells are rich in cytoskeletal 
proteins such as NFs and MTs (Schubert et al., 1969).  
 
One drawback of the N2a model is that axons and dendrites generated from this 
cell line may not replicate some of the complex characteristics of neurites 
observed in original primary neurons (Radio and Mundy, 2008). However, the 
ability of N2a cells to express NFs, MTs and AChE together with their 
commercial availability makes them an attractive model for screening CPF 
neurotoxicity on neurite outgrowth in this study.  
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1.6.2 Human neural stem cells (ReNcell CX) 
ReNcell CX is human neural progenitor cell line, which was isolated by the 
ReNeuron Group (Guildford, Surrey, UK). The cell line is available 
commercially (Merck Millipore) and has the ability for self-renewal and to 
produce a co-culture of neurons and glial cell types including oligodendrocytes 
and astrocytes (Seaberg and van der Kooy, 2003). ReNcell CX cells were 
derived from the cortical region of a 14-week gestation human foetal brain, 
which has a normal male karyotype. This cell line has been immortalized by 
retroviral transduction of the c-myc oncogene to produce unlimited clonal human 
neural stem cells (Donato et al., 2007, Kornblum, 2007). ReNcell CX cell 
morphology is that of typically round neurospheres in their undifferentiated state 
when grown in uncoated tissue culture flasks. However, when cultured as a 
monolayer on laminin coated surfaces in the presence of growth factors, the cell 
line maintains its normal diploid karyotype even after prolonged passage (Jakel 
et al., 2004). After removing mitogenic growth factors from the culture medium, 
neural progenitor stem cells migrate from the neurospheres onto a laminin coated 
surface, extracellular matrix (ECM) coating protein, and can be differentiated 
into a mixed population of three main cell types of the nervous system, including 
neurons, oligodendrocytes and astrocytes (Kornblum, 2007). These differentiated 
cells are identical to those detected in the human nervous system. In addition, 
unlike the N2a cell line, the axons and dendrites elaborated from differentiated 
neuronal stem cells have the same complexity of original neurons (Bal-Price et 
al., 2008, Radio and Mundy, 2008). Therefore, using the neural progenitor 
ReNcell CX cell line in the current thesis has enabled us to investigate the effects 
of CPF and its metabolite on cell differentiation in a more human relevant 
model. 
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1.7 Aims of the thesis 
There is considerable evidence that CPF insecticide and its oxon form CPO can 
inhibit the outgrowth of extensions and disrupt the levels of cytoskeletal proteins 
in differentiating neural cell lines. It is, however, known that the toxicity may 
depend on the developmental stage at which exposure occurs. The majority of 
previous in vitro studies have involved the administration of OPs at the same 
point of induction of cell differentiation. However, little was known about the 
effects of OPs on cells that have been committed to differentiation and have 
already elaborated neurites. Such a study was performed in the current work in 
order to make an original contribution to knowledge, as the toxic effects of these 
OPs were to be examined at developmental points other than those reported in 
previous work. 
 
Earlier studies by research colleagues had shown that exposing differentiating 
mouse N2a neuroblastoma cells to a sub-lethal concentration of CPF inhibited 
the outgrowth of axons (Sachana et al., 2001). By replicating the same culture 
conditions of the previous study, the aims of this thesis were to: 
 
1. Investigate the effects of a neurite inhibitory concentration of CPF and 
CPO on cell viability, AChE and neurite retraction in pre-differentiated 
N2a cells over a range of time points.  
2. Relate the effects on neurite maintenance to the levels of expression and 
activities of cytoskeletal and associated regulatory proteins in pre-
differentiated N2a cells using quantitative Western blotting. 
3. Evaluate the sensitivity of different parameters of neurite outgrowth (e.g. 
average cell number, average neurite number, average and maximum 
neurite length, mean processes and branches per cell) and the underlying 
effects on cytoskeletal proteins following exposure to range 
concentrations of both OPs by high content analysis and cell ELISA. 
4. Apply the same high throughput approaches to test the effects of both 
compounds in a human neural progenitor stem cell model using human 
ReNcell CX stem cells that form a co-culture of neuronal and glial cells.
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2 Materials and methods 
2.1 Materials 
2.1.1 Reagents 
All reagents used in the laboratory were of the highest grade and purchased from 
Sigma-Aldrich Chemical Company, Poole, UK, unless otherwise specified. They 
are listed in tables 2.1 and 2.2. 
 
Table 2.1. List of cell culture reagents 
 
Reagents Code Supplier 
Dulbecco’s Modified Eagles Medium (DMEM) with 
4.5g/L glucose and 2mM L-glutamine 
BE12-614F 
Lonza, UK 
Penicillin/streptomycin  
(Penicillin 5,000 units/ml, Streptomycin 5,000 units/ml) 
DE17-603E 
Foetal bovine serum (FBS) South American origin FB-1001 Biosera 
3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium 
bromide (MTT) 
M2128 
Sigma-Aldrich 
N
6
,2'-O-Dibutyryladenosine 3',5'-cyclic monophosphate 
sodium salt (dbcAMP) 
D0627 
Dimethylsulphoxide (DMSO) sterile-filtered hybridoma 
tested  
D2650 
Trypan blue solution 0.4% (w/v) T8154 
Laminin from Engelbreth-Holm-Swarm murine sarcoma 
basement membrane 
L2020 
L-glutamine   
 
Gibco, Life 
Technologies 
USA 
StemPro
® 
Accutase
® 
cell dissociation reagent A11105-01 
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StemPro
®
 Neural supplement A10508-01 
KnockOut™ DMEM/F-12 (1X) 12660-012 
Neurobasal
®
 -A medium, no L-glutamine, L-glutamic 
acid or aspartic acid 
10888-022 
Recombinant human EGF (10 µg) 1380077C 
Recombinant human FGFb (10 µg) 1424760B 
 
 
Table 2.2. List of other reagents and materials. 
 
Reagents Code Supplier 
3MM chromatography paper CJF240090 
Fisher 
Scientific 
3,3',5,5'-Tetramethylbenzidine (TMB)  
T0440 
Sigma-Aldrich 
3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium 
bromide (MTT) 
M2128 
5, 5 Dithiobis 2-nitrobenzoic acid (DTNB) D8130 
5-Carboxy fluorescein diacetate N-succinimidyl ester 
(CFSE) fluorescent cell staining dye 
87444 
AccuGel 29:1 acrylamide  
(40% (w/v) acrylamide/bisacrylamide 29:1) 
EC852 Geneflow 
Acetone 121403/0031 
Fisher 
Scientific 
Acetylthiocholine iodide (ATCh) A5751 Sigma-Aldrich 
Amersham Protran 0.2 μm pore size nitrocellulose 
membrane 
10600001 
General 
Electric 
Ammonium persulphate (APS) A3678 
Sigma-Aldrich 
Bicinchoninic acid (BCA) 23223 
Blueye prestained protein ladder  
(Approx. 0.1-0.4 mg/ml of proteins in buffer (20 mM 
Tris-phosphate pH 7.5, 2% w/v SDS, 0.2 mM 
dithiothreitol, 3.6 M urea and 15% (v/v) glycerol) 
PM007-0500 GeneDirex 
Bovine serum albumin (BSA) A1302 Melford 
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Bromophenol blue 18030 Fluka 
Copper (II) phthalocyanine C2284 Sigma-Aldrich 
Dimethylsulphoxide (DMSO) CHE1854 
Fisher 
Scientific 
Enhanced chemiluminescence reagent (ECL) ME157124 
Thermo 
Scientific 
Ethanol 101076H Fisher 
Scientific 
 Glacial acetic acid 200.580-7 
Glycerol 10% (v/v) 15892001C 
ACROS 
organics 
Hydrochloric acid H1000PB17 
Fisher 
Scientific 
Hydrogen peroxide (H2O2) H1009 
Sigma-Aldrich 
Iodoacetamide 1149 
Methanol M400/17 
Fisher 
Scientific 
β-Mercaptoethanol M3148 
Sigma-Aldrich 
Mineral oil EC2324558 
N,N,N,N-tetramethylethylene diamine (TEMED) EC503 
National 
diagnostic 
Paraformaldehyde 4% (w/v)   HT501128 
Sigma-Aldrich 
p-Nitrophenyl phosphate liquid substrate system SLBC2208V 
Protogel
® 
resolving buffer (4x) 
(1.5 M Tris-HCl buffer pH 8.8, 0.4% (w/v) SDS) 
EC892 
Geneflow 
Protogel
® 
stacking buffer (4x)   
(0.5 M Tris-HCl buffer pH 6.8, 0.4% (w/v) SDS) 
EC893 
Sodium acetate S2889 Sigma-Aldrich 
Sodium azide S2002 
Fisher 
Scientific 
Sodium chloride B22297 Sigma-Aldrich 
Sodium dodecyl sulphate (SDS) 18299 Melford 
Sodium hydroxide (NaOH) 1823 Sigma-Aldrich 
Sodium phosphate dibasic 94046 
Fisher 
Scientific 
Sodium phosphate monobasic 71505 
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Sulphuric acid (H2SO4) 339741 
Sigma-Aldrich 
Tris (hydroxymethyl) aminomethane C22561 
Triton X-100 T8787 
Tween 20 P1379 
Urea U6504 
VectaShield
®
 mounting medium for fluorescence 
containing 4',6-diamidino-2-phenylindole (DAPI) 
H1400 
Vector 
Laboratories 
Ltd 
 
2.1.2 Cell culture plastic-ware 
All sterile cell culture plastic ware were supplied by Scientific Laboratory 
Supplies (Nottingham, UK). Cryotube vials (Nunc brand products), were 
purchased from Merck Ltd. Leicester, UK. Disposable Haemocytometer C-Chip 
slides, were supplied by Labtech International Ltd, UK. Eight-well 15μ-slides for 
live cell analysis (IbiTreat), were purchased from Thistle Scientific, UK. Ninety 
six-well plates (NUNC-immuno plate), were purchased from Thermo Scientific, 
UK. 
 
2.1.3 Test compounds 
Chlorpyrifos and chlorpyrifos oxon (purity 97.6%) from Chem Service Inc. 
(West Chester, PA, USA), were supplied by Greyhound Chromatography 
(Birkenhead, UK). 
 
2.1.4 Cell lines 
2.1.4.1 Mouse N2a neuroblastoma cells 
Neuro 2A (N2a) is a neuroblastoma line derived from mouse neural crest. N2a is 
a well-established cell line and has widely been used to study neuronal 
differentiation, axonal outgrowth and cell signalling pathways (Ostrea et al., 
2002). It also has the ability to differentiate into neurons within a few days. It 
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was purchased from American Type Culture Collection (ATCC
® 
- product no. 
CCL-131™, Middlesex, UK). 
 
2.1.4.2 Human ReNcell CX  
ReNcell CX human neural progenitor cell line was derived from cortical brain 
tissue of a 14-week gestating human foetus following normal terminations and in 
accordance with nationally UK approved ethical and legal guidelines. It was 
purchased from Merck Millipore (MILLIPORE
®
 - catalogue no. SCC007, UK).  
 
 
2.2 Methods 
2.2.1 Mouse N2a neuroblastoma cells 
2.2.1.1 N2a cell maintenance 
Mouse N2a cells were grown and maintained as a monolayer in DMEM 
containing 4.5g/L glucose and 2 mM L-glutamine, and supplemented with 10% 
(v/v) FBS, penicillin (100 units/ml) and streptomycin (100 units/ml). Cells were 
incubated at 37°C in a humidified atmosphere of 95% air /5% CO2.  
 
Cells were passaged or sub-cultured when growth reached 70-80% confluence 
(i.e. every 3-5 days). On reaching 80% confluence, the cell cultures were either 
used to seed monolayers on cell culture plates for assays, T75 flasks for Western 
blot analysis or passaged to maintain the cell line.  
 
2.2.1.2 N2a cell restoration from liquid nitrogen storage 
When it was needed to perform experiments, a vial of frozen cells was removed 
from liquid nitrogen storage and thawed quickly by incubation in a 37
o
C water 
bath for 2 min. The outside of the vial was sterilised with 70% (v/v) ethanol. The 
contents were diluted with 1 ml of pre warmed fresh growth medium and then 
rapidly transferred into a Sterlin tube containing 9 ml of pre warmed fresh 
growth medium. The Sterlin tube was then centrifuged at 300 g for 5 min and the 
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supernatant was decanted to remove any residual cryopreservation medium 
(DMEM containing 5% (v/v) DMSO as a cryopreservation agent). The resultant 
cell pellet was resuspended in 1 ml of pre warmed growth medium and mixed 
gently by slow pipetting up and down before being transferred into a T25 flask 
containing 10 ml of fresh growth medium. Cells were allowed to recover for 24 h 
at 37
o
C in a humidified atmosphere of 95% air/5% CO2, after which the medium 
was changed. They were then cultured until the growth reached 60-80% 
confluence. Upon reaching 80% confluence, cells were passaged and transferred 
into T75 flasks and cultured until ready for experimental use. 
 
2.2.1.3 N2a cell culture 
To passage the cell cultures, half of the growth medium was carefully poured off 
the flask into a waste beaker without disturbing the attached cell monolayer. 
Cells were mechanically removed from the flask surface using a sterile Pasteur 
pipette to detach the cells by aspirating growth medium and squirting it out on 
the monolayer surface of the cell culture flask. Cell suspensions were then 
transferred into Sterilin tubes and harvested by centrifugation at 300 g at room 
temperature for 5 min. The supernatant was carefully discarded and the resultant 
pellet was resuspended in 1 ml of growth medium by passing the cell suspension 
several times through a 1000 µl Gilson pipette to break up the pellet. Using a 
Pasteur pipette, three to four drops of cell suspension were placed in a T75 flask 
containing 40 ml of fresh growth medium. In the case of T25 flasks, one to two 
drops were transferred in 10 ml of growth medium. Cells were incubated at 37°C 
in a humidified atmosphere of 95% air/5% CO2 and kept until the monolayer 
became 80% confluent. Only cells that had not yet reached passage number 20 
were used in differentiation experiments because later passages are more 
susceptible to genetic drift. 
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2.2.2 Human neural ReNcell CX stem cells 
2.2.2.1 Preparation of coated cell culture ware 
All tissue culture flasks, plates or other plastic ware that were used to culture 
ReNcell CX cells were coated with laminin for 24 h before the day that cells 
needed to be seeded. Laminin is an ECM protein, which supports and enhances 
neural progenitor stem cell adhesion, proliferation, differentiation and neurite 
elongation (Flanagan et al., 2006). For coating, 1mg/ml laminin from 
Engelbreth-Holm-Swarm murine sarcoma basement membrane (Sigma–Aldrich) 
was thawed at room temperature before use. Laminin was diluted to 20 μg/ml 
final concentration in Neurobasal
®
 medium (Gibco) that contained no L-
glutamine, L-glutamic acid, or aspartic acid. Laminin solution was added to 
cover the surface of the required tissue culture vessel. A five ml volume of this 
solution was used to coat a T75 flask and 2 ml volume for a T25 flask. Coated 
flasks were incubated at 37°C in a 5% CO2 incubator for at least 4 h if these 
flasks were going to be used on the same day that cells needed to be passaged; 
otherwise, coated flasks were stored at 4°C for 24 h or until needed. Just before 
using a coated flask for culturing ReNcell CX cells, the laminin solution was 
aspirated and flasks rinsed once with sterile PBS. 
 
2.2.2.2 Preparation of ReNcell CX maintenance medium 
ReNcell CX cells were maintained in KnockOut™ DMEM: nutrient mixture F-
12 (DMEM/F-12) low osmolality medium without HEPES buffer. The medium 
(500 ml) was supplemented with recombinant human epidermal growth factor 
(EGF) (20 ng/ml; Gibco), basic fibroblast growth factor (FGFb) (20 ng/ml; 
Gibco), StemPro
® 
neural supplement (2% by volume; Gibco), L-glutamine (0.5 
mM), penicillin (100 units/ml) and streptomycin (100 units/ml). 
 
2.2.2.3 ReNcell CX cell restoration from liquid nitrogen storage 
Cells were thawed from the liquid nitrogen when a coated laminin flask was 
ready to be used. A vial of ReNcell CX cells was removed from the liquid 
nitrogen storage and incubated in a 37
o
C water bath for 1 or 2 min until it 
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completely thawed. The outside of the vial was wiped with 70% ethanol to 
sterilise and the cells were transferred into a Sterilin tube using a 2 ml sterile 
pipette. After the cells had been transferred into the tube, 9 ml of maintenance 
medium (pre warmed to 37
o
C) were immediately added drop by drop to avoid 
osmotic shock that may result in decreased cell viability. The cell suspension 
was gently mixed by slow pipetting up and down with 1000 µl Gilson pipette 
and centrifuged at 300 g for 5 min. Following centrifugation, the supernatant was 
decanted completely to remove any residual cryopreservation medium 
(KnockOut™ DMEM/F-12 medium containing 5% (v/v) DMSO), and the 
resultant pellet was resuspended in 1 ml of pre warmed maintenance medium. 
The cell suspension was then plated onto a laminin coated T75 flask containing 
10 ml of fresh maintenance medium. Cells were allowed to recover for 24 h in a 
humidified atmosphere of 95% air/5% CO2 until the cells were approximately 
80% confluent and the medium was changed every 48 h. Upon reaching 80% 
confluence, cells were passaged or cryopreserved for later use. 
 
2.2.2.4 Culturing of ReNcell CX cells 
ReNcell CX cells were passaged or subcultured by carefully removing the 
maintenance medium from the coated flask and rinsing the detached monolayers 
with pre warmed PBS. After that, the PBS was aspirated and 1-2 ml of accutase 
(Gibco) were applied according to the size of flask (1 ml for T25 and 2 ml for 
T75 flasks) to dissociate the cells. Accutase was pre warmed at room 
temperature before use. Flasks were then immediately incubated for 2 min in a 
37°C incubator and the flask was gently tapped as cell detachment was 
monitored using a microscope. Without removing the accutase, fresh 
KnockOut™ DMEM/F-12 maintenance medium was added in the proportion of 
twice the volume of accutase to stop its activity, and the cell suspension was 
transferred into a Sterilin tube and centrifuged for 5 min at 300 × g at room 
temperature. The resultant pellet was resuspended in 1 ml of maintenance 
medium by pipetting gently back and forth to break up the pellet. Using a Pasteur 
pipette, three to four drops of cell suspension were placed in a laminin coated 
T25 flask containing 5 ml of maintenance medium. Cells were incubated at 37°C 
in a humidified atmosphere of 95% air/5% CO2 and monitored until they reached 
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70-80% confluence. For all experiments conducted in this study, ReNcell CX 
cells lower than passage 15 were used to reduce the possibility of changing cell 
features. 
 
2.2.3 Seeding and counting of cells for experiments 
To seed the cells, cell monolayers were grown to reach 60-80% confluence, then 
detached and harvested by centrifugation at 300 g for 5 min as described in 
sections 2.2.1.3 and 2.2.2.4. Cell pellets were resuspended in 1 ml of growth 
medium. Cell dilutions were then prepared and cells were counted either 
manually using a haemocytometer, or automatically using an automated cell 
counter. 
 
2.2.3.1 Manual cell counting 
Cell counting using a haemocytometer was firstly developed for the quantitation 
of blood cells but then became a common and effective tool for counting a 
variety of other cell types. However, it can be a time consuming operation and 
may result in poor counting due to low sample concentration or device misuse. 
Manual cell counting was used initially for N2a cells only. To seed the cells and 
count them manually, a 1 in 20 dilution of N2a cell suspension was prepared by 
mixing 10 μl of N2a cell suspension with 190 μl of fresh growth medium in an 
Eppendorf tube. A volume of 10 μl of cell dilution was loaded into the chamber 
of a disposable haemocytometer (Labtech International Ltd, UK) (0.1 mm depth 
under the coverslip) where cells in five squares (four corners and one centre) of 1 
mm
2
 each were counted at 100× magnification. Since each square is 1×1 mm and 
the depth is 0.1 mm, the volume correction factor for the haemocytometer is 10
4
. 
The average cell number per ml was calculated according to the following 
calculations: 
Cells/ml = average count per square × dilution factor × 10
4
 
Total cells = cells/ml × total original volume of cell suspension from which the 
sample was taken. 
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N2a cells were then seeded in new flasks/plates to yield a cell density of 50,000 
cells/ml medium and allowed to recover before treatments for 24 h at 37
o
C in a 
humidified atmosphere of 95% air/ 5% CO2 (Table 2.3). 
 
2.2.3.2 Automated cell counting 
Over recent years, automated cell counting has become the robust alternative 
process to manual haemocytometer cell counting as it can provide a total cell 
count in a fraction of the time. In addition to the rapid performance, automated 
cell counting produces an accurate, reproducible result and assesses cell viability 
in a single step. A TC20 automated cell counter (BioRad, USA) was used in this 
study. The device utilised already prepared TC20 Trypan blue dye, which was 
composed of 0.4% Trypan blue (w/v) in 0.81% (w/v) sodium chloride and 0.06% 
(w/v) potassium phosphate dibasic solution. Trypan blue is a vital stain that 
differentiates between live and dead cells. The principle of this dye is based on 
the blue acid dye chromophores which react and are taken up by the internal 
region of dead (non-viable) cells through a damaged membrane, whereas live 
(viable) cells do not take up this dye. 
 
For this, 10 μl of cell suspension were added to10 μl of Trypan blue solution in a 
test tube. The tube was thoroughly mixed by pipetting and left to stand for 4 min 
to allow for cells to be exposed to the stain. A volume of 10 μl of this mixture 
was then loaded by pipette tip into a chamber of the counting slide. The slide 
was inserted into the slide slot of the TC20 cell counter and cell counting was 
automatically initiated as soon as the cell counter detected the presence of the 
slide and Trypan blue dye. When Trypan blue was detected in a sample, the 
result was adjusted to account for the 1 to 1 cell dilution. For example, a 1 × 10
6 
cells/ml mixed 1 to 1 with Trypan blue was at a concentration of 5 × 10
5 
cells/ml. 
The TC20 takes the dilution into account and multiplies results by 2. The result 
was reported on the monitor as the estimated concentration of the undiluted 
sample: 1 × 10
6 
cells/ml. The percentage of live cells
 
also appears on the count 
screen. Once the cell counter completed the cell count, the slide was removed 
from the slide slot and screen returned to home mode ready for another slide. 
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Cell counts per ml were used to determine the volume necessary to seed the cells 
at a required cell density in growth medium. Cell density of 50,000 cells/ml was 
used to plate out mouse N2a cells and 100,000 cells/ml was used for ReNcell CX 
cells (Table 2.3). Flasks were then incubated at 37
o
C in a humidified atmosphere 
of 95% air/5% CO2 for 24 h to allow for cell recovery. 
 
 
Table 2.3. Loading cell density for experiments with N2a and ReNcell CX cells. 
 
Type of cell 
culture ware 
N2a ReNcell CX 
Loading 
volume 
Total cells 
number 
Loading 
volume 
Total cells 
number 
T75 flask 40 ml/flask 2,000,000 10 ml/flask 1,000,000 
T25 flask 10 ml/flask 500,000 5 ml/flask 500,000 
8 well slide 300 µl/well 15,000 200 µl/well 20,000 
24 well plate 500 µl/well 25,000 300 µl/well 30,000 
96 well plate 200 µl/well 10,000 200 µl/well 20,000 
 
 
 
2.2.4 Induction of cell differentiation 
Prior to the induction of N2a or ReNcell CX cell differentiation, mitotic cell 
monolayers were detached at 70-80% confluence and harvested by centrifugation 
as previously described in sections 2.2.1.3 and 2.2.2.4. Cell pellets were 
resuspended in 1 ml of DMEM (N2a) or KnockOut™ DMEM/F-12 medium 
(ReNcell CX) and cell density was plated out at 50,000 cell/ml for N2a or 
100,000 cells/ml for ReNcell CX according to the required size of flask. Each 
cell type was maintained at 37
o
C in a humidified atmosphere of 95% air/5% CO2 
for 24 h to allow for cell recovery. The growth medium was then carefully 
removed by aspiration from the edge of the culture-ware to avoid disturbing the 
attached cells. ReNcell CX differentiation was initiated by replacing the 
maintenance culture medium with mitogen free medium. The Removal of growth 
factors EGF and FGFb from the maintenance culture medium induces ReNcell 
CX cells differentiate by stopping cell proliferation. N2a cell differentiation was 
induced by replacing growth medium with serum free medium (i.e. growth 
medium minus FBS) containing 0.3 mM dibutyryl cyclic adenosine 
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monophosphate (dbcAMP). The addition of dbcAMP to serum free medium 
induces N2a cell differentiation by decreasing cell division and increasing 
intracellular cAMP, which stimulate the development of axon-like neurites 
(Prashad and Rosenberg, 1978). 
 
For this, dbcAMP was dissolved in sterile-filtered serum free medium from a 
stock solution 30 mM. The final concentration of 0.3 mM dbcAMP was given by 
adding 100 μl of stock solution to 10 ml of serum free medium. Both cell lines 
were induced to differentiate at 37
o
C in an atmosphere of 5% CO2, 95% air for 
20 h before being treated with or without the test OP compounds. 
 
 
2.2.5 Exposure of cells to organophosphate compounds 
CPF and CPO were prepared as 200-fold concentrated stock solutions in DMSO 
and added to the serum free medium immediately before use. Controls cells were 
treated with serum free medium containing the same concentration of DMSO 
0.5% (v/v). Both compounds were dissolved in DMSO as it provides rapid and 
complete absorption. 
 
Following induction of N2a cell differentiation, serum free medium was 
removed and replaced with an equal volume of fresh serum free medium 
containing 0.3 mM dbcAMP and various concentrations of OP compounds (1, 3 
and 10 μM final concentrations). Control cells were incubated with the same 
amount of serum free medium containing 0.3 mM dbcAMP and an appropriate 
volume of DMSO (final concentration 0.5% v/v). Cells were returned to the CO2 
incubator and exposed to the toxins for a further 2, 4 or 8 h, after which cell 
pellets or lysates were prepared according to the required assay. 
 
Similarly, ReNcell CX cells were induced to differentiate by withdrawing the 
growth factors EGF and FGFb from the maintenance medium and again various 
concentrations of test OP compounds were added to the medium just prior to its 
addition to the cells. Plates were then incubated at 37
o
C incubator for the 
required exposure time. 
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The 3 μM final concentration of both OP compounds was chosen for initial work 
on the basis that it was a sub-cytotoxic axon outgrowth inhibitory level towards 
differentiating N2a cells, as determined by a previous group study (Sachana et 
al., 2001). 
 
2.2.6 Cryopreservation of cell lines 
In order to store and preserve the cells for long term use, cells were stored in 
liquid nitrogen cryovessel until needed. Briefly, the contents of a T25 flask of 
confluent cells were detached, harvested and resuspended in 1 ml of freezing 
medium (DMEM for N2a or knockout DMEM/F-12 medium for ReNcell CX, 
supplemented with 5% (v/v) DMSO). This cell suspension was placed into 1 ml 
cryo vials and lagged in tissue paper before being incubated overnight at -80
o
C 
for a minimum of 8 h. The cryo vials were then transferred to a liquid nitrogen 
container (-196
o
C) and stored until needed.  
 
The two step freezing method is carried out instead of immersing the warm cell 
sample directly into liquid nitrogen to reduce the effects of forming a gaseous 
nitrogen layer (Leidenfrost effects), which limits heat transfer (Gottfried et al., 
1966). 
 
2.2.7 Cell viability assessment 
Measurement of cell viability is considered the cornerstone for the most in vitro 
studies of cellular response to toxic agents. The effects of CPF and CPO on the 
viability of N2a cells were determined by the MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5 diphenyltetrazolium bromide) reduction assay, which was first described 
by Mosmann (1983). MTT is a colorimetric assay based on the ability of cellular 
dehydrogenase enzymes (mainly succinate dehydrogenase) from viable cells to 
cleave the tetrazolium rings of the pale yellow MTT and form purple formazan 
crystals. These crystals are largely impermeable to the cell membrane resulting 
in their accumulation within healthy cells. Solubilisation of the crystals by the 
addition of DMSO results in their liberation, which can be detected using a 
spectrophotometer. The ability of the cells to reduce MTT provides an indication 
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of metabolic activity, as the quantified level of the formazan product is directly 
proportional to the number of surviving cells. This in turn may be interpreted as 
a measure of cell viability. 
 
The MTT approach is safe, sensitive, easy to perform and provides rapid 
measurement. Moreover, its reagent yields stable colour and low background 
absorbance value in the absence of cells. Additionally, there is a linear 
relationship between MTT absorbance and cell number, which allow for an 
accurate quantification of changes in cell growth. Therefore, it is widely 
accepted among toxicity studies and considered as a reliable tool to determine 
cell viability (Mosmann, 1983). 
 
2.2.7.1 Preparation of buffers and reagents 
2.2.7.1.1  Phosphate buffered saline (PBS)  
The buffer was prepared in a total volume of 1 L containing 137 mM NaCl, 2.7 
mM KCl, 8.1 mM Na2HPO4, 2 mM KH2PO4 at pH 7.4. 
 
2.2.7.1.2  (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) 
MTT  
This was prepared by dissolving 5 mg of MTT per ml of PBS. Aliquots (1 ml) 
were stored frozen at -20 ºC until required. 
 
2.2.7.2 Assay protocol 
Cells were plated out at the required density in Corning 24 well plates and grown 
for 24 h in growth medium prior to the induction of cell differentiation. 
Differentiating cells were treated without or with different concentrations of CPF 
or CPO (1, 3, 10 μM) for 2, 4 or 8 h as described in sections 2.2.1.3, 2.2.3, 2.2.4 
and 2.2.5. Thirty minutes prior to the end of the experimental incubation time, a 
volume of 50 μl MTT was added to each well and cells were incubated at 37oC. 
After 30 min, serum free medium was then aspirated from the wells and 500 μl 
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of DMSO were added to each well. Treatment of the cell monolayers with 
DMSO results in the liberation of blue, water-insoluble formazan crystals. The 
plate was then agitated to dissolve this product completely. A total of 200 μl of 
each of the resulting solutions was transferred into a 96-well plate and the 
absorbance was read at a wavelength of 570 nm using a microplate reader 
(ASYS Expert 96, Biochrom, UK). The absorbance then expressed as a 
percentage of MTT reduction for the corresponding control. 
 
 
2.2.8 Measurement of N2a cell differentiation 
Differentiation of N2a cells was assessed using the 5-carboxyfluorescein 
diacetate N-succinimidyl ester (CFSE) fluorescent cell staining dye. The cell 
labelling marker has been used in a wide variety of different experimental 
applications, such as monitoring lymphocytes and bacterial proliferation, cell 
migration and tracking fibroblast division (Hoefel et al., 2003, Li et al., 2003). In 
this study, CFSE labelling was used as a new research tool for the detection of 
the neurotoxic effects of CPF and CPO on N2a cell differentiation. 
 
Visualisation of cells with fluorescent esterase substrate provides an alternative 
to Coomassie Brilliant Blue (CBB) staining, which has long been utilised in 
determination of cell differentiation (Flaskos et al., 1998, Flaskos et al., 1999, 
Sachana et al., 2001, Sachana et al., 2003, Sachana et al., 2005, Hargreaves et al., 
2006, Flaskos et al., 2007). The non-fluorescent molecules of the succinimidyl 
ester pass into viable cells through cell membranes and become converted by 
intracellular non-specific esterases into fluorescent products. This fluorescein 
derived from CFSE covalently binds to cellular components and retained inside 
the cells for several weeks. Once the cells were labelled with this dye, 
differentiated cells were monitored for the presence of neurites using 
epifluorescence or confocal microscopy. Not only is CFSE highly specific, stable 
and more sensitive than CBB, it can also provide a useful marker for visual 
identification of both fixed and living cells (Garton and Schoenwolf, 1996). 
Furthermore, CFSE dye can be used for both in vitro and in vivo experiments 
(Lyons, 1999). The only drawback of CFSE is that it can be toxic to cells at high 
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concentration. However, this problem can be eliminated by determining the 
optimum loading time and concentration of the dye, which does not affect the 
normal functions of cells and yields a good fluorescent stain (Parish, 1999).    
 
2.2.8.1 Preparation of reagents 
2.2.8.1.1 5-carboxyfluorescein diacetate N-succinimidyl ester (CFSE) 
This was prepared by dissolving 50 mM CFSE stock into 0.5% (v/v) DMSO to 
give a total volume of 1 ml. 
 
2.2.8.2 Determination of optimum concentration of CFSE 
Working stock concentrations of CFSE were prepared in 0.5% (v/v) DMSO (20 
mM, 2 mM, 0.2 mM, 0.02 mM and 0.002 mM). After N2a cells were harvested 
and resuspended in 1ml of growth medium, they were loaded in a Corning 24 
well plate. The plate was incubated at 37C for 24 h and induced to differentiate 
for 20 h as previously described in section 2.2.4. The different stock 
concentrations of CFSE in 0.5% (v/v) DMSO were applied directly to each well 
at 1 to 200 dilution (5 μl/ml) to give final concentrations of (100 µM, 10 µM, 1 
µM, 100 nM, 10 nM) and re-incubated for 10 min at 37C.  Medium including 
the dye was then removed and the cell monolayer rinsed with fresh pre warmed 
serum free medium. To check the health status of differentiated cells following 
exposure to the dye, a MTT reduction assay was performed. The optimal 
concentration of CFSE was chosen on the basis that this level was not considered 
to be cytotoxic towards differentiated cells, as determined by MTT reduction 
assay (see section 2.2.7). 
 
2.2.8.3 Staining of cells with CFSE dye 
N2a cells were seeded into an 8-well cell culture slide at an original density of 
50,000 cells/ml and induced to differentiate for 20 h as indicated in sections 
2.2.1.3, 2.2.3 and 2.2.4. They were then incubated for 10 min with the optimum 
concentration of CFSE dye (10 μM) in pre warmed sterile PBS, before being 
incubated for 2, 4 or 8 h in the presence and absence of 1, 3 or 10 μM CPF or 
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CPO at 37°C. After the required length of toxin exposure, cells were fixed for 15 
min at room temperature in pre warmed 4% (w/v) paraformaldehyde followed by 
three 10-min washes in PBS. Cells were then mounted under glass cover slips 
using VectaShield mounting medium for fluorescence and viewed using an 
Olympus DP71 epifluorescence microscope. CFSE was excited with 488 nm 
fluorescein isothiocyanate (FITC) laser-line and emitted in green. From each 
well, five random fields were selected giving a total cell count of 200-300 
cells/well. In each well, the total number of axon-like processes, which are 
defined as extensions greater than two cell body diameters in length with an 
extension foot (Keilbaugh et al., 1991), were recorded and the mean number of 
axon-like processes per 100 cells was calculated (Flaskos et al., 1998). 
 
 
2.2.9 Acetylcholinesterase activity assay 
Measurement of AChE activity is routinely evaluated in cultured cell lines that 
are used to model the mechanisms associated with OP neurotoxicity in in vitro 
studies (Flaskos et al., 1994). Inhibition of the enzymatic activity of AChE by 
OPs is one of the proposed mechanisms underlying the effects on neurite 
outgrowth. The screening assay is extremely sensitive and suitable for the 
detection of the enzymatic activity of AChE in a small number of cells (Ellman 
et al., 1961). The activity of AChE enzyme in cells exposed to OP compounds 
was measured in a spectrophotometric assay developed by Ellman and 
colleagues in (1961). The method is based on the production of thiocholine by 
the action of AChE on acetylthiocholine, which forms a yellow coloured product 
with 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB). This colour intensity can be 
measured at 412 nm and it is proportional to the enzyme activity in the sample. 
 
Acetylthiocholine      AChE           thiocholine + acetic acid 
Thiocholine   +DTNB          yellow product 
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2.2.9.1 Preparation of reagents 
2.2.9.1.1 Acetylthiocholine iodide (ATCh) 
The substrate was prepared in a total volume of 20 ml containing 1.25mM ATCh 
and 200mM sodium phosphate buffer at pH 7.4 and kept on ice until required. 
 
2.2.9.1.2 5,5-dithiobis (2-nitrobenzoic acid) (DTNB)  
This reagent was freshly prepared in a total volume of 20 ml containing 1.25 mM 
DNTB and 200 mM sodium phosphate buffer at pH 7.4 and kept on ice until 
required. 
 
2.2.9.1.3 Sodium phosphate buffer  
The buffer was prepared in a total volume of 200 ml containing 200 mM sodium 
phosphate (monobasic) and 200 mM sodium phosphate (dibasic) at pH7.4. 
 
2.2.9.2 Assay protocol 
Cells were plated out at the required density in T75 or T25 culture flasks and 
cultured for 24 h prior to the induction of cell differentiation. Differentiating 
cells were treated with different concentrations of CPF or CPO (1, 3, 10 μM) for 
the required length of time as described in sections 2.2.1.3, 2.2.3, 2.2.4 and 2.2.5. 
Harvested cells were then, resuspended in 1 ml of ice cold PBS at 4°C and 
transferred into a micro centrifuge tube. Cells were micro-centrifuged at 10,000 
g for 3 min to remove traces of culture medium. PBS was then carefully removed 
from the micro centrifuge tube and cell pellets were resuspended in 1 ml of ice 
cold 200 mM sodium phosphate buffer (pH 7.4) containing 0.1% (v/v) Triton 
X100 at 4°C.  
 
A volume of 100 μl of the cell lysate was transferred into a 96-well plate in 4 
replicates. Then, 100 μl of a 1:1 mixture containing ATCh substrate and the 
colour indicator DTNB were added to each well. The activity of AChE in N2a 
cells was determined in each sample. Absorbance was immediately measured at 
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412 nm and recorded at 1 minute intervals for a total of 10 min at 25°C using a 
microplate reader (ASYS Expert 96, Biochrom, UK). The absorbance in blank 
wells (with the assay buffer only) was used as a control, and subtracted from the 
values for those wells with the AChE reactions. As the absorbance background 
was increasing with time, the absorbance intensity value of the blank wells was 
subtracted for each data point. 
 
The amount of protein was determined in the remaining cell extract by the 
bicinchoninic acid (BCA) assay as described in section 2.2.11. BSA protein 
standards were prepared in a range of 0-2 mg/ml in the same assay buffer 
(sodium phosphate buffer) as that used to lyse the cell pellets (Table 2.5). AChE 
data were plotted as absorbance at 412 nm vs. time in minutes. Specific activity 
of AChE (Absorbance change/min/mg protein) was expressed as a percentage of 
the corresponding control value ± SEM. 
 
 
2.2.10 Phosphatase assay 
The activity of alkaline phosphatase (ALP) was detected using para-Nitrophenyl 
Phosphate (pNPP) liquid substrate system (Sigma). The assay principle utilises 
pNPP that turns into a yellow coloured product (maximal absorbance at 405 nm) 
when hydrolysed by ALP. The rate of colour change is directly proportional to 
the enzyme activity. 
 
p-nitrophenyl phosphate (pNPP)    phosphatase     p -nitrophenol + phosphate 
 
N2a cells were seeded and induced to differentiate in the presence and absence 
of OPs in T75 culture flasks for 2, 4 or 8 h as described in sections 2.2.1.3, 2.2.3 
and 2.2.4. Cells were harvested by centrifugation, resuspended in 1 ml ice-cold 
PBS (pH 7.4) and transferred into micro centrifuge tubes. All tubes were then 
centrifuged at 10,000 g for 3 min. The PBS was then removed and cell pellets 
were kept on ice and resuspended in 300 μl of ice cold TBS containing 0.5% 
(v/v) Triton X100. Cell pellets were broken down by pipetting and 50 μl of each 
lysate were transferred into a 96-well microtitre plate in 4 replicates. The 
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reaction was started when 100 μl of pNPP liquid substrate system were added 
into each well. The absorbance was then recorded at regular intervals for 30 min 
at 405 nm at 25°C using a microtitre plate reader (ASYS Expert 96, Biochrom, 
UK). Protein was estimated in the retained 100 μl of cell lysate by BCA assay, 
and specific activity (Absorbance change/min/mg protein) was expressed as a 
percentage of the corresponding control value ± SEM. 
 
 
2.2.11 Protein determination assay 
Total amount of protein in samples was determined using a modified 
bicinchoninic acid (BCA) protein assay kit from Sigma-Aldrich. The assay is 
similar to the method of Lowry with minor modifications (Lowry et al., 1951), 
using bovine serum albumin (BSA) as standard . The principle of the BCA assay 
relies on the formation of a Cu
2+ 
-protein complex under alkaline conditions, 
followed by reduction of the Cu
2+ 
ions from cupric sulphate to Cu
+ 
by the peptide 
bonds in a protein. The molecules of BCA then bind with Cu
+ 
forming a purple-
blue product, which can be measured at 570 nm by spectrophotometry. The 
absorbance is proportional to the amount of protein present in the sample.  
 
Using a BCA assay kit from Sigma-Aldrich, the BCA working reagent was 
prepared by mixing 50 parts of BCA reagent A (1% (w/v) bicinchoninic acid 
sodium salt, 2% (w/v) sodium carbonate, 0.16% (w/v) sodium tartrate and 0.95% 
(w/v) sodium bicarbonate in 0.1 M sodium hydroxide at pH 11.5) with 1 part of 
reagent B (4% (w/v) copper (II) sulphate pentahydrate). A light green solution 
was obtained. The amount of reagents needed was dependent on the number of 
used wells as indicated in (Table 2.4). 
 
Table 2.4. BCA working reagent preparation. 
 
Number of wells to be used in 
a 96-well plate assay 
Amount of reagent A 
(ml) 
Amount of reagent B 
(μl) 
40 8 160 
80 16 320 
96 19 380 
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To produce a standard curve, serial dilutions of BCA standards ranging from 0 to 
2 mg/ml were prepared from a 2 mg/ml BSA stock solution in the same buffer 
that was used in preparing the cell lysates. The serial dilutions of BCA were 
prepared in 2 ml micro centrifuge tube as indicated in Table 2.5, and vortex 
mixed. The assay was performed in a 96-well plate, where 25 μl of standards or 
protein sample were mixed with 200 μl of BCA working reagent and incubated 
for 30 min at 37°C in an LEEC incubator (LSC 2933). Absorbance was then read 
at 570 nm and protein concentration of each sample was determined from the 
average of triplicates using the linear correlation obtained from the BSA standard 
curve. 
 
Table 2.5. Preparation of BSA protein standards for protein determination. 
 
Volume of 2 mg/ml 
BSA (μl) 
Volume of assay buffer 
(μl) 
Final concentration of 
BSA (mg/ml) 
0 1000 0 
200 800 0.4 
400 600 0.8 
600 400 1.2 
800 200 1.6 
1000 0 2 
 
 
 
2.2.12 One dimensional polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blotting 
2.2.12.1 Preparation of buffers and reagents 
2.2.12.1.1 ×4 Laemmli sample buffer 
The buffer was prepared in a total volume of 10.2 ml containing 40% (v/v) 
glycerol, 8% (w/v) SDS, 20% (v/v) β-mercaptoethanol, 0.01% (w/v) 
Bromophenol blue and 0.1 M Tris HCl, at pH 6.8. 
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2.2.12.1.2 10% (w/v) Ammonium persulphate (APS) 
This was prepared by dissolving 5 mg of APS into 50 μl of dH2O. 
 
2.2.12.1.3 Running buffer 
The buffer was prepared in a total volume of 1 L containing 25.6 mM Tris-base, 
192 mM glycine and 0.1% (w/v) SDS at pH 8.3. 
 
2.2.12.1.4 Transfer buffer 
The buffer was prepared in a total volume of 1 L containing 48 mM Tris-base, 
39 mM glycine, 0.037% (w/v) SDS and 20% (v/v) methanol. 
 
2.2.12.1.5 Tris-buffered saline (TBS)  
The buffer was prepared in a total volume of 1 L containing 10 mM Tris and 140 
mM NaCl at pH 7.4. 
 
2.2.12.1.6 Bovine serum albumin (BSA)  
The blocking buffer was prepared in TBS containing 3% (w/v) BSA and 0.01% 
(w/v) sodium azide. 
 
 
2.2.12.2 Preparation of N2a cell lysates for SDS-PAGE 
N2a cells were plated out at a density of 50,000 cells/ml in T75 flasks (2 million 
cells/T75 flask) and differentiated for 20 h before being treated with OP 
compounds for 2, 4 or 8 h as described in sections 2.2.1.3, 2.2.3 and 2.2.4. After 
the required period of toxin exposure, serum free medium was carefully removed 
from the flasks and cell monolayers were rinsed gently with pre warmed PBS. 
Intact cell monolayers were then solubilised by boiling in 2 ml of 0.5% (w/v) 
sodium dodecyl sulphate (SDS) in 18.0 megohm-cm nanopure water 
(Barnstead™ Nanopure® Diamond™, Life science, UK). Lysates were detached 
mechanically by cell scraper and transferred to micro centrifuge tubes, boiled for 
5 min and then allowed to cool to room temperature for 10-15 min.  
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DNA was then extracted from each lysate by placing 500 μl of cell lysate into a 
spin column (Dutscher Scientific, catalogue no. 789068) and centrifuging for 
few seconds at 10,000 g at room temperature. After centrifugation, the filter with 
the captured DNA was carefully removed and discarded. The supernatant from 
the lower chamber was placed into a clean micro centrifuge tube labelled as 
protein lysate sample minus DNA. This step was repeated few times until the 
required amount of sample was obtained. The amount of protein presented in 
each sample was then estimated by BCA assay.  
 
When the protein concentration of cell lysates was very low, the sample was 
precipitated by ice-cold acetone. In brief, 9 parts of ice cold acetone were added 
to 1 part of protein sample in a micro centrifuge tube, vortex mixed and 
incubated at −20 °C overnight. The tubes were then centrifuged at maximum 
speed of 10,000 g for 20 min at 4°C to pellet the precipitated protein. The 
acetone was then carefully decanted from the tube and discarded properly in 
non-chlorinated waste bottles, and the remaining protein pellets were left to air-
dry at room temperature for 30 min. After complete acetone evaporation, pellets 
were resuspended with 100 μl of 0.5% (w/v) SDS in TBS and mixed thoroughly 
by a 100µl Gilson pipette to dissolve the protein. BCA assay was performed 
again to estimate the amount of protein presented in each sample. Once the 
protein concentration had been determined, samples were prepared for SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) by mixing 150 μl of each cell 
lysate with 50 μl of ×4 Laemmli sample buffer and boiled for 5 min prior to 
loading.  
 
2.2.12.3 SDS-PAGE assay 
The resultant proteins from cell lysates were subsequently separated according to 
their molecular weight using SDS-PAGE. 
 
2.2.12.3.1 Preparation of resolving gels 
Based on the molecular weight of the investigated proteins, a 10% (w/v) 
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acrylamide resolving gel was prepared in all the experiments (Table 2.6). The 
resolving gel is also called separating gel, which separates the proteins by size. A 
Bio-Rad mini-PROTEAN III™ electrophoresis chamber was used. Spacers, 
combs and two glass plates of 1.5 mm thickness were washed and wiped 
thoroughly with 70% (v/v) ethanol prior to assembly. One foam pad was placed 
in the casting apparatus and glass plates were assembled evenly into the plate 
holders. Once the plates were mounted on the casting stands, it was first filled 
with water and allowed to stand for 5 min to check for any leakage and the water 
was then removed before being replaced with the gel mixtures. The 10% (w/v) 
acrylamide resolving gel mixture was prepared according to the number of gels 
that were going to be used, as indicated in Table 2.6. Acrylamide polymerisation 
was then initiated by the addition of the volumes indicated of 10% (w/v) APS 
and TEMED, after which the mixture was swirled gently. Then 8 ml of resolving 
gel mixture were transferred into each cast to allow sufficient space for a 
stacking gel to be added later. Distilled water was carefully overlaid on the top 
layer of the freshly poured gel mixture to create a smooth interface and prevent 
any gel shrinkage. The gel mix was allowed to polymerise at room temperature 
for approximately 30 to 40 min. 
 
Table 2.6. Preparation of 10% (w/v) acrylamide resolving gel. 
 
10% (w/v) acrylamide resolving gel reagents Volume (for 2 gels) 
Accu gel 29:1 
40% (w/v) acrylamide:bisacrylamide (29:1) 
5.0 ml 
Protogel
® 
Resolving buffer  
(1.5 M Tris-HCl buffer pH 8.8, 0.4% (w/v) SDS) 
5.0 ml 
Distilled water 9.78 ml 
10% (w/v) Ammonium persulphate (APS) 200 μl 
TEMED 40 μl 
Total volume 20 ml 
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2.2.12.3.2 Preparation of stacking gel 
The required amount of 4% (w/v) polyacrylamide stacking gel was prepared and 
polymerised by the presence of 10% APS and TEMED as indicated in Table 2.7. 
The stacking gel solution was mixed gently and poured onto the polymerised 
resolving gel after removing the top layer of distilled water. The stacking gel is 
used because it allows proteins entry and accumulation at the interface of the 
resolving gel. After filling the chamber with stacking gel solution, a comb of the 
correct thickness was immediately inserted into the unpolymerised gel mixture to 
create the wells into which the samples would be loaded. The gel mixture was 
then allowed to polymerise for 30 min at room temperature. After this, the comb 
was carefully removed and wells were rinsed by flushing with running buffer 
using a 1000 µl Gilson pipette before loading the samples. 
 
Table 2.7. Preparation of 4% (w/v) acrylamide stacking gel. 
 
4% (w/v) acrylamide stacking gel reagents Volume (for 2 gels) 
Accu gel 29:1 
(40% (w/v) acrylamide:bisacrylamide (29:1)) 
1.0 ml 
Protogel
® 
stacking buffer 
(0.5 M Tris-HCl buffer pH 6.8, 0.4% (w/v) SDS) 
2.5 ml 
Distilled water 6.4 ml 
10% APS 100 μl 
TEMED 20 μl 
Total volume 10 ml 
 
 
2.2.12.3.3  Preparation of protein samples for loading 
Equal amounts of cell protein, as estimated by BCA assay, were loaded into the 
gel to ensure even protein loading.  A Blueye prestained protein ladder (2 μl) 
was loaded along with the protein samples to allow estimation of molecular 
weight. The Blueye prestained protein ladder (GeneDirex, UK) used in this study 
is a three colour protein standard with 12 prestained proteins, in which molecular 
weights range from 10 to 245 kDa). 
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2.2.12.3.4  Separation of proteins in cell lysates by gel electrophoresis 
To separate the proteins, gels were placed vertically in the electrophoresis 
chamber and filled with running buffer. Electrophoresis was run initially at 50 
volts using a Bio-Rad power pac 300 for 10 min. This voltage was used first to 
organise the samples in the stacking gel. After that, the voltage was increased to 
150 volts and electrophoresis allowed to continue until the dye front reached the 
base of the gel plates. As the dye reached the end of the gel, the voltage was 
switched off.  Gels were carefully removed to avoid damaging the glass plates or 
the gel. 
 
 
2.2.12.4  Western blotting 
On completion of the separation of proteins by SDS-PAGE, the gels were 
mechanically removed from the plates and the stacking gels were cut off. The 
remaining resolving gel, which contained the separated proteins, was 
electrophoretically transferred onto nitrocellulose membrane filters by wet 
blotting (Towbin et al., 1979).  
 
Briefly, gels to be blotted, nitrocellulose membranes (0.45 μM pore size) 
(Hybond C, Amersham) and 3 MM filter papers (Whatman® filter paper, from 
Sigma-Aldrich) were soaked in transfer buffer for 5 min. The presence of 
methanol in the transfer buffer is necessary to remove any non-protein-bound 
SDS and to enhance the adsorption of protein to the nitrocellulose membrane. 
Filter papers and membranes were carefully cut to the same size as the gel to 
avoid wastage. 
 
A transfer sandwich was then physically built on the side of the transfer cassette 
facing the anode (+) starting with a wet sponge and followed by three wetted 
filter papers, nitrocellulose membrane, the gel, three additional wetted filter 
papers and finally a second sponge. Any wrinkles, folds or air bubbles between 
the different layers of the sandwich were avoided by rolling a glass rod lightly 
across the components. Bubbles were removed as they can cause blank spots on 
the membrane where no protein transfer occurs. This assembled sandwich was 
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then securely fixed in the transfer cassette and immersed in the blotting chamber 
(Mini Trans-Blot® Electrophoretic Transfer cell; Bio-Rad) containing transfer 
buffer. A voltage of 30 volts was applied overnight at room temperature. 
 
 
2.2.12.5 Immunoprobing of nitrocellulose blots 
The resultant Western blots were blocked with 3% (w/v) BSA in TBS 
(BSA/TBS), containing 0.01% (w/v) sodium azide as a preservative. Blocking is 
essential to inhibit non-specific binding between protein and the membrane. For 
this, blots were placed on a shaker (Heidolph Unimax 1010) and agitated slowly 
with the blocking solution for at least 1 h at room temperature. Following the 
blocking step, blots were incubated with appropriate dilutions of primary 
antibodies made in BSA/TBS at 4°C overnight (Table 2.8). Blots were then 
washed to remove excess primary antibody that can cause high background using 
0.05% (v/v) Tween-20 in TBS detergent solution (TBS/Tween). This wash was 
performed six times (10 min/wash) with constant agitation at room temperature. 
After washing, blots were probed with horseradish peroxidase (HRP)-conjugated 
secondary antibodies for 2 h at room temperature (Table 2.9). Following 6 
further washes with TBS/Tween, the unbound secondary antibodies were 
removed from the membrane and antibody reactivity was visualized with 
enhanced chemiluminescence (ECL) reagents (Thermo Scientific, USA) in a 
G:BOX imager dark system (Syngene, Cambridge, UK). The ECL reagents were 
allowed to equilibrate at room temperature before an equal volume of ECL 
reagent A and B were mixed freshly and applied on the membrane to detect the 
band of interest. A densitometric analysis of antibody reactivity was then 
performed, where band densities on images of developed blots were determined 
using Advanced Image Data Analysis (AIDA) software (version 4.03) (Raytest 
GmbH, Straubenhardt, Germany). Using this software, each individual band was 
superimposed over the region of interest and a peak profile was constructed. An 
arbitrary value of the area beneath the peak, which represents the antibody 
reactivity, was then obtained. All band densities were measured and corrected for 
background, then normalised to band densities for B512 reactivity, which was 
used as internal control. Data are expressed as a percentage of the average value 
of the peak area compared to its corresponding control ± SEM. 
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Table 2.8. List of monoclonal and polyclonal primary antibodies used in Western 
blotting. 
 
Primary antibody Clone Dilution Species 
Approx. 
molecular 
weight of 
target 
(kDa) 
Code Supplier 
Cytoskeletal proteins 
Anti-phospho 
neurofilament H 
Ta51 1:1000 Rat 200 
MAB5
448 
Chemicon 
International 
Anti-neurofilament 
200 (phos and non 
phos) 
N52 1:250 Mouse 200 N0142 
Sigma-Aldrich 
 
Anti-growth 
associated protein-43 
(GAP-43) 
GAP-
7B10 
1:1000 Mouse 43 G9264 
Anti-α-tubulin B512 1:2000 Mouse 55 T6074 
Anti-βIII-tubulin 2G10 1:1000 Mouse 55 T8578 
Anti-tubulin 
polyglutamylated 
B3 1:1000 Mouse 55 T9822 
Anti-acetylated 
tubulin 
611B1 1:1000 Mouse 55 T6793 
Anti-tyrosine tubulin 
TUB-
1A2 
1:1000 Mouse 55 T9028 
Anti-MAP-1B H130 1:1000 Rabbit 200 B1904 
Santa Cruz 
Biotechnology 
 
Anti-MAP-2 H300 1:1000 Rabbit 200-140 J1805 
Cell signalling proteins 
Anti-total ERK1/2 K-23 1:1000 Rabbit 44-42 D1906 
Santa Cruz 
Biotechnology  
Anti-phosphorylated 
ERK1/2  
E-4 1:500 Mouse 44-42 
sc-
7383 
Heat shock proteins 
Anti-HSP90 AC16 1:1000 Mouse 90 H1775 
Sigma-Aldrich 
Anti-HSP70 
BRM2
2 
1:1000 Mouse 70 H5147 
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Anti-HSP60 LK2 1:1000 Mouse 60 H3524 
 
 
Table 2.9. List of secondary antibodies used in Western blotting. 
 
Secondary Antibody Type Dilution Code Supplier 
Anti-mouse IgG HRP 1:1000 A9044 
Sigma-Aldrich 
Anti-rabbit IgG HRP 1:1000 A6154 
Anti-goat IgG (H+L) HRP 1:1000 805-035-180 
Jackson Immuno 
Research 
Anti-rat IgG HRP 1:1000 P0450 DAKO-Cytomation 
 
 
2.2.13 Indirect immunofluorescence 
Indirect immunofluorescence staining is a technique that relies on using 
fluorescently-labeled antibodies to detect specific target antigens in two steps. 
First, cells are stained with unconjugated primary antibody that binds to the 
antigen. Then a fluorescent-conjugated secondary antibody is used to detect the 
primary antibody (Odell and Cook, 2013). The fluorescent dye allows 
visualisation and study of the intracellular distribution of neurofilament and 
microtubule proteins by utilising an epifluorescence or confocal microscope.  
 
Initially, N2a cells were plated at a density of 50,000 cells/ml on an 8-well cell 
culture chamber slide (NUNC, Thermo Scientific) in a total volume of 300 μl of 
growth medium per well. Cells were induced to differentiate for 20 h before 
being treated in the presence and absence of 3 µM CPF or CPO for 2, 4 or 8 h at 
37°C as mentioned in sections 2.2.1.3, 2.2.3 and 2.2.4. After the required time of 
toxin exposure, the medium was aspirated from each well and cells were fixed to 
retain the shape and locations of all cellular proteins using 500 μl/well of pre 
warmed 4% (w/v) paraformaldehyde (Sigma-Aldrich, UK) for 15 min at room 
temperature. Cells were then washed three times with 300 μl/well of ice cold 
PBS (2 min/rinse). Cell membrane permeabilisation was then performed by 
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incubating the cells for 15 min at room temperature in 0.05% (v/v) Tween-20 in 
PBS. This detergent solution created small holes in the membrane, which 
allowed the antibody to access the cytoplasm. Following three further rinses with 
PBS, non-specific binding was prevented by blocking the fixed cells with 500 μl 
of BSA/TBS per well for 1 h at room temperature. After blocking, cells were 
incubated with 200 μl/well of primary antibodies (diluted 1 in 500 in BSA/TBS) 
against NFH (N52), phosphorylated NFH (SMI34) and tubulin (B512) overnight 
at 4°C and washed three times with TBS/Tween to remove unbound primary 
antibodies. The cells were then incubated for 1 h at room temperature with Alexa 
Fluor
® 
anti-IgG secondary antibody diluted 1/500 in BSA/TBS blocking buffer 
(Table 2.10). After 3 further washes in TBS/Tween, the chamber partitions and 
mounting silicon were carefully removed from the slide. For mounting, anti-fade 
mountant (VectaShield mounting medium for fluorescence; Vector 
Laboratories Ltd., Peterborough, UK) containing 4',6-diamidino-2-phenylindole 
(DAPI) counterstain for nuclei visualization was applied to the exposed cell 
monolayers after careful aspiration of excess TBS. A glass cover slip was then 
placed in position and air bubbles were carefully removed by gentle pressure. A 
layer of clear nail polish was then applied around the extreme edges of the cover 
slip to fix it in place. Finally, the slide was viewed using an Olympus DP71 
epifluorescence microscope system, which equipped with an argon/krypton laser 
(FITC: Excitation 493/ Emission 528; DAPI: Excitation 360/ Emission 460). 
Cell images were acquired using Cell
F
 software. Negative control was included 
in this experiment by incubating non OP-treated cells with the secondary 
antibody only to confirm the specificity of the primary antibody. 
 
Table 2.10. Secondary antibodies used in indirect immunofluorescence staining. 
 
 IF Secondary antibody 
Target 
species 
Dilution Code Supplier 
Alexa Fluor
® 
568 IgG Rabbit 1:500 A21069 
Invitrogen 
Alexa Fluor
® 
488 IgG (H+L) Mouse 1:500 A21204 
 
 
 
Materials and Methods                                                                        Chapter 2                                                    
75 
 
2.2.14 Live cell imaging 
The real time changes in cell morphology following OP toxin exposure were 
determined by CFSE fluorescent dye and monitored using a Leica TCS SP5 
confocal laser scanning microscope with epifluorescence optics and in an 
environmental chamber. In this experiment, live N2a cells were labelled by 
CFSE. Since CFSE fluorescent dye is dependent on the activity of esterase, only 
live cells are labelled. 
 
N2a cells were plated out at a density of 50,000 cells/ml (10,000 cells/well) in a 
black clear 96-well treated plate (BD Bioscience, USA) and incubated overnight 
at 37 C to allow for the cells to adhere to the bottom of the plate. After 24 h of 
cell recovery, cells were differentiated for 20 h as indicated in sections 2.2.1.3, 
2.2.3 and 2.2.4. After the induction of differentiation, cells were incubated for 10 
min with 10 μM CFSE dye in pre-warmed sterile PBS at 37 °C. After CFSE 
labelling, PBS was replaced by serum free medium including 0.3 mM dbcAMP, 
and the plate was transported directly to a Leica TCS SP5 confocal laser 
scanning microscope. This system is equipped with true confocal scanner and 
five spectrophotometer channels. The N2a cells were incubated in an 
environmental chamber, which controlled the temperature at 37
o
C in a 
humidified atmosphere of 95% air/5% CO2 Following incubation, Leica 
application suite advanced fluorescence lite (LAS AF) was configured for 
fluorescence by setting the laser intensity to 25%. The live cell images were 
acquired using (xyzt) scanning mode, a frame size of 512 x 512 pixels, a 
scanning speed at 400Hz, a pixel size of 785 x 785 nm and image size of 387.5 x 
20 μm. The fluorophore was then selected from the beam path window and 
CFSE was excited with 488 nm fluorescein isothiocyanate (FITC) laser-line and 
emitted in green. Once the laser had been activated, non-treated live cells were 
first observed in order to create a time zero measurement before the addition of 
toxins. After that, a 3 μM concentration of CPF or CPO was added to each 
treatment well (see section 2.2.5) and the same positions were viewed every 30 
min for an interval of 8 h exposure time. The scanned images were shown at 
maximum intensity Z-projections of 25 slices of 1 micron thickness. After 
collecting a stack of optical sections (Z-series), the sample was reconstructed in 
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three dimensions, then rotated or tilted to view cells that would otherwise be 
obscured. The fixed images were then manipulated using LAS AF lite and some 
neurites were detected and labelled. A time-lapse imaging in one focal plane was 
then obtained and a play back movie was prepared using Windows Movie Maker 
software. 
 
2.2.15 Cell ELISA 
The levels of and post translational modifications to cytoskeletal proteins in both 
N2a and RenCell CX cell cultures were further determined and quantified using 
a cell-based enzyme linked immunosorbent assay (ELISA) technique, based on 
the approach of Schmuck and Ahr (1997) but with modifications (Schmuck and 
Ahr, 1997). The immunoassay uses an enzyme linked to an antibody as a marker 
for the detection of a specific antigen in a wet sample. This subsequent reaction 
forms a yellow colour product, which can be measured at 405 nm by 
spectrophotometer. The intensity of the colour change is proportional to the 
protein or antigen present in the sample. 
 
2.2.15.1 Preparation of buffer and reagents 
2.2.15.1.1   100 mM Sodium acetate buffer 
The buffer was prepared by dissolving 8.2 g of sodium acetate in 900 ml of 
distilled water at pH 6. The final volume made up to 1 L with distilled water. 
 
2.2.15.1.2   5 M Sulphuric acid (H2SO4) 
50 ml of H2SO4 were added to 200 ml of distilled water. 
 
2.2.15.1.3   3,3,5,5'-Tetramethylbenzidine (TMB) 
A total of 10 mg of TMB was dissolved in 1 ml of DMSO (stock). The 
developing substrate was prepared using TMB and 3% (v/v) hydrogen peroxide 
(H2O2) in 100 mM sodium acetate buffer at pH 6. 
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2.2.15.1.4   3% (v/v) Hydrogen peroxide (H2O2) 
A volume of 10 µl of 30% (v/v) H2O2 (stock) was added to 90 µl of distilled 
water. 
 
2.2.15.1.5   Developing buffer 
The developing substrate was prepared by the addition of 150 µl of TMB and 30 
µl of 3% (v/v) H2O2 into 20 ml of 100 mM sodium acetate pH 6. 
 
2.2.15.2  Assay protocol 
The assay was performed in a sterile flat bottom 96-well plate (Sarstedt, USA). 
Cells were plated out at the density of 50,000 cells/ml for N2a and 100,000 
cells/ml for ReNcell CX in a total volume of 200 μl growth medium per well in 
four replicates and incubated overnight at 37C in 5% CO2. After 24 h recovery, 
cells were differentiated before being treated with or without OP test compounds 
at different concentrations 1, 3, and 10 μM in fresh differentiation medium for 2 
or 8 h as indicated in sections 2.2.1.3, 2.2.2.4, 2.2.3, 2.2.4 and 2.2.5. On 
termination of toxin exposure, serum free medium was aspirated from each well 
and cell monolayers were fixed by pre warmed 4% (w/v) paraformaldehyde 
(Sigma-Aldrich, UK) (200 μl/well) for 10 min at room temperature. Fixative was 
then removed and the plate was washed twice with 200 μl/well of ice cold TBS 
(2 min/wash). Cells were then incubated in permeabilisation buffer (0.5% (v/v) 
Tween-20 in TBS) for 15 min at room temperature after which they were rinsed 
twice with TBS. A volume of 300 μl/well of BSA/TBS (blocking buffer) was 
then applied and the plate was covered and incubated overnight at 4C. The 
blocking buffer was then removed and 100 μl/well of primary antibodies diluted 
1 to 1000 in blocking solution were added and incubated overnight at 4C (Table 
2.11).  
 
After removing the primary antibodies, wells were washed again twice with 
TBS/Tween, followed by 2 h incubation in 200 μl/well of diluted HRP 
conjugated secondary antibodies (1:2000 dilution) at room temperature (Table 
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2.12). After the secondary antibodies had been removed from the plate, two final 
washes with TBS/Tween 20 were applied for 2 min each and then wash solution 
was removed completely from wells by turning the plate upside down and 
tapping gently on a paper towel to remove traces of wash buffer. The reaction 
was started by the addition of 100 μl of developing substrate buffer into each 
well. After 5 min incubation at room temperature, a blue colour product was 
developed which was then stopped by adding 100 μl of 5 N sulphuric acid. 
Absorbance was measured spectrophometrically using a micro plate reader 
(ASYS Expert 96, Biochrom, UK) at 405 nm. Results were expressed as 
antibody binding in treated cells as a percentage of that in untreated controls (set 
as 100%) ± SEM. The background level was estimated by omitting the primary 
antibodies. The specificity of antibody was confirmed by non OP-treated cells 
incubated with the secondary antibody only.   
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Table 2.11. List of primary antibodies used in cell ELISA. 
 
Primary Antibody  
Clone 
or 
batch 
Dilutio
n 
Species Code Supplier 
Anti- neurofilament 
200 
 (phos and non 
phos) 
N52 1:1000 Mouse N0142 
 
Sigma-Aldrich 
 
Anti- phospho 
neurofilament H (1) 
Ta51 1:1000 Rat MAB5448 Chemicon
®
 
Anti- phospho 
neurofilament H (2) 
SMI34 1:1000 Rabbit 14814302 Covance 
Anti- α tubulin B512 1:1000 Mouse T6074 
 
Sigma-Aldrich 
 
Anti- total ERK1/2 K-23 1:1000 Rabbit D1906 
Santa Cruz 
Biotechnology 
Anti- 
phosphorylated 
ERK1/2 
E-4 1:1000 Mouse Sc-7383 
Anti- βIII tubulin 2G10 1:1000 Mouse T8578 
Sigma-Aldrich 
 
Anti- glial fibrillary 
acidic protein 
(GFAP) 
GA5 1:1000 Mouse G3893 
 
 
Table 2.12. List of secondary antibodies used in cell ELISA. 
 
Secondary 
Antibody 
Type Dilution Code Supplier 
Anti- rabbit IgG HRP 1:2000 A6154 
Sigma-Aldrich 
Anti- mouse IgG HRP 1:2000 A9044 
Anti- rat IgG HRP 1:2000 P0450 DAKO-Cytomation 
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2.2.16 High-throughput analysis 
In the later stages of the project, the cytotoxic effects of CPF and CPO on neurite 
outgrowth of N2a and ReNcell CX cells were further determined using the 
ImageXpress Micro Widefield High Content Analysis System (Molecular 
Devices, USA). This technique permits rapid assessment of the effects of a wide 
range of chemicals at different concentrations on multiple parameters of neurite 
outgrowth. The screening system integrates an inverted epifluorescence 
microscope combined with automated image acquisition and analysis software to 
quantify different subcellular measurements of neurite outgrowth such as, cell 
count, neurite count, neurite length and cell body area (Smith and Eisenstein, 
2005, Dragunow, 2008). 
 
Typically, cells were plated out at the density of 50,000 cells/ml for N2a and 
100,000 cells/ml for ReNcell CX cells in 8-well Ibidi μ-slides. The cells were 
grown for 24 h in growth medium prior to the induction of cell differentiation for 
20 h. Differentiating cells were then treated without or with different 
concentrations of CPF or CPO (1, 3 and 10 μM) for 2 or 8 h at 37°C as 
previously described in sections 2.2.1.3, 2.2.3, 2.2.4 and 2.2.5. Following OP 
exposure, cells were fixed for 10 min using 500 μl of pre warmed 4% (w/v) 
paraformaldehyde (Sigma-Aldrich, UK) at 37C. After fixing, cells were washed 
three times with 300 μl/well of ice cold TBS (2 min/rinse) and cell membranes 
were permeabilised using 0.5% (v/v) Tween-20 in TBS for 15 min at room 
temperature. Following three further rinses with TBS, cells were blocked in 
BSA/TBS (500 μl/well) overnight at 4C. After blocking, fixed cell monolayers 
were incubated with 200 μl of primary antibodies. For N2a cells, anti-α-tubulin 
(clone B512) and anti- pNFH (SMI34 and Ta51) antibodies were used. For 
ReNcell CX cells, anti-neuronal marker (βIII tubulin and Ta51) and anti-astro-
glial marker (GFAP) antibodies were used. All primary antibodies were diluted 
1:1000 in BSA/TBS and added to each well, after which the fixed monolayers 
were then incubated overnight at 4°C. Unbound primary antibodies were 
removed by three washes in 200 μl of TBS/Tween for 5 min. Conjugated 
secondary antibodies, Alexa Fluor
® 
488 goat anti-mouse or Alexa Fluor
® 
568 
goat anti-rabbit immunoglobulins (both diluted 1:500 in BSA/TBS) (Invitrogen), 
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were added to each well for 1 h at room temperature. Three further washes were 
then applied using 300 μl of TBS/Tween, five min each. Cell nuclei were 
labelled with DAPI counterstain for 1 min, followed by a further TBS wash. In 
the final wash slides were filled with TBS containing 0.01% (w/v) sodium azide 
as a preservative and stored at 4C prior to image acquisition and analysis. 
Negative control was included in this experiment by incubating non OP-treated 
cells with the secondary antibody only to confirm the specificity of the primary 
antibody. 
 
Ibidi μ-slides were then loaded into an ImageXpress Micro Widefield High 
Content Screening System plate holder for automated image acquisition and 
analysis. The system uses a widefield automated microscope capable of 
fluorescence, transmitted light and phase-contrast imaging of fixed-cell assays. 
The system was set to automatically focus and record images from four different 
sites in each individual well. The size of each well is 9.4 × 9.4 mm, and acquired 
image is 741.6 × 587.6 µm. Fluorescence images were produced using multiple 
emission filter and matched laser excitation filters for two different channels, 
(DAPI) for nuclei (ex= 377/50 nm, em= 447/60 nm) and (FITC) for cell body 
and neurites (ex= 482/35 nm, em=536/40 nm). Images were acquired using a 
Nikon 10x objective lens and 1.4 megapixel cooled CCD camera, with a stand-
alone illuminator (Lambda LS) connected to the system, which involves a 175W 
Xenon-arc lamp, lamp housing, cold mirror and power supply (Sutter Instrument, 
USA). The 10x objective lens was used in order to acquire all neurites in one 
field of view, thus enabling more reliable analysis of neurite outgrowth. 
 
The acquired images were then segmented by multi-coloured tracing masks on 
neurites and cell bodies. Segmentation masks were generated using the 
MetaXpress imaging and analysis software (version 5.1.0.46; Molecular devices, 
USA), where each neurite segment is given the same coloured mask as that of 
their parent neuronal cell bodies. The segmentation images were then analysed 
by the neurite outgrowth module integrated within the MetaXpress imaging and 
analysis software, using neurite outgrowth configuration setting to measure a 
number of morphological parameters including average number of cells/field, 
average cell body area/field, neurite length/cell, mean processes/cell, mean 
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branches/cell, percentage of cells with significant outgrowth and average 
intensity of staining within the positive cells. Particles from each image were 
identified as cells if valid nuclei width between 5 to 10 µm had been detected 
and cell body width ranged from 15 to 20 μm. Outgrowth was recorded as 
significant when minimum cell outgrowth was more than 10 μm (approximately 
half a cell body diameter in length). The measurement ranges for cell bodies and 
outgrowths were determined in preliminary studies using untreated cells from 
multiple cultures to develop settings to exclude non-cellular particles from the 
analysis. Using a 10x objective, four fields/well from four independent 
experiments were acquired for the analysis of at least 200 cells/well. The cellular 
results obtained by the analysis software were then transferred to a GraphPad 
Prism spreadsheet and results were plotted as mean ± SEM. Each OP treatment 
was compared to its corresponding control. 
 
2.2.17 Statistical analysis 
All sets of data were based on a minimum of 4 separate experiments and 
expressed as mean ± standard error of the mean (SEM). The analysis was 
conducted using GraphPad Prism (version 6.0f) (GraphPad software, California, 
USA), a statistics and scientific 2D graphing software. Average values for each 
treatment were compared to the corresponding controls or other treatment group 
by one-way or two-way analyses of variance (ANOVA). The analysis was 
followed by a Tukey post hoc test, which takes into account multiple 
comparisons, with 95% confidence interval. Results were considered to be 
significantly different when p < 0.05. 
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3  Effects of chlorpyrifos and chlorpyrifos oxon on 
neurite outgrowth in pre-differentiated mouse N2a 
neuroblastoma cells 
3.1 Introduction 
To this day, CPF remains one of the most extensively used OP insecticides 
worldwide. Despite the strict bans on its household applications, CPF is still 
widely used on corn and fruits crops, posing high risks to farm workers, 
applicators, families and children living in close proximity to agricultural areas 
where this OP is applied (EPA, 2015). Exposure to CPF can cause acute 
neurotoxicity symptoms as a result of the inhibition of AChE activity in central 
and peripheral cholinergic synapses. This inhibition prevents the breakdown of 
the neurotransmitter ACh, which plays major roles both in neurotransmission 
and in the developmental process of the brain (Barr and Angerer, 2006). As a 
result, increased ACh accumulation in the synaptic cleft and consequent over 
stimulation of muscarinic and nicotinic  receptors lead to convulsions, 
neuromuscular block and respiratory failure (Costa, 2006, Flaskos, 2012).   
 
The metabolic activation of CPF to CPO is known to be the main causative event 
behind most cases of acute neurotoxicity induced by OPs in adults (Richardson, 
1995). This is due to the fact that CPO is much more potent than CPF at 
inhibiting the activity of AChE (Monnet-Tschudi et al., 2000).  However, there is 
a large amount of epidemiological evidence demonstrating that both CPF and 
CPO are also capable of inducing developmental neurotoxicity in developing 
organisms through their interference with developmental processes in the 
nervous system, such as neurite outgrowth (Campbell et al., 1997, Crumpton et 
al., 2000, Flaskos, 2012). Several in vitro and in vivo experimental studies have 
shown that the toxic action of CPF and CPO on the developing brain is not 
limited to hyper activation of the cholinergic system, but that it involves other 
potential targets (Slotkin, 2004). For example, CPF and CPO were found to 
interfere with the unique developmental process of the brain and the nervous 
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system by causing several morphological changes in the formation of neurites. 
These neurites have an essential role in axonal plasticity (Andrieux et al., 2002, 
Wall, 2005). Clinical signs of neurological syndromes associated with CPF and 
CPO induced neurotoxicity may arise as a consequence of its effects on axon 
production, especially in the developing brain in children.  
 
To investigate the impact of OPs on neurite outgrowth in neural cell culture 
systems, several experimental protocols have been implemented. The majority of 
previous studies share a common differentiation condition, in which cells are 
treated with OPs at the same time as induction of cell differentiation (Sachana et 
al., 2008, Flaskos et al., 2011). This method, known as co-differentiation 
exposure, can be used to evaluate the ability of OP to inhibit the outgrowth of 
neurites. However, little work has been done regarding the impact of OPs on 
cells that have been committed to differentiation and have already formed 
neurites, a treatment referred to as post-differentiation exposure. Since the 
mechanisms involved in OP-induced neurotoxicity may vary depending on the 
differentiation condition used, Sachana and colleagues adopted the post-
differentiation exposure strategy to evaluate the effects of CPF on the mouse 
N2a neuroblastoma cell line (Sachana et al., 2001, Sachana et al., 2005).  
 
Initially, the neuronal cells were allowed to differentiate for 20 h by the removal 
of serum and in the presence of 0.3 mM dbcAMP to exhibit a network of axons 
and dendrites, and then treated with or without 3 µM of CPF for 4 and 8 h 
(Sachana et al., 2001). Work by Sachana et al showed that this non- cytotoxic 
concentration of CPF caused a significant reduction in the number of axon-like 
processes in pre-differentiated N2a cells by 50% compared to non-CPF treated 
controls following 4 and 8 h exposure (Sachana et al., 2001, Sachana et al., 
2005). The results obtained from these studies not only demonstrated the ability 
of CPF to inhibit neurite outgrowth but also its capability to cause a retraction of 
pre-formed neurites.  
 
Although the strategy conducted at such a developmental stage by Sachana et al 
(2001, 2005) was the least investigated among the literature, it provides valuable 
information regarding the toxic effect of OP toxins on the outgrowth of pre-
 Effects of CPF and CPO on neurite outgrowth in N2a cells                   Chapter 3 
85 
 
formed neurites. Since only the effects of CPF were investigated on 
differentiated N2a cells with pre-formed axons, it was of interest to know 
whether a similar concentration of CPO acts in the same manner as CPF on 
neurite outgrowth produced in this cellular system. Additionally, it was 
important to elucidate whether the neurotoxic actions of both OPs on cell 
morphology were associated with AChE inhibition. Previously, reduced activity 
of AChE was observed in N2a cells exposed to 1-10 µM CPO for up to 24 h 
from the point of induction of cell differentiation (Flaskos et al., 2011). 
However, it was suggested that AChE inhibition was not directly related to 
neurite inhibitory effects of CPO.  
 
By applying post-differentiation exposure conditions, the aim of the current 
study was to compare the effects of CPO to that seen with CPF towards pre-
differentiated N2a cells. Therefore, both compounds at a concentration of 3 µM 
were investigated in parallel with respect to their ability to interfere with the 
outgrowth of neurites produced from differentiated N2a cells following 2, 4 and 
8 h exposure. To achieve this aim, a range of experimental techniques such as 
MTT reduction assay, CFSE fluorescence cell staining and live cell imaging 
were used in this study. A further aim was to determine whether the 
morphological effects on axon-like neurites were related to the acute toxicity 
target (AChE) using enzymatic activity assay. 
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3.2 Results 
 
3.2.1 Effects of CPF and CPO on the viability of pre-
differentiated N2a cells 
Mouse N2a neuroblastoma cells were induced to differentiate by serum 
withdrawal and the addition of 0.3 mM dbcAMP for 20 h before being treated 
without (0.5% v/v DMSO control) or with 3 µM CPF or CPO for 2, 4 and 8 h. 
To examine the viability of pre-differentiated N2a cells after being exposed to 
both OPs, MTT reduction assays were performed as described in section 2.2.7. 
The results demonstrated in figure 3.1 show no effect on the reduction of MTT 
by pre-differentiated N2a cells when compared to its corresponding control after 
2, 4, and 8 h exposure to 3 µM CPF or CPO.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Effects of 3 µM concentration of CPF and CPO on pre-
differentiated N2a cell viability. After 20 h of differentiation, N2a cells were treated 
without (0.5% v/v DMSO control) or with 3 µM CPF or CPO for 2, 4 and 8 h and the 
levels of MTT reduction were measured to evaluate cell viability. Results are expressed 
as a mean percentage of the corresponding untreated control at each time point ± SEM 
from four separate experiments. Statistical significance of data was analysed using one 
way ANOVA. When SEM bar is not apparent, this means that error is smaller than the 
symbol size. 
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3.2.2 The optimal concentration of CFSE fluorescent dye 
N2a cell differentiation was assessed in cells stained with CFSE fluorescent dye. 
Since high concentrations of CFSE can be toxic to cells and lead to impairment 
in cell division, the appropriate concentration of the dye to be used was 
determined based on its effects on MTT reduction. Various concentrations of 
CFSE ranging between 10 nM and 100 µM were tested for their ability to inhibit 
the MTT reduction assay (explained in section 2.2.8.2).  
 
In figure 3.2, it can be seen that there was no significant decrease in MTT 
reduction in pre-differentiated N2a cells incubated with 10 nM to 100 µM CFSE 
compared to control (no CFSE). On the basis of this result, 10 µM CFSE was 
considered to be non-cytotoxic towards N2a cells and was chosen to be the 
optimal concentration for staining the pre-differentiated N2a cells in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Effects of CFSE on MTT reduction in pre-differentiated N2a 
cells. After 20 h of induction cell differentiation, N2a cells were labelled with 
different concentration of CFSE and the levels of MTT reduction were measured to 
evaluate cell viability. Results are expressed as a mean percentage of the 
corresponding untreated control ± SEM from four separate experiments. Statistical 
significance of data was analysed using one way ANOVA. When SEM bar is not 
apparent, this means that error is smaller than the symbol size.
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3.2.3 Effects of CPF and CPO on cell morphology and neurite 
outgrowth in pre-differentiated N2a cells 
The previous work by Sachana et al (2001) showed that CPF at a sub-cytotoxic 
concentration of 3 µM had the ability to induce retraction of approximately 50% 
of axon-like processes formed by differentiated N2a cells following 8 h of 
exposure, as determined by CBB staining (Sachana et al., 2001). However, the 
effects of CPO on the morphology of pre-differentiated N2a cells and neurite 
outgrowth had not been previously tested. In order to achieve comparable results 
to the previous work with CPF, pre-differentiated live N2a cells were stained 
directly with 10 µM CFSE dye, exposed to OPs for 2, 4 and 8 h, then fixed. The 
cells were then viewed by using an Olympus DP71 epifluorescence microscope 
(see section 2.2.8.3). At each time point, fluorescence images of non OP-treated 
controls and treated cells were taken (Figure 3.3), and the total number of axon-
like neurites was recorded (Figure 3.4). 
 
The fluorescence images in figure 3.3 show that pre-differentiated N2a cells in 
the absence of both OP had typical neuronal cell morphology of round cell 
bodies with long extending axons-like processes. After exposure to 3 µM CPF 
and CPO, a retraction of long axons was apparent compared to control cells. 
However, this alteration in neurite outgrowth was more pronounced in CPO-
treated cells compared to CPF and control at each time point. As the exposure 
time to both OPs increased, the reduction in neurite outgrowth also increased 
compared to the non-treated controls at each time point.  
 
These findings were further confirmed by quantitative analysis of the effects of 
both OPs on neurite outgrowth formed by pre-differentiated N2a cells (Figure 
3.4), which indicated a time-dependent reduction in the outgrowth of axon-like 
processes following exposure to 3 µM CPF or CPO compared to the non OP-
treated controls. Both CPF and CPO at a concentration of 3 µM were able to 
induce a significant reduction in the number of axons per 100 cells compared to 
their corresponding controls at each time point in pre-differentiated N2a cells (p 
˂ 0.0001). Additionally, a significant difference on the inhibition of axon 
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outgrowth was also observed when the CPF treatment was compared to CPO at 
each time point (p = 0.005) (Figure 3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 3.3. Effects of 3 µM concentration of CPF and CPO on the morphology 
of pre-differentiated N2a cells. Displayed are representative fluorescence images of 
N2a cells induced to differentiate for 20 h prior to being incubated in the absence 
(Control) or presence of  3 µM CPF or 3 µM CPO for 2, 4 and 8 h. Cells were stained 
with CFSE and fixed. Arrows show typical axon-like processes detected in non-OP 
treated controls. Scale bar represents 50 µm.                                                           .
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Figure 3.4. Quantitative analysis of the effects of CPF and CPO on neurite 
outgrowth. N2a cells were induced to differentiate for 20 h, labelled with CFSE then 
incubated with or without 3 µM CPF or CPO for 2, 4, and 8 h. Data are expressed as 
mean number of axon-like processes per 100 cells ± SEM for four independent 
experiments. Asterisks indicate where OP treated cell values were significantly 
different from the corresponding control (p ˂ 0.0001). Bars with asterisks indicate 
significant differences between CPF and CPO treatments at each time point (p = 
0.005).
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3.2.4 The real time effects of CPF and CPO on axon stability in 
pre-differentiated N2a cells 
In order to determine the time scale of the morphological changes reported in the 
previous section, the real time changes induced by CPF and CPO on axon 
outgrowth in pre-differentiated N2a cells were further studied using a live cell 
imaging approach, as described in section 2.2.14. The first images of control and 
OP-treated cell panel were taken at minute 20, whereas subsequent images were 
recorded at 1 h intervals for a period of 8 h from the point of toxin addition. 
Neurites were labelled by arrows and numbers to track the changes over time. 
Time-lapse videos of control and OP-treated cells were also prepared from a 
sequence of images at 30 min time intervals and are provided on a CD 
accompanying this thesis.  
 
As indicated in figure 3.5, there was no observed retraction of neurites in non 
OP-treated controls. Following exposure to 3 µM CPF or CPO, neurite length 
was shown to be highly affected over time compared to non OP-treated controls 
(Figure 3.6 and 3.7). Approximately 25% of neurites retracted within the first 2 
to 4 h after treatment with both OPs, suggesting that some of these changes were 
occurring at a very early stage. At 8 h treatment with CPO, the images showed 
some cell vesiculation. However, no other alterations in cell morphology were 
detected, such as changes in cell body shape or size in both controls and treated 
cells (Figure 3.5 and 3.7). 
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Figure 3.5. The real time measurements of neurites in pre-differentiated N2a 
cells determined by live cell imaging. N2a cells were induced to differentiate for 20 
h, stained with CFSE then incubated for further 8 h in the absence of OP to monitor the 
real time changes in cell morphology. Shown are digital images of a representative field 
of view for the non OP-treated control. The first image was taken at minute 20. 
Subsequent images were taken 1 h intervals, using a Leica TCS SP5 confocal laser 
scanning microscope with epifluorescence optics. Arrows-labelled 1-3 show typical 
neurites in pre-differentiated N2a cells (untreated control). Scale bar represents 50 µm. 
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Figure 3.6. The real time effects of CPF on pre-differentiated N2a cells 
determined by live cell imaging. N2a cells were induced to differentiate for 20 h, 
stained with CFSE then incubated for further 8 h in the presence of 3 µM CPF. The real 
time changes in cell morphology following OP exposure were recorded for a period of 8 
h. Shown are digital images of a representative field of CPF treated cells. The first 
image was taken at minute 20. Subsequent images were taken 1 h intervals, using a 
Leica TCS SP5 confocal laser scanning microscope with epifluorescence optics. Arrows 
labelled 1-4 show retracting neurites detected in pre-differentiated N2a cells treated with 
CPF for 8 h. Scale bar represents 50 µm. 
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Figure 3.7. The real time effects of CPO on pre-differentiated N2a cells determined 
by live cell imaging. N2a cells were induced to differentiate for 20 h, stained with 
CFSE then incubated for further 8 h in the presence of 3 µM CPO. The real time 
changes in cell morphology following OP exposure were recorded for a period of 8 h. 
Shown are digital images of a representative field of CPO treated cells. The first image 
was taken at minute 20. Subsequent images were taken 1 h intervals, using a Leica TCS 
SP5 confocal laser scanning microscope with epifluorescence optics. Arrows labelled 1-
5 show retracting neurites detected in pre-differentiated N2a cells treated with CPO for 
8 h. Scale bar represents 50 µm. 
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3.2.5 Effects of CPF and CPO exposure on AChE activity of pre-
differentiated N2a cells 
To determine whether the observed morphological changes in the outgrowth of 
neurites in pre-differentiated N2a cells could be related to the effect on the acute 
toxicity target (AChE), the impact of 3 µM CPF and CPO on the activity of 
AChE was assessed in parallel, as explained in section 2.2.9.  
 
After 2, 4, and 8 h exposure of pre-differentiated N2a cells to CPO, a sustained 
significant reduction (˃ 70%) in the specific activity of AChE was observed 
compared to the non OP-treated control (p ˂ 0.0001) (Figure 3.8). However, 
CPF-treated cells showed little or no effect on AChE activity compared to the 
untreated control at all exposure time points.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Effects of 3 µM CPF and CPO on AChE activity in pre-
differentiated N2a cells. Mouse N2a cells were induced to differentiate for 20 h 
before being incubated with or without 3 µM CPF and CPO for 2, 4, and 8 h, after 
which the activity of AChE was measured. Enzyme specific activity (Absorbance 
change/min/mg protein) is expressed as a percentage of the corresponding control 
value ± SEM from four independent experiments. Asterisks indicate statistically 
significant changes compared to the non OP-treated control values at each time point 
(p ˂ 0.0001). 
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3.3 Discussion 
The non-cytotoxic effect observed towards pre-differentiated N2a cells incubated 
with 10 µM CFSE suggested that this concentration is optimal for cell staining in 
this study. The data presented on neurite outgrowth in CFSE-labelled cells 
demonstrated that both CPF and CPO caused neurite retraction when pre-
differentiated N2a cells were exposed for 2, 4, and 8 h. Although inhibition of 
neurite outgrowth from N2a cells has been previously investigated following 
CPF exposure (Sachana et al., 2001), and other OPs such as leptophos, phenyl 
saligenin phosphate (PSP), diazinon and CPO (Sachana et al., 2003, Hargreaves 
et al., 2006, Harris et al., 2009b, Flaskos et al., 2011) using CBB staining, this is 
the first time that CFSE was used to measure the development and maintenance 
of neurites by N2a cells. The current data showed that CFSE provided 
comparable results to CBB, which has been widely used to study the effects of 
OPs on neurite outgrowth previously. In addition, CFSE is highly specific, stable 
and more sensitive than CBB. Another major advantage of CFSE, is that it can 
be used as a useful marker for visual identification of both fixed and living cells 
(Garton and Schoenwolf, 1996). Therefore, CFSE labelling provides a novel and 
reliable approach to assess cell differentiation and neurite outgrowth as an 
alternative to CBB.  
 
The observed retraction of neurites induced by CPF in cultured N2a cells under 
post-differentiation conditions is in good agreement with that noted in the same 
culture system using a similar concentration of CPF under both post and co-
differentiation conditions (Sachana et al., 2001). In addition, the current study 
revealed for the first time the potential ability of CPO to induce neurite retraction 
in pre-differentiated N2a cells, an effect which appears to be even stronger than 
that of CPF. The fact that CPO was found to be more potent in reducing the 
length of axon-like neurites compared to its parent compound in the current work 
is in agreement with a number of previous studies. In pre-differentiated rat PC12 
pheochromocytoma cells, CPO at a concentration of 1 nM was 1000-times more 
potent in reducing the neurite outgrowth than 1 µM CPF following 24 h 
exposure (Das and Barone, 1999). Under co-differentiation conditions, CPO at 
the much lower concentration of 0.001 nM also showed greater ability than CPF 
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(0.001 µM) to reduce axonal length in primary cultures of sympathetic and 
sensory neurons derived from embryonic rat after 24 h (Howard et al., 2005, 
Yang et al., 2008).  
 
The inability of either compound to affect MTT reduction after 2, 4 and 8 h of 
exposure suggested that the 3 μM concentration used in this study was sub-
cytotoxic towards pre-differentiated N2a cells. Hence, it is likely that alterations 
in neurite outgrowth were not due to cell death, but were a genuine cellular 
response to OP exposure. This finding is consistent with previous studies, which 
employed similar concentrations of CPF and other OPs such as diazinon and 
diazinon oxon and found no significant effects on the viability of differentiating 
N2a cells when exposed for periods of up to 24 h (Sachana et al., 2003, Sachana 
et al., 2005, Flaskos et al., 2007, Sidiropoulou et al., 2009a).  
 
The rapid collapse of neurites observed using live cell imaging further confirms 
the neurite inhibitory effect of CPF and CPO towards pre-differentiated N2a 
cells. All neurites, irrespective of initial size, exhibited reduced lengths within 2 
h of exposure to both compounds. However, cell body shape and size were found 
to be relatively unaffected following OP exposure for the same time periods. 
This finding suggests that the retraction of pre-formed axons in N2a cells, which 
is initiated at an early time point following exposure to 3 µM CPF and CPO, is 
the first visible sign of the effects of both compounds on neurite outgrowth.   
 
The significant reduction in the specific activity of AChE observed at all time-
points following CPO exposure is in line with a previous study by Flaskos et al. 
(2011). They demonstrated sustained inhibition of AChE in N2a cells after CPO 
exposure from the point of induction of cell differentiation for 4 or 24 h (Flaskos 
et al., 2011). A reduced activity of AChE was also noted in N2a cells exposed 
for 4 h from the point of induction of differentiation to the OP diazinon oxon, 
although in that case no significant effect on enzyme activity was observed after 
24 h (Sidiropoulou et al., 2009a). However, it is unlikely that inhibition of AChE 
alone could account for the observed changes in the outgrowth of neurites in N2a 
cells, as CPF (as would be expected) had little effect on AChE in the current 
work. A number of in vivo (Slotkin et al., 2006) and in vitro (Das and Barone, 
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1999, Fowler et al., 2001, Howard et al., 2005) studies suggest that OPs that are 
weak inhibitors of AChE can also induce marked impairment in the development 
of neurites. In this respect, the OP trio-ortho-cresyl phosphate significantly 
inhibited the development of axon-like processes in N2a cells (Fowler et al., 
2001). However, it is only a weak inhibitor of AChE (Lock and Johnson, 1990).  
Therefore, inhibition of AChE enzymatic activity by CPF or CPO is unlikely to 
be the main cause of retraction of axon-like neurites in pre- differentiated N2a 
cells, although neurite outgrowth data in the current study are consistent with the 
possibility that it may contribute to the severity of the effects. 
 
As previously discussed, the post differentiation conditions may reflect a model 
of developmental toxicity. The concentration of 3 µM CPF and CPO was chosen 
due to its proven ability to induce a reduction by 50% in both neurite outgrowth 
and in the number of pre-formed neurites in differentiating N2a cells without 
affecting cell viability. CPO-induced morphological and biochemical impacts 
were also observed in vivo in the developing organism following administration 
of similar OP concentrations to those employed in this study. Using meconium 
analysis (used to estimate the foetal exposure to environmental toxicants), about 
22.8 µM CPF has been detected in meconium samples of new-born children 
(Ostrea et al., 2002) and low micromolar levels of oxon metabolites are 
attainable in the developing human foetus (Flaskos, 2012). Therefore, the applied 
OP concentration in this study has clinical relevance to human developmental 
neurotoxicity.  
 
With regard to the possible  transfer of the oxon form from the maternal tissue to 
the foetus, oxon metabolites have higher water solubility compared to their 
respective parent compounds (Sogorb and Vilanova, 2010). This would affect 
their ability to enter the foetus via the lipid membranes of the placenta. The 
detection of significant cholinesterase inhibition in the mammalian foetus 
following in vivo exposure of pregnant animals to organophosphorothionate 
pesticides suggests that foetal exposure to CPO can occur (Gupta, 1995). The 
foetus is thought to be primarily exposed to the parent compound, but may also 
encounter oxon metabolite in the maternal tissues. The relatively low expression 
of CYP2B6 (a key enzyme in the process of oxon formation in humans) in 
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human placenta suggest that the placenta does not make a major contribution to 
oxon formation (Pelkonen et al., 2006, Foxenberg et al., 2007, Croom et al., 
2010). Although CYP2B6 is present at low levels in the human foetus compared 
to later stages of development (Croom et al., 2010), paraoxonase 1 (PON 1), 
which is responsible for hydrolysing and detoxifying the oxon forms of certain 
OPs such as CPO, is also relatively low at this stage (Costa, 2006). This could 
allow some oxon formation and/or accumulation in foetal tissue. Additionally, 
reduced levels of serum PON1 due to genetic polymorphisms in the PON1 gene 
is found to be associated with increased susceptibility to the toxic effect of the 
oxon metabolite (Costa, 2006).  
 
The observed dying back of axons in this pre-differentiated N2a cell model could 
also reflect what it might occur following OP toxicity in adults. It is highly likely 
that such a concentration of CPO (3 µM), which caused severe inhibition in 
AChE levels to more than 70% would be lethal to the foetus (Heilmair et al., 
2008). However, there are numerous case studies of patients who have survived 
such levels of cholinesterase inhibition with the help of pharmacological 
intervention, such as adrenaline and/or oxime administration, only to develop 
delayed neuropathy. For example, a 19 year old male who ingested a large dose 
of CPF and was hospitalised suffering from cholinergic crisis. After he was 
treated with atropine and pralidoxime, the patient recovered partially from 
neurological symptoms (Nand et al., 2007). Administration of this combined 
treatment has an important role in reversing the respiratory muscles weakness or 
paralysis, and other parasympathetic effects associated with OP poisoning (Tush 
and Anstead, 1997). However, after 24 h of CPF exposure, he developed 
respiratory paralysis and required mechanical ventilation for 16 days. Weeks 
later, he had progressive signs of OPIDN, such as deficits in the lower limbs and 
muscular atrophy (Nand et al., 2007). Thus, survivors of acute cholinergic crisis 
can be affected by a delayed neuropathy involving dying back of axons in 
peripheral/central neurons (Clegg and van Gemert, 1999a, Nand et al., 2007, 
Thivakaran et al., 2012). Indeed, it has been shown that CPF administered at 
acute levels in animal models can lead to OPIDN (Gupta, 2006). Therefore the 
morphological changes in neurite outgrowth following CPO exposure have 
potential clinical relevance in terms of delayed neuropathy. 
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From the results presented in this chapter, it can be concluded that exposing pre-
differentiated N2a cells to a sub-cytotoxic concentration of CPF and CPO causes 
neurite retraction. The findings also demonstrate that CPO exerts more potent 
effects compared to those of CPF on neurite outgrowth and AChE. However, the 
morphological effects on axon-like neurites are not completely dependent on the 
inhibition of AChE. They could be associated with other non-cholinergic targets, 
which will be investigated in depth at the molecular level in the next chapter. 
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4 Effects of chlorpyrifos and chlorpyrifos oxon on 
cytoskeletal and associated regulatory proteins in pre-
differentiated N2a cells 
4.1 Introduction 
The previous chapter demonstrated that sub-cytotoxic concentration of 3 µM 
CPF and CPO had the capacity to induce the retraction of axon-like neurites in 
pre-differentiated N2a cells. Since the observed morphological alterations in 
neurite outgrowth were not directly related to the inhibition of the enzymatic 
activity of AChE, it was of interest to investigate whether the retraction of axon-
like processes was associated with altered expression and activities of 
cytoskeletal and associated regulatory proteins in pre-differentiated N2a cells. 
 
The neuronal cytoskeleton, and in particular the microtubule and neurofilament 
networks play an important role in neurite development and stability (Cambray-
Deakin, 1991b). Impairment of neurite outgrowth following exposure to OPs has 
been linked with disruption of the expression levels of cytoskeletal proteins 
(Fowler et al., 1997, Flaskos et al., 1998, Sachana et al., 2001, Sachana et al., 
2003, Sachana et al., 2005, Hargreaves et al., 2006, Flaskos et al., 2007, Flaskos 
et al., 2011, Sachana et al., 2014). Earlier reports evaluated the effects of CPF on 
a number of cytoskeletal and associated regulatory proteins in N2a cells under 
different differentiation and exposure conditions (Sachana et al., 2001, Sachana 
et al., 2005). N2a cells treated with CPF showed increased levels of HSP-70 
under co-differentiation exposure conditions, whereas no observed effects were 
found on HSP-70 levels in pre-differentiated cells (Sachana et al., 2001). 
Additionally, Sachana and colleagues (2005) showed reduced levels of GAP-43 
in pre-differentiated N2a cells treated with CPF. However, when N2a cells were 
exposed to CPF at the point of induction of cell differentiation, it had no impact 
on GAP-43 expression (Sachana et al., 2005). The findings of these studies 
suggest that the effects of CPF on these proteins depend to some extent on the 
differentiation stage of the cells.  
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With regard to CPO, Flaskos and colleagues (2011) investigated the CPO-related 
effects on cytoskeletal proteins in N2a cells using co-differentiation experimental 
protocols. Data obtained from that work showed reduced levels of GAP-43 and 
NFH in differentiating N2a cells following CPO exposure for 24 h (Flaskos et 
al., 2011). The effects of CPO on cytoskeletal proteins in pre-differentiated N2a 
cells have not been determined in post-differentiation experiments, and there is a 
lack of quantitative data in the case of CPF. 
 
The aim of this chapter was to assess the impacts of sub-cytotoxic concentrations 
of both CPF and CPO on cytoskeletal and associated regulatory proteins in pre-
differentiated N2a cells following 2, 4 and 8 h exposure. The study focused on 
the effects of both OPs on the levels of specific microtubule, neurofilament and 
heat shock proteins, which were determined using quantitative Western blotting.  
Subsequently, alterations in the activation status of MAP kinase ERK 1/2 and the 
enzymatic activity of phosphatase were investigated to relate them to any 
changes observed in NFH phosphorylation. Additionally, disruption of the 
intracellular distribution of microtubule and neurofilament networks was 
analysed using indirect immunofluorescence staining. This work was done in 
order to relate the alterations in neurite outgrowth observed in the chapter three 
to the levels of expression and activities of cytoskeletal and associated regulatory 
proteins in pre-differentiated N2a cells. 
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4.2 Results 
4.2.1 Effects of CPF and CPO on the expression levels of 
microtubule proteins 
The molecular changes underlying the morphological effects of 3 µM CPF and 
CPO on neurite outgrowth in pre-differentiated N2a cells were studied further by 
quantitative Western blotting. For immunoblotting, Western blots of lysates of 
pre-differentiated N2a cells exposed to 3 µM CPF or CPO for 2, 4, and 8 h were 
probed with antibodies against a range of microtubule proteins. These included 
antibodies to MAP-1B, MAP-2, acetylated and tyrosinated α-tubulin, 
polyglutamylated tubulin and βIII tubulin, as described in section 2.2.12 and 
table 2.12. 
 
As indicated in figure 4.1 and table 4.1, the reactivity of anti-α-tubulin showed 
no significant changes following exposure of cells to both CPF and CPO at any 
time point. Therefore, the band densities for all proteins were normalised to that 
for α-tubulin (using monoclonal antibody clone B512), which was used as 
internal control. Similarly, there were no significant effects on the cross 
reactivity of lysates of pre-differentiated N2a cells with antibodies that recognise 
MAP-1B, MAP-2, acetylated, tyrosinated and polyglutamylated forms of α-
tubulin and βIII-tubulin following exposure to both CPF and CPO at all time-
points compared to control.  
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Figure 4.1. Detection of microtubule proteins on Western blots of pre-
differentiated N2a cell lysates.  N2a cells were induced to differentiate for 20 h prior 
to treatment with 3 µM CPF or 3 µM CPO, or without OP (Control) for 2, 4, and 8 h. 
The N2a cell lysates were then subjected to SDS-PAGE and Western blotting as 
described in Materials and methods. Shown are typical blots probed with antibodies 
against MAP-1B, MAP-2, βIII-tubulin, acetylated, tyrosinated and polyglutamylated 
α-tubulin, followed by HRP-conjugated secondary antibodies and developed by ECL 
reagents. Blots probed with anti-α-tubulin were used as internal control. 
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Table 4.1. Densitometric analysis of Western blots probed with antibodies to 
microtubule proteins. Western blots probed with antibodies that recognise MAP-1B, 
MAP-2, βIII-tubulin, acetylated, tyrosinated and polyglutamylated α-tubulin. The 
antibody reactivity was then visualized with ECL reagents as described in Materials and 
methods. Densitometric peak areas were quantified using AIDA software and values are 
expressed as a percentage of the corresponding time point control ± SEM for four 
separate experiments. Band densities for all proteins were normalised to blots probed 
with anti-α-tubulin. Asterisks indicate significant differences compared to the 
corresponding untreated control. 
 
Antigens 
Incubation  
time (h) 
Densitometric peak area 
 (% control  SEM) 
3 μM CPF 3 μM CPO 
MAP-1B 
2 98 ± 4 96±8 
4 106 ± 8 112±13 
8 85 ± 10 89±11 
MAP-2 
2 101±5 98±5 
4 100±4 105±5 
8 111±13 89±15 
Acetylated tubulin 
 
 
2 102±2 103±4 
4 103±4 123±19 
8 125±11 102±13 
Tyrosinated tubulin 
2 103±4 102±2 
4 102±1 105±7 
8 112±5 110±10 
Polyglutamylated 
tubulin 
2 94±6 95±5 
4 102±7 89±11 
8 88±18 87±16 
βIII tubulin 
2 107±12 96±5 
4 99±5 104±11 
8 99±6 94±10 
Total α-tubulin 
2 107±8 96±7 
4 102±4 109±7 
8 103±6 106±7 
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4.2.2 Effects of CPF and CPO on the expression levels of 
neurofilament and growth-associated proteins 
As indicated in figure 4.2 and table 4.2, a transient significant reduction was 
observed in the levels of antibody reactivity with GAP-43 on blots of lysates 
(using monoclonal antibody clone GAP7B10) after 4 h exposure of cells to CPF 
(p ˂ 0.004), and CPO (p ˂ 0.002). However, GAP-43 reactivity was unaffected 
following exposure to both OPs at the earlier time point (2 h) and seemed to 
recover following 8 h exposure. Reactivity of cell lysates with anti-total NFH 
antibody (clone N52) was similar to the corresponding control at all time-points. 
In contrast, reactivity with anti-pNFH (clone Ta51) was considerably higher than 
the reactivity level of lysates from non OP-treated controls following 2 h 
exposure to both CPF (p ˂ 0.02), and CPO (p ˂ 0.0006). This increase in the 
levels of pNFH at 2 h was then followed by a significant decline in comparison 
to control values after 8 h exposure to both CPF (p ˂ 0.004) and CPO (p ˂ 
0.0002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Detection of neurofilaments and growth associated proteins on 
Western blots of pre-differentiated N2a cell lysates. N2a cells were induced to 
differentiate for 20 h before treatment with or without 3 µM CPF or CPO for 2, 4, 
and 8 h. N2a cell lysates were then subjected to SDS-PAGE and Western blotting as 
described in Materials and methods. Shown are typical blots probed with antibodies 
to NFH, pNFH and GAP-43 followed by HRP-conjugated secondary antibodies and 
developed by ECL reagents. Blots probed with anti-α-tubulin were used as internal 
control. 
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Table 4.2. Densitometric analysis of Western blots probed with antibodies to 
neurofilaments and growth associated proteins.  Western blots of cell lysates were 
probed with antibodies that recognise NFH, pNFH and GAP-43, followed by 
visualisation of antibody reactivity with ECL reagents as described in Materials and 
methods. Densitometric peak areas were quantified using AIDA software and values are 
expressed as a percentage of the corresponding time point control ± SEM for four 
separate experiments. Band densities for all proteins were normalised to blots probed 
with anti-α-tubulin. Asterisks indicate values that were statistically significant from their 
corresponding non OP-treated control; *p ˂ 0.02, **p < 0.004, ***p < 0.002, ▲p < 
0.0002, 
■
p < 0.0006. 
 
Antigens 
Incubation  
time (h) 
Densitometric peak area 
 (% control  SEM) 
3μM CPF 3μM CPO 
NFH 
2              107 ± 9              101 ± 8 
4              102 ± 18     81 ± 22 
8              120 ± 12              105 ± 16 
pNFH  
2             214 ± 16*             444 ± 90
■
 
4               84 ± 7  93 ± 12 
8               36 ± 13**  30 ± 7
▲ 
GAP-43 
2             107 ± 12               96 ± 5 
4      75 ± 10**         60 ± 10*** 
8             106 ± 11             117 ± 17 
 
 
 
In order to confirm the observed alteration in the phosphorylation status of NFH, 
the phosphorylation ratio was calculated (pNFH:NFH) at all time-points. As can 
be seen in table 4.3, there was a significant increase in the phosphorylation ratio 
following exposure to both CPF and CPO (p < 0.01) for 2 h. Although the level 
returned to normal at the 4 h time point, it showed a significant reduction to 29% 
and 27% of normal levels with CPF and CPO treatment for 8 h, respectively (p < 
0.001). 
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Table 4.3. The phosphorylation ratio of the change in pNFH:NFH following OP 
exposure over time.  Band intensities of pNFH relative to control were calculated as a 
ratio to that of NFH. A value of 1 represents normal level of phosphorylation of NFH. 
Asterisks indicate changes that were statistically significant compared to normal levels; 
*p ˂ 0.01, **p < 0.001. 
 
 
Phosphorylation 
ratio 
Incubation  
time (h) 
3μM CPF 3μM CPO 
pNFH:NFH 
2   2.02 ± 0.23*   4.19 ± 0.80* 
4 1.03 ± 0.21 1.53 ± 0.22 
8     0.29 ± 0.08**     0.27 ± 0.03** 
 
 
 
 
4.2.3 Effects of CPF and CPO on the expression levels of heat 
shock proteins 
In order to determine whether altered levels of HSPs could be indicative of 
cellular injury induced by OP exposure, the effects of both CPF and CPO on the 
expression levels of three families of HSPs (HSP-90, HSP-70 and HSP-60) were 
investigated by quantitative Western blotting, as described in section 2.2.12. 
 
As illustrated in figure 4.3 and table 4.4, the densitometric analysis of probed 
Western blots of pre-differentiated N2a cell lysates treated with 3 µM CPO for 4 
h revealed transient significant reduction in the levels of HSP-90 compared to 
controls (p ˂ 0.003). However, reactivity with HSP-90 antibody was unaffected 
at the earlier time point (2 h) and seemed to recover following 8 h exposure to 
CPO.  
 
Although exposure of lysates of pre-differentiated N2a cells treated with CPO 
for 4 h had reduced levels of the HSP-70 and HSP-60, the effects were not 
statistically significant at that time point, nor at 2 or 8 h. In CPF-treated cells, no 
significant change in reactivity levels was detected with all three anti-HSP 
antibodies at all time-points. 
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Table 4.4. Densitometric analysis of Western blots probed with antibodies to heat 
shock proteins. Western blots of cell lysates were probed with antibodies that recognise 
HSP-90, HSP-70 and HSP-60, after which antibody reactivity was visualised with ECL 
reagents, as described in Materials and methods. Densitometric peak areas were 
quantified using AIDA software and values are expressed as a percentage of the 
corresponding time point control ± SEM for four separate experiments. Band densities 
for all proteins were normalised to blots probed with anti-α-tubulin. Asterisks indicate 
values that were statistically significant changes from their corresponding non OP-
treated control; *p < 0.003. 
 
Antigens 
Incubation  
time (h) 
Densitometric peak area 
 (% control  SEM) 
3μM CPF 3μM CPO 
HSP-90 
2  97 ± 4 96 ± 7 
4              101 ± 8            77 ± 3* 
8   97 ± 4 94 ± 2 
HSP-70 
2                95 ± 6 96 ± 5 
4  92 ± 5   90 ± 11 
8              109 ± 6         106 ±  9 
HSP-60 
2 102 ± 3 97 ± 3 
4 106 ± 6 89 ± 5 
8   100 ± 12   90 ± 26 
 
Figure 4.3. Detection of heat shock proteins on Western blots of pre-
differentiated N2a cell lysates. N2a cells were induced to differentiate for 20 h 
before treatment with or without 3 µM CPF or CPO for 2, 4, and 8 h. N2a cell lysates 
were then subjected to SDS-PAGE and Western blotting as described in Materials and 
methods. Shown are typical blots probed with monoclonal antibodies to HSP-90 
(clone AC16), HSP-70 (clone BRM22) and HSP-60 (clone LK2) followed by HRP-
conjugated secondary antibodies and developed by ECL reagents. Blots probed with 
anti-α-tubulin were used as internal control. 
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4.2.4 Effects of CPF and CPO on activation status of MAP 
kinase ERK1/2 
Further analyses were performed to determine whether the altered levels of 
reactivity of lysates with antibody to pNFH could be attributed to changes in the 
activation status of MAP kinase ERK 1/2, which is known to be a convergence 
point of signalling pathways involved in neurite outgrowth and to play an 
important role in the phosphorylation of NFH (Veeranna et al., 1998, Perron and 
Bixby, 1999). 
 
As indicated in figure 4.4 and table 4.5, data from Western blotting analyses 
using anti-total ERK antibody showed no significant changes in reactivity levels 
with lysates from pre-differentiated N2a cells treated with either CPF or CPO 
compared to non OP-treated controls at any time-point. In contrast, anti-pERK 
antibodies showed increased reactivity compared to the corresponding control at 
all time-points but the changes were only statistically significant at the early time 
point (2 h). The data in table 4.6, showed that there was a significant increase in 
the phosphorylation ratio following exposure to both CPF and CPO (p < 0.05) at 
2 h exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Detection of the activation status of MAP kinase ERK 1/2 on Western 
blots of lysates from pre-differentiated N2a cells. N2a cells were induced to 
differentiate for 20 h before treatment with or without 3 µM CPF or CPO for 2, 4, and 
8 h. N2a cell lysates were then subjected to SDS-PAGE and Western blotting as 
described in Materials and methods. Shown are typical blots probed with antibodies to 
total ERK (K-23) and phosphorylated ERK (E-4) followed by HRP-conjugated 
secondary antibodies and developed by ECL reagents. Blots probed with anti-α-tubulin 
were used as internal control. 
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Table 4.5. Densitometric analysis of Western blots probed with antibodies to MAP 
kinase ERK1/2. Western blots of cell lysates were probed with antibodies that 
recognise total ERK and phosphorylated ERK, after which antibody reactivity was 
visualised with ECL reagents, as described in Materials and methods. Densitometric 
peak areas were quantified using AIDA software and values are expressed as a 
percentage of the corresponding time point control ± SEM for four separate 
experiments. Band densities for all proteins were normalised to blots probed with anti-α-
tubulin Asterisks indicate values that showed statistically significant differences from 
their corresponding non OP-treated control; *p ˂ 0.02, **p < 0.001. 
 
Antigens 
Incubation 
time (h) 
Densitometric peak area 
 (%control  S.E.M.) 
3μM CPF 3μM CPO 
Total ERK 
2 106 ± 7  95 ± 11 
4   111 ± 14     115 ± 20 
8 107 ± 7     107 ± 8 
pERK  
2    147 ± 21*
 
    128 ± 6** 
4  149 ± 33     142 ± 34 
8  113 ± 15       91 ± 2 
 
 
 
 
Table 4.6. The phosphorylation ratio of the change in pERK:total ERK following 
OP exposure over time. Band intensities of pERK relative to control were calculated as 
a ratio to that of total ERK. A value of 1 represents normal level of phosphorylation of 
ERK. Asterisks indicate changes that were statistically significant compared to normal 
levels; *p ˂ 0.05. 
 
Phosphorylation 
ratio 
Incubation  
time (h) 
3μM CPF 3μM CPO 
pERK: tERK 
2   1.3 ± 0.02*   1.3 ± 0.02* 
4 1.3 ± 0.21 1.2 ± 0.22 
8 1.0 ± 0.08 0.8 ± 0.03 
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4.2.5 Effects of CPF and CPO on phosphatase activity in pre-
differentiated N2a cells  
Since there was a clear relationship between the early changes in reactivity of 
antibodies against pNFH and pERK in OP-treated cell lysates at 2 h, further 
experiments were carried out to detect the possible cause for the subsequently 
significant reductions in NFH phosphorylation following 8 h exposure. For this, 
phosphatase activity was detected using the pNPP liquid substrate system with 
lysates prepared from cells incubated with or without OPs under the same post 
differentiation exposure conditions, as described in section 2.2.10. 
 
As demonstrated in figure 4.5, there was an observed increase relative to the 
controls in the level of phosphatase activity in pre-differentiated N2a cell lysates 
treated with either CPF or CPO for 2 and 8 h. However, this effect appeared to 
be statistically significant only at 8 h exposure (p ˂ 0.002) when analysed by 
two-way ANOVA. At 4 h treatment, no noticeable changes in phosphatase 
activity were detected in OP-treated cells compared to untreated control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Effects of CPF and CPO on phosphatase activity in pre-
differentiated N2a cells.  Mouse N2a cells were induced to differentiate for 20 
h before being incubated with or without 3 µM CPF or CPO for 2, 4, and 8 h, 
after which the activity of phosphatase was measured as described in Materials 
and methods. Enzyme specific activity is expressed as percentage of the 
corresponding control value ± SEM from four separate experiments. Asterisks 
in the 8 h treatment indicate changes that are statistically significantly different 
from the non OP-treated corresponding control (p ˂ 0.002). 
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4.2.6 Effects of CPF and CPO on the intracellular distribution of 
cytoskeletal proteins 
Since 3 µM CPF and CPO were able to cause retraction of pre-formed neurites 
and interfere with the expression levels of cytoskeletal proteins, it was of interest 
to determine whether they were also capable of disrupting the intracellular 
distribution of neuronal cytoskeleton proteins. The neurotoxic effects of both 
OPs on microtubule and neurofilament protein distribution were studied by 
indirect immunofluorescence staining of pre-differentiated N2a cells following 2 
and 8 h exposure. As previously explained in section 2.2.13, pre-differentiated 
N2a cells were stained with antibodies against total NFH (clone N52), pNFH 
(clone SMI34) and βIII-tubulin (clone 2G10). 
 
As shown in figures 4.6 and 4.7, anti-βIII-tubulin antibody demonstrated intense 
staining in neurites and cell bodies of treated and non OP-treated cells at both 
exposure time points. In the case of anti-total NFH, it can be seen that there was 
relatively strong staining of axons in control cells, as shown by horizontal 
arrows, but weak neurite staining was observed in CPF and CPO treated cells at 
both 2 and 8 h exposure. The staining intensity of anti-pNFH in axons was 
similar to that of anti-total NFH in non OP-treated controls. However, much less 
neurite staining was observed and more aggregates were detected in cell bodies 
(vertical arrows) with anti-pNFH in OP treated cells at both time-points. 
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Figure 4.6. Effects of 2 h exposure to CPF and CPO on the intracellular 
distribution of cytoskeletal proteins in pre-differentiated N2a cells. Following 20 h 
of cell differentiation, N2a cells were treated without (control) or with 3 µM CPF or 
CPO for 2 h. N2a cells were then fixed and stained by indirect immunofluorescence as 
described in Materials and methods. Shown are digital images of non OP-treated 
controls and cells exposed to 3 µM CPF or CPO stained with anti-total NFH (N52), 
anti-pNFH (SMI34) and anti-βIII-tubulin (2G10). Horizontal arrows highlight typical 
axon-like neurites and vertical arrows indicate the presence of aggregates in cell 
bodies. Scale bar represents 30 µM. 
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Figure 4.7. Effects of 8 h exposure to CPF and CPO on the intracellular 
distribution of cytoskeletal proteins in pre-differentiated N2a cells. Following 20 h 
of cell differentiation, N2a cells were treated without (control) or with 3 µM CPF or 
CPO for 2 h, after which, cells were fixed and stained by indirect immunofluorescence 
as described in Materials and methods. Shown are digital images of non OP-treated 
controls and cells exposed to 3 µM CPF or CPO stained with anti-total NFH (N52), 
anti-pNFH (SMI34) and anti-βIII-tubulin (2G10). Horizontal arrows highlight typical 
axon-like neurites and vertical arrows indicate the presence of aggregates in cell 
bodies. Scale bar represents 30 µM. 
 
Effects of CPF and CPO on cytoskeletal proteins in N2a cells                Chapter 4 
116 
 
4.3 Discussion 
The neurite retraction observed in pre-differentiated N2a cells following 
exposure to a sub-cytotoxic neurite inhibitory concentration of CPF and CPO 
indicated that these effects were not related to AChE inhibition (Chapter three). 
The aim of this chapter was to reveal whether retraction of neurite outgrowth 
was associated with disruption of cytoskeletal and associated regulatory proteins 
and whether the effects on these non-cholinergic targets could underlie the 
morphological changes in neurite outgrowth produced from pre-differentiated 
N2a cells. 
 
Microtubule proteins such as tubulin and MAPs are mainly involved in neuronal 
cell differentiation and neurite development (Cambray-Deakin, 1991b). The fact 
that densitometric analysis in the current study revealed a lack of detectable 
changes in the reactivity of N2a cell lysates with antibodies against α-tubulin, 
tubulin posttranslational modifications, βIII-tubulin and MAPs following 
treatment with CPF and CPO together with the lack of effect in indirect 
immunofluorescence staining with anti-tubulin, suggested that the levels of 
microtubule proteins were unaffected under our experimental conditions. Similar 
findings were observed in previous studies, which found that the same 
concentration of CPF and CPO had no effect on the levels of α-tubulin when 
applied to pre-differentiated N2a cells (Sachana et al., 2005) or at the point of 
induction of cell differentiation (Flaskos et al., 2011). Unchanged levels of α-
tubulin have also been observed following exposure to other OPs such as PSP, 
diazinon and the pyrethroid cypermethrin (Hargreaves et al., 2006, Flaskos et al., 
2007). The previous data together with the current findings suggest that the 
microtubule network is not a primary target of these OPs. 
 
Neurofilaments, in particular NFH, play a key role in regulating axon growth and 
stability (Williamson et al., 1996) and are increasingly expressed and 
phosphorylated as axons develop (Lee and Cleveland, 1994, Veeranna et al., 
1998). The importance of NFH phosphorylation is that it regulates the transport 
of neurofilaments within axons, which plays an essential role in axonal growth 
and stability (Shaw, 1991, Sihag et al., 2007). Extensive phosphorylation of NFH 
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results in a slower rate of axonal transport (Yuan et al., 2006). Thus, it was of 
interest to determine whether neurite retraction could be reflected at the 
molecular level by altered levels of phosphorylation of NFH. The observed 
increase in the reactivity of antibodies against pNFH and the calculated 
phosphorylation ratios in OP-treated cell lysates at 2 h and the following decline 
at 8 h exposure, together with the lack of statistically significant effects of OPs 
on the reactivity of antibodies that recognise total NFH at all time-points are 
consistent with an early transient hyperphosphorylation followed by a reduced 
phosphorylation state of NFH, with no overall effect on the total levels of NFH 
protein. The transient increase in NFH phosphorylation in pre-differentiated N2a 
cells treated with CPF and CPO mirrored the effect of other OPs such as phenyl 
saligenin phosphate (PSP) and trio-ortho-cresyl phosphate (TOCP) in N2a cells 
under co-differentiation conditions (Fowler et al., 2001, Hargreaves et al., 2006). 
In animal studies, altered phosphorylation status of NFH has also been found in 
the spinal cord of hens treated with TOCP (Suwita et al., 1986) and PSP (Jortner 
et al., 1999). Taken together, these findings suggest that several OPs may be able 
to disrupt the phosphorylation status of NFH. 
 
The data for CPF are in agreement with the study of Sachana et al. (2001), which 
revealed little or no effect on the levels of NFH from N2a cells following 
exposure to CPF under similar post differentiation conditions (Sachana et al., 
2001). However, in a study by Flaskos et al. (2011), where CPO was added to 
N2a cells at the same time as induction of differentiation, immunoblot analysis 
indicated significant reduction in NFH protein but the level of NFH 
phosphorylation remained close to the control values (Flaskos et al., 2011), 
suggesting that the effect of CPO observed in the current work was specific for 
pre-differentiated cells. Thus, the toxicity response appears to be related to the 
developmental stage of cell differentiation at which the exposure to OPs occurs, 
although the possibility that the longer exposure time (24 h) in the latter study 
may have affected the outcome cannot be discounted. 
 
Results obtained from immunoblot analysis using monoclonal antibody 
GAP7B10, which recognises GAP-43, suggested that CPF and CPO induced a 
transient reduction in GAP-43 after 4 h exposure. GAP-43 is a cytoskeleton 
Effects of CPF and CPO on cytoskeletal proteins in N2a cells                Chapter 4 
118 
 
membrane linker that is highly expressed in the growth cones and extending 
axons in neuronal cells (Skene, 1989, Das et al., 2004). During 
neurodevelopment, GAP-43 regulates the formation of growth cones, and 
modulates the development and stability of axons (Meiri et al., 1986, Benowitz 
and Routtenberg, 1997, Meiri et al., 1998). It has been demonstrated that GAP-
43 synthesis is elevated during axonal outgrowth (Skene, 1989, Pekiner et al., 
1996) and thus, inhibition of neurite outgrowth could be associated with altered 
expression level of GAP-43 (Das et al., 2004). Since reduced levels of GAP-43 
in the current study occurred in parallel with the collapse in axon outgrowth 
observed by live cell imaging following exposure of pre-differentiated N2a cells 
to CPF and CPO (chapter three), it could also have contributed to the detachment 
of the growth cones. This finding is consistent with previous studies, which 
showed reduced levels of GAP-43 in pre-differentiated N2a cells exposed to 
similar concentration of CPF and other OPs (i.e. CPF-methyl) for 4 h (Sachana et 
al., 2005) and in N2a cells induced to differentiate for 24 h in the presence of 
CPO (Flaskos et al., 2011). However, this is the first time that reduced level of 
GAP-43 was observed under post-differentiation exposure conditions for CPO.  
 
The decreased levels of GAP-43 were also associated with impaired axon 
outgrowth in N2a cells treated for 4-24 h from the point of induction of 
differentiation with different OPs such as TOCP, leptophos, diazinon and the 
carbamate ester carbaryl (Fowler et al., 2001, Sachana et al., 2003, Harris et al., 
2009b). Taken together, the current and previous findings suggest that reduced 
levels of GAP-43 can be considered as a common molecular marker for the 
neurite inhibitory effects caused by these OPs. Interestingly, the observed 
recovery in the level of GAP-43 at 8 h after its significant reduction in 4 h time 
point suggested the ability of the expression of this protein to recover to equal 
levels to that of controls. The transient reduction in the levels of GAP-43 may 
further suggest that this could be due to changes in proteolytic degradation 
and/or gene expression, which was then subsequently recovered by increase 
synthesis. 
 
The chaperone role played by HSPs is important in maintaining the integrity of 
neuronal proteins against abnormal protein folding, which may also be related to 
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their protective role against apoptosis induced by OP toxicity (Hartl and Hayer-
Hartl, 2002, Bukau et al., 2006). Elevated levels of these proteins were detected 
in brains affected by neurodegenerative disease (Hamos et al., 1991, Anthony et 
al., 2003). In addition, it has been demonstrated that increased levels of HSP-70 
could provide a potential marker of toxic injury in mammalian brain (Gonzalez 
et al., 1989). In the current study, the lack of detectable changes in the 
expression levels of HSP-70 in CPF and CPO-treated cells at all exposure time 
points is compatible with an earlier study conducted under similar experimental 
and differentiation conditions, which also showed no effect on the levels of HSP-
70 in CPF-treated pre-differentiated N2a cells (Sachana et al., 2001). The 
observation that CPO had no effects on the levels of HSP-70 in the current study 
indicated that CPO is acting in a similar manner as CPF with respect to this HSP 
under the post-differentiation exposure conditions used. However, under co-
differentiation exposure conditions, raised levels of HSP-70 compared to control 
were detected in N2a cells following exposure to 3 µM CPF for 4 and 8 h 
(Sachana et al., 2001), and diazinon oxon (1 to 10 µM) for 24 h (Sidiropoulou et 
al., 2009a). Interestingly, reduced levels of HSP-70 were found in N2a cells 
exposed for 24 h to 10 µM diazinon under co-differentiation conditions (Flaskos 
et al., 2007). Taken together, these findings suggest that, with respect to HSP 
expression, the effects of CPF and CPO could involve distinct mechanisms that 
are dependent on the developmental stage at which exposure occurs. 
 
HSP-60 is a mitochondrial stress protein, which is mainly found in the 
mitochondria (Anthony et al., 2003). The current study showed that the levels of 
HSP-60 were not altered in pre-differentiated N2a cells exposed to 3 µM CPF 
and CPO compared to non OP-treated controls. Previously, increased 
immunoreactivity of HSP-60 in brain epithelial cells was detected in patients 
with Alzheimer’s disease compared to normal subjects, which indicated that 
mitochondrial damage was associated with this neurodegenerative condition 
(Anthony et al., 2003). However, the lack of noticeable differences on the 
expression of HSP-60 presented in this study suggested that mitochondrial stress 
proteins were not a major target for CPF and CPO toxicity in pre-differentiated 
N2a cells under our experimental conditions.  
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HSP-90 is another chaperone protein that is found abundantly in the cytosol and 
highly expressed in mammalian brain cells (Gupta et al., 2010). HSP-90 binds to 
cytoskeletal proteins such as tubulin and actin, and is thought to have a role in 
stabilising the neuronal cytoskeleton (Csermely, 2001). It also interacts with 
protein kinases that are important in regulating the cell death and survival 
(Sreedhar et al., 2004). Under stress conditions such as pesticide exposure, HSP-
90 with the assistance of HSP-70 plays an important role in degradation of 
misfolded, damaged or denatured proteins (Gupta et al., 2010). The transient 
reduction observed in levels of HSP-90 in CPO-treated cells but not CPF-treated 
cells in the current study could reflect the ability of CPO to disrupt the functions 
of HSP-90, as it has been reported that decreased levels of HSP-90 could affect 
many cellular processes and increase the mortality of mammalian cells upon 
thermal stress (Bansal et al., 1991, Gopinath et al., 2014). 
 
On the other hand, the lack of alterations in the expression of HSP-90 in CPF-
treated cells is inconsistent with previous work, in which a much lower 
concentration of CPF (50-200 nM) induced synthesis of HSP-90 in 
undifferentiated rat pheochromocytoma PC12 neuronal cells following 24 h 
exposure (Bagchi et al., 1996). This discrepancy could be explained by several 
experimental differences in the cell lines, differentiation conditions, sub-
cytotoxic OP concentrations, and/or exposure times used. With respect to the 
latter, the shorter exposure time in the current study, may not have been 
sufficient for the threshold levels required to induce expression of HSP-90 to be 
reached. It is important to mention that the total cellular HSP content was 
measured this study. It would be beneficial for future work to measure these 
proteins in the cytosolic and mitochondrial fractions separately after OP 
exposure. 
  
The observed alterations in NFH phosphorylation were consistent with the 
possible disruption of cell signalling pathways involved in cytoskeletal 
regulation. In the current study, it was important to relate these changes to the 
activation status of the MAP kinase ERK 1/2, since it known as a convergence 
point for cell signalling pathways involved in neuronal cell differentiation 
(Perron and Bixby, 1999). This protein kinase is activated in N2a cells following 
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induction of cell differentiation by serum withdrawal (Hargreaves et al., 2006) 
and such activation is required for the development of neurites (Singleton et al. 
2000; Lopez-Maderuelo et al. 2001). Moreover, it is known to be important in 
the phosphorylation of NFH (Perron and Bixby, 1999). In the current study, the 
increase in reactivity of anti-pERK and the calculated phosphorylation ratios 
with a lack of detectable changes in anti-total ERK reactivity after 2 h exposure 
to both compounds suggested that OP treatment lead to increased activation of 
ERK, which may account for the changes in NFH phosphorylation at that time 
point. However, the lack of significant changes in anti-pERK in OP-treated cells 
compared to the control after 4 and 8 h exposure suggested that the OP-induced 
activation was short-lived. The finding of the current study, with respect to the 
activation status of the MAP kinase ERK1/2, is compatible with a previous study 
conducted under co-differentiation conditions, which also showed transient 
increased reactivity of anti-pERK but not anti-total ERK in N2a cells exposed to 
PSP for 4 h (Hargreaves et al., 2006). These data together suggest that several 
OPs are capable of inducing transient changes in ERK activation that might 
disrupt NFH phosphorylation in treated cells. 
 
Interestingly, the data obtained from the measurement of phosphatase activity 
were consistent with the possibility that increased phosphatase activity could 
account for the observed reduction in NFH phosphorylation at the later time 
point. Previously, it has been reported that protein phosphatase 2A from both rat 
spinal cord and rabbit skeletal muscle can reduce the phosphorylation of NFH 
following hyperphosphorylation by cyclin-dependent kinase-5 (cdk5) in 
neurodegenerative disease (Veeranna et al., 1995). In addition, reduced levels of 
protein phosphatase 2A and other phosphatases were found to be associated with 
altered NFH phosphorylation in protein aggregates found in Alzheimer’s disease 
(Vogelsberg-Ragaglia et al., 2001) and amyotrophic lateral sclerosis brain 
(Kesavapany et al., 2007). Therefore, protein phosphatase 2A might be one 
potential NF-associated phosphatase involved in the reduced phosphorylation of 
NFH following 8 h exposure to both CPF and CPO. However, further 
investigation is needed to identify specific phosphatases involved in the 
regulation of NFH phosphorylation in OP treated cells. 
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Indirect immunofluorescence findings further confirmed the idea that both 
compounds used in the current study can impair neurite development and 
interfere with the expression levels of cytoskeletal proteins. The relatively strong 
staining of axon-like neurites for total NFH in control cells, and in cell body-
located aggregates with weaker staining of the axon-like neurites that remained 
in OP-treated cells, may reflect disruption of the neurofilament network in 
treated cells. This was even more apparent from changes in the staining pattern 
with anti-p-NFH from clear axonal staining in the control cells to mainly 
aggregates in the cell bodies of treated cells suggested that the phosphorylated 
NFH was more highly affected by CPF and CPO treatment at both time points (2 
and 8 h). This disruption in the intracellular distribution of neurofilaments is 
consistent with that observed in previous studies, in which cells were induced to 
differentiate for 24 h in the presence and absence of sub-lethal neurite inhibitory 
concentrations of PSP (Hargreaves et al., 2006), diazinon (Flaskos et al., 2007) 
and CPO (Flaskos et al., 2011).  
 
On the other hand, strong staining patterns with β-tubulin antibody obtained by 
indirect immunofluorescence further confirm the observation of the 
densitometric analysis which revealed no changes in the reactivity of pre-
differentiated N2a cell lysates with antibodies against β-tubulin following 
treatment with 3 µM concentration of either compound. The similar distribution 
of tubulin in cell bodies and neurites of treated and non-treated cells indicated no 
major disruption of the microtubule network, suggesting that microtubules are 
not the main target for OP pesticides in pre-differentiated N2a cells. 
 
In summary, the results presented in this chapter suggest that OP-induced neurite 
retraction in pre-differentiated N2a cells is associated with early transient 
increases in NFH phosphorylation, which is then followed by a decline at 8 h, 
and a transient reduction in GAP-43 but that the level of total NFH and 
microtubules was unaffected.  Increased activation of the ERK1/2 MAP kinase 
signalling pathway accounts for the observed alterations in pNFH at 2 h, whereas 
increased levels of phosphatase activity mediate the dephosphorylation at 8 h. 
Although neither compound was able to affect the levels of HSP-70 and HSP-60, 
CPO seemed to cause a transient inhibition in levels of HSP-90. These findings 
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together demonstrate that, at a molecular level, sub-cytotoxic concentrations of 
CPO induce a similar pattern of effects to those of CPF in pre-differentiated N2a 
cells with respect to the levels and intracellular distribution of cytoskeletal 
proteins and on the levels of growth associated proteins, activation status of 
ERK1/2 and phosphatase activity.  
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5 Development of medium to high throughput assays of 
organophosphate toxicity in pre-differentiated N2a 
cells 
5.1 Introduction 
Neurite outgrowth is one of the main morphological features of 
neurodevelopment, and has been investigated in numerous in vitro studies. 
Extension of neurites (axons and dendrites) during brain development is a crucial 
factor that determines neuronal connectivity (Radio et al., 2008). Thus, 
disruption of this critical cellular process as a result of OP exposure could lead to 
neurodegenerative effects in developing organisms (Rice and Barone, 2000, 
Costa, 2006, Grandjean and Landrigan, 2006). As neurite outgrowth in vitro 
exhibits many of the morphological and molecular changes that occur in axon 
outgrowth during nerve regeneration in vivo, neurotoxin-induced changes in this 
phenomenon may also reflect the ability of xenobiotics to cause axon retraction 
and/or inhibit nerve regeneration in adult animals (Burgoyne, 1991, Berger-
Sweeney and Hohmann, 1997). 
 
The neurotoxic effects of CPF and CPO on neurite outgrowth in pre-
differentiated N2a cells observed in chapter three were assessed using manual 
laboratory techniques, by which the number of axon-like processes was 
quantified per 100 cells following CFSE staining. Although this method 
demonstrated the ability of both compounds to induce changes in the process of 
neurite outgrowth, the acquisition of microscopic images and the subsequent 
quantitative analyses were time-consuming and gave information only about 
neurites that were longer than two cell body diameters in length only (i.e. axon-
like). In addition, the assessment of neurite outgrowth was based on a single 
concentration of both compounds. Although this concentration (3 µM) for CPF 
was previously demonstrated to induce 50% inhibition in the outgrowth of axon-
like processes in pre-differentiated N2a cells without affecting cell viability 
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(Sachana et al., 2001), it provides no information about the concentration-effect 
relationship of these OPs on the cellular model. 
  
Therefore, high throughput/high content screening has been developed using 
fully automated integrated systems for cell imaging and data analysis (Abraham 
et al., 2004, Smith and Eisenstein, 2005). This advanced technology provides 
reliable, time efficient and rapid measurements of neurite outgrowth overcoming 
the common limitations of manual methods used in this study. Additionally, high 
throughput/high content screening can assess the effects of a wide range of 
chemicals and neurotoxicants on multiple parameters of neurite outgrowth such 
as neurite number, neurite length, cell body area and the extent of neurite 
branching. Changes in each endpoint can be analysed and presented as average 
or total count per each individual cell in the captured image (Radio and Mundy, 
2008). Moreover, high throughput/high content assays can be used with different 
cellular models in order to compare and characterise the effects of several OPs or 
other chemicals on neurite outgrowth in multiple cell types (Mundy et al., 2010). 
Earlier reports have validated the feasibility of this approach for evaluating the 
neurotoxicity potential of various chemicals on neurite outgrowth in neural cell 
lines under post- differentiation (Wilson et al., 2014) and co-differentiation 
exposure conditions (Radio et al., 2008, Radio et al., 2010, Harrill et al., 2011, 
Harrill and Mundy, 2011). 
 
As previously mentioned, the molecular basis of the OP-induced effects on 
neurite outgrowth in pre-differentiated N2a cells observed in chapter four were 
examined using immunoblotting techniques. However, the procedure was time 
consuming and effects of both OPs on cytoskeletal proteins and their regulatory 
pathways in pre-differentiated N2a cells was again based on only one 
concentration of both compounds. In order to provide rapid, quantitative dose-
response analysis for the effects of CPF and CPO at different time points, a 
medium to high throughput method such as cell ELISA was developed as part of 
the current study. This idea was first described by Schmuck and Ahr (1997), who 
showed that cells can be differentiated in the presence and absence of OPs and 
the levels of neurite enriched cytoskeletal proteins can be determined by the aid 
of cell ELISA (Schmuck and Ahr, 1997). Some of the advantages of this 
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technique when used as an alternative to Western blotting approach used in the 
previous chapter is the ability to apply several concentrations of both CPF and 
CPO simultaneously on a single microtitre plate and thus, reducing the amount 
of reagents, materials, costs and processing time.  
 
The key aims of this chapter were to develop medium to high throughput assays 
in order to examine the effects of multiple concentrations of CPF and CPO at 
different time points on neurite outgrowth, cytoskeletal proteins and their 
regulatory pathways in pre-differentiated N2a cells in a rapid quantitative 
analysis. This would, in turn, validate the previous findings obtained from 
analysis of CFSE staining and antibody reactivity with Western blots of cell 
lysates treated with a single concentration (3 µM) of both compounds, and help 
to determine the concentration dependence of the response.  
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5.2 Results 
5.2.1 Development of high throughput assays of neurite 
outgrowth    
To quantitatively analyse multiple parameters of neurite outgrowth in pre-
differentiated N2a cells following CPF and CPO treatment, cells were fixed and 
stained by indirect immunofluorescence with antibodies against α-tubulin (clone 
B512) and pNFH (clones Ta51 and SMI34). Monoclonal antibody B512 was 
expected to stain microtubules in axons, dendrites and cell bodies, whereas the 
anti-pNFH antibodies were expected to preferentially stain mainly 
neurofilaments in axons of neuronal cells. These particular antibodies were used 
because they are neurite-enriched cytoskeletal proteins and thus, allowing for the 
OP-induced effects on multiple parameters of neurite outgrowth in pre-
differentiated N2a cells to be investigated. Images of stained monolayers were 
acquired using the ImageXpress Micro Widefield High Content Screening 
System and neurite outgrowth analysis was performed using MetaXpress 
imaging and analysis software, as described in section 2.2.16. 
 
Figure 5.1 demonstrates the segmentation of acquired images obtained by high 
throughput assays used in this part of the current study. All representative images 
shown are from non OP-treated controls stained with B512, Ta51 and SMI34. 
Image acquisition was performed using two wavelengths; FITC to detect cell 
body and neurites (green) and DAPI to identify nucleus of all cells in a field 
(blue). The resultant merged images showed staining distribution of FITC and 
DAPI within each neuronal cell. Image segmentation was then performed using 
MetaXpress imaging and analysis software and displayed as multicoloured 
masks tracing the neurites and cell bodies in the acquired image. For accurate 
image segmentation, the analysis settings of the integrated neurite outgrowth 
application module were optimised and configured to catch maximum relevant 
detail with minimal background noise. The following parameters of neurite 
outgrowth were chosen for the analysis and measurements were provided in 
mathematical algorithms: 
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 Average number of cells/field (total number of neural cell bodies 
averaged by the number of fields) 
 Average cell body area/field (total area of cell bodies in square micron 
averaged by the number of fields) 
 Average number of neurites (total number of neurites produced from the 
cell bodies averaged by the number of fields ) 
 Maximum neurite length/cell (the length in microns of the longest neurite 
from the neuronal cell body to an extreme segment per cell)  
 Average neurite length/cell (the total length in microns of all significant 
outgrowths averaged by the number of cells) 
 Mean processes/cell (average number of neurites longer than 10 µm/cell). 
 Mean branches/cell (average number of branches originating from 
neurites produced by each cell) 
 Significant outgrowth (neurites longer than 10 µm in length) 
 Percentage of cells with significant outgrowth (cells with at least one 
neurite ˃ 10 µm in length). 
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Figure 5.1. Segmentation of stained pre-differentiated N2a cells using high 
throughput screening assays. Cells were fixed and stained with antibodies recognising 
α-tubulin (B512) and pNFH (Ta51 and SMI34) followed by Alexa Fluor® conjugated 
anti-IgG secondary antibodies. All Images shown are from non OP-treated controls from 
a single field of view. Acquired images were obtained using ImageXpress Micro system 
(10x objective) with two wavelengths; FITC for cell body and neurites detection and 
DAPI for nucleus counting. Segmented images with multicoloured tracing masks on 
neurites and cell bodies were generated using the Neurite Outgrowth Module within the 
MetaXpress imaging and analysis software for monitoring different parameters of 
neurite outgrowth. 
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5.2.2 Monitoring multi-parameters of neurite outgrowth in pre-
differentiated N2a cells 
The concentration-range (1, 3, 10 µM) effects of CPF and CPO on neurite 
outgrowth in pre-differentiated N2a cells were investigated following 2 and 8 h 
exposure using high throughput assay. Data of multi-parametric analysis of 
neurite outgrowth obtained by quantitation of B512 and pNFH (clone Ta51) 
staining are shown in this chapter. Confirmatory data using another anti-pNFH 
antibody (clone SMI34) are displayed in appendix (Figure 8.1-8.4). The current 
study focused on the effects of CPF and CPO at 2 and 8 h time points because 
most alterations in neurite outgrowth and associated protein changes were 
observed at these two exposure times in earlier chapters. 
 
Figure 5.2 shows the high throughput data for cell number and cell body area 
obtained by analysis of B512 and Ta51 staining at 2 and 8 h exposure. The 
presented data show that all concentrations of CPF and CPO had no effects on 
the average neuronal cell number/field after 2 and 8 h exposure compared to the 
untreated controls (Figure 5.2A1-A4). Similarly, both B512 and Ta51 staining 
showed no effects on the measurements of cell body area/field of pre-
differentiated N2a cells following 2 h exposure to both OPs (Figure 5.2B1 and 
B2). After 8 h treatment, staining with both antibodies showed slight but not 
significant decreases in the average cell body area/field following exposure to 1 
and 3 µM CPF and CPO compared to non OP-treated control (Figure 5.2B3 and 
B4). However, the highest concentration (10 µM) of both OPs significantly 
reduced this parameter as indicated with B512 (p ˂ 0.01) and Ta51 (p ˂ 0.0001) 
staining (Figure 5.2B3 and B4).   
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Figure 5.2. Effects of CPF and CPO on cell number and cell body area in pre-differentiated N2a cells as assessed by high throughput assays.  Cell 
were then fixed and stained with B512 and Ta51, after which data were acquired using the ImageXpress Micro system and the cell number and cell body 
area were measured using MetaXpress imaging and analysis software. Data show dose-related effects of both CPF and CPO on the average cell number/field 
(A) and the average cell body area (µm
2
)/field (B) with B512 and Ta51 staining at 2 h and 8 h. High throughput data are represented as mean values ± SEM 
from four independent experiments. Data were analysed using two-way ANOVA. The CPF effects are presented as blue solid lines with circles; the CPO 
effects are presented as red dashed lines with triangles. Asterisks indicate changes that are statistically different from the non OP-treated controls with B512 
(*p ˂ 0.01) and Ta51 (*p ˂ 0.0001) staining. When SEM bars are not apparent, this means that error is smaller than the symbol size.  
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The effects of multiple concentrations of CPF and CPO on the average number 
of neurites/field and the percentage of cells with significant outgrowth (neurites 
˃ 10 µm in length) are shown in figure 5.3. As indicated in figure 5.3A1-A4, no 
effects were observed on the average neurite number/field in cells treated with 1 
µM CPF and CPO, but significant decreases (p ˂ 0.001) were detected with 
B512 and Ta51 staining at 3 and 10 µM of both compounds at both time points. 
Following 2 h exposure, the quantitative analysis of both stains for the average 
number of neurites/field in pre-differentiated N2a cells showed that the treatment 
of 3 µM CPF and CPO caused 13% and 18% decline, respectively, compared to 
the corresponding non OP-treated control (Figure 5.3A1 and A2). In addition, 
exposing the cells to a higher concentration of 10 µM reduced the average 
neurite number/field to 30% with CPF and 40% with CPO using both stains 
(Figure 5.3A1 and A2).  
 
When pre-differentiated N2a cells were exposed to both OPs for 8 h, the 
reduction in the average neurite number/field detected by Ta51 staining was 
greater than those obtained with B512 (Figure 5.3A3 and A4). The quantitative 
analysis of B512 staining for the average number of neurites/field in pre-
differentiated N2a cells showed that 3 and 10 µM CPO resulted in 30% and 36% 
decline, respectively (Figure 5.3A3). However, Ta51 analysis demonstrated 33% 
and 55% fall in the average number of axon-like neurite compared to the non 
OP-treated controls at 3 and 10 µM CPO, respectively (Figure 5.3A4). 
 
Figure 5.3B illustrates the number of cells with neurites length above 10 µm (i.e 
significant outgrowth) as quantified by B512 and Ta51 staining following OP 
treatment for 2 and 8 h. Quantitation of B512 staining showed lack of detectable 
changes on the number of cells with significant outgrowth in pre-differentiated 
N2a cells treated with multiple concentrations of CPF and CPO for 2 and 8 h 
(Figure 5.3B1 and B3). In contrast, Ta51 staining showed dose and time-
dependent decreases in this parameter in OP-treated cells at both time points. 
The observed reduction in the number of cells with long neurites was statistically 
significant at 3 and 10 µM CPF and CPO in compare to the non OP-treated 
controls (p ˂0.05). The reduction in number of cells with significant outgrowth 
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was greater at 8 than at 2 h for CPO at both 3 and 10 µM concentrations (Figure 
5.3B2 and B4). 
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Figure 5.3. Effects of CPF and CPO on neurite number and percentage of cells with significant outgrowth in pre-differentiated N2a cells as 
assessed by high throughput analysis.  Cells were stained with B512 and Ta51, after which data were acquired using ImageXpress Micro system and 
measured using MetaXpress imaging and analysis software. Data show dose-related effects of both CPF and CPO on the average neurite number/field (A) 
and the percentage of cells with significant outgrowth (B) at 2 and 8 h with B512 and Ta51 staining. Data are presented as mean values ± SEM from four 
independent experiments for both time points. Data were analysed using two-way ANOVA. The CPF effects are presented as blue solid lines with circles; 
the CPO effects are presented as red dashed lines with triangles. Asterisks indicate changes that are statistically different from the non OP-treated controls    
(p ˂ 0.05). When SEM bars are not apparent, this means that error is smaller than the symbol size. 
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Further parameters of neurite outgrowth such as the maximum and average 
neurite length per neuronal cell were also assessed using high throughput assays. 
Following 2 and 8 h exposure, there was a dose-dependent decrease in both 
parameters of neurite outgrowth in OP-treated cells compared to the non OP-
treated controls. A significant dose-related reduction (p ˂ 0.05) was observed at 
two concentrations (3 and 10 µM) of both CPF and CPO (Figure 5.4A and B).  
 
With regard to the measurement of maximum neurite length per neuronal cell, 
Ta51 staining was more sensitive in detecting long neurites than B512 staining 
(Figure 5.4A1-A4). It can be seen that the maximum neurite length/cell in non 
OP-treated controls obtained by B512 stain ranged from 30 to 37 µm, whereas, 
those measured with Ta51 stain were 46 to 58 µm. Figure 5.4A1 and A3 shows 
the quantitative analyses of B512 for the dose-related effects of both CPF and 
CPO on maximum neurite length/cell; CPF exposure for 2 h had no significant 
effects on this parameter at all concentrations (Figure 5.4A1). However, 8 h 
exposure to 10 µM CPF significantly decreased the maximum length of B512-
positive neurites/cell by 53% compared to the control (p ˂ 0.0001) (Figure 
5.4A3). On the other hand, Ta51 staining exhibited a dose-dependent decline in 
the maximum neurite length/cell following CPO treatment for 2 and 8 h. The 
treatment of pre-differentiated N2a cells with 3 and 10 µM CPO caused a 
significant reduction in maximum neurite length/cell when compared to the non 
OP-treated control (p = 0.005 at 2 h, and p ˂ 0.0001 at 8 h) (Figure 5.4A1 and 
A3). Figure 5.4A2 and A4 shows the measurements of maximum neurite 
length/cell obtained by the analysis of Ta51 staining. This indicated that both 
CPF and CPO at concentrations of 3 and 10 µM were able to induce significant 
reductions in the maximum length of neurites per cell compared to controls at 
both time points in pre-differentiated N2a cells (p ˂ 0.007 at 2 h; p ˂ 0.0001 at 8 
h). 
 
As illustrated in figure 5.4B1-B4, both B512 and Ta51 staining generated similar 
trends for the impacts of multiple concentrations of CPF and CPO on the average 
neurite length per cell at both time points. Following 2 h exposure of both 
compounds, both staining showed that the average neurite length per cell 
measurements were significantly reduced by approximately 25% and 40% at 3 
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and 10 µM, respectively (p ˂0.0001) (Figure 5.4B1 and B2). A further reduction 
in average neurite length per cell was observed following 8 h exposure to CPF 
and CPO. The treatment of 3 µM of both OPs resulted in 30% decrease (p ˂ 
0.0001) in this parameter, while a higher concentration of 10 µM significantly 
reduced the average length of neurites per cell to 45% (p ˂ 0.0001) (Figure 
5.4B3 and B4).  
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Figure 5.4. Effects of CPF and CPO on maximum and average neurite length/cell in pre-differentiated N2a cells as assessed by high throughput 
analysis. Cells were stained with B512 and Ta51, after which data were acquired using ImageXpress Micro system and measured using MetaXpress 
imaging and analysis software. Data show dose-related effects of both CPF and CPO on the maximum neurite length/cell (A) and the average neurite 
length/cell (B) at 2 and 8 h with B512 and Ta51 staining. Data are presented as mean values ± SEM from four independent experiments for both time 
points. Data were analysed using two-way ANOVA. The CPF effects are presented as blue solid lines with circles; the CPO effects are presented as red 
dashed lines with triangles. Asterisks indicate changes that are statistically different from the non OP-treated controls (*p ˂ 0.05). When SEM bars are not 
apparent, this means that error is smaller than the symbol size. 
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Further parameters of neurite outgrowth such as the mean number of processes 
and branches per neuronal cell were also assessed using high throughput assay. 
As demonstrated in figure 5.5A and B, measurements with both B512 and Ta51 
staining show that there was a concentration-dependent decline in the number of 
processes and branches/cell in pre-differentiated N2a cells treated with both CPF 
and CPO for 2 and 8 h compared to non OP-treated controls. A significant dose-
related decrease (p ˂ 0.01) was observed at 3 and 10 µM CPF and CPO at both 
exposure time points. Staining neurites with B512 revealed a higher number of 
processes and branches/cell than those detected by Ta51 staining.   
 
Similar data on the effects of CPF and CPO on neurite outgrowth parameters 
were obtained when another anti-pNFH antibody (SMI34) was used (see 
appendix; Figure 8.1-8.4). 
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Figure 5.5. Effects of CPF and CPO on the mean number of processes and branches/cell in pre-differentiated N2a cells as assessed by high 
throughput analysis. Cells were stained with B512 and Ta51, after which data were acquired using ImageXpress Micro system and measured using 
MetaXpress imaging and analysis software. Data show dose-related effects of both CPF and CPO on the mean processes/cell (A) and the mean branches/cell 
(B) at 2 and 8 h with B512 and Ta51 staining. Data are presented as mean values ± SEM from four independent experiments for both time points. Data were 
analysed using two-way ANOVA. The CPF effects are presented as blue solid lines with circles; the CPO effects are presented as red dashed lines with 
triangles. Asterisks indicate changes that are statistically different from the non OP-treated controls (*p ˂ 0.05). When SEM bars are not apparent, this means 
that error is smaller than the symbol size. 
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5.2.3 Effects of CPF and CPO on the viability of pre-
differentiated N2a cells 
To ensure that the 1-10 µM dose-range of CPF and CPO used in this study was 
non-cytotoxic towards pre-differentiated N2a cells, MTT reduction assays were 
carried out, as described earlier in section 2.2.7. The results demonstrated in 
figure 5.6A and B show that all concentrations of CPF and CPO had no effect on 
the reduction of MTT in OP-treated cells at either time point when compared to 
their corresponding non OP-treated controls. The results obtained from 
traditional MTT viability assay was compatible with high throughput data on cell 
count, which showed that treatment of pre-differentiated N2a cells with 1, 3 and 
10 µM CPF and CPO had no inhibitory effects on cell number. 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. Effects of CPF and CPO on MTT reduction in pre-differentiated N2a 
cells. After 20 h of differentiation, N2a cells were treated without (0.5% v/v DMSO 
control) or with 1, 3 and 10 µM CPF or CPO for 2 and 8 h. The effects of both OPs on 
MTT reduction were measured to evaluate cell viability after 2 h (A) and 8 h (B) 
exposure. Data are expressed as a percentage of the non-OP treated control ± SEM 
from four separate experiments. Data were analysed using one way ANOVA. The CPF 
effects are presented as blue solid lines with circles; the CPO effects are presented as 
red dashed lines with triangles. The lack of asterisks reflect the fact that no statistically 
significant changes were found in MTT reduction in OP-treated cells compared to the 
untreated controls at both time points. When SEM bars are not apparent, this means 
that the error is smaller than the symbol size. 
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5.2.4 Determination of concentration-response effects of CPF 
and CPO on cytoskeletal and associated regulatory 
proteins using cell ELISA 
The effects of multiple concentrations of CPF and CPO on cytoskeletal proteins 
and cell signalling pathway associated with their regulation in neurite outgrowth 
were further assessed in pre-differentiated N2a cells using cell ELISA technique 
for rapid quantification. The changes in the binding levels of these proteins using 
monoclonal antibodies against α-tubulin (clone B512), NFH (clone N52), pNFH 
(clones Ta51 and SMI34), and ERK1/2 MAP kinase were determined and 
quantified in controls and OP-treated cells following 2 and 8 h exposure, as 
described in section 2.2.15. These time points were chosen to focus on 
conditions under which both OPs induced significant changes in Western 
blotting analysis of lysates from cells exposed to a single concentration (3 µM) 
of each compound (Chapter 4). 
 
Quantification of B512 reactivity (which detects total α-tubulin) by cell ELISA 
showed that it was not affected under any of the exposure conditions tested 
(Figure 5.7A1 and A2). Similarly, treatment of pre-differentiated N2a cells with 
all concentrations of both compounds had no effect at either time point on the 
binding levels of N52 (which recognises total NFH) when compared to controls 
(Figure 5.7B1 and B2). 
 
Figure 5.7C1-D2 shows data from cell ELISAs using monoclonal antibodies 
Ta51 and SMI34, which both recognise pNFH. In figure 5.7C1, a dose-
dependent increase was seen in the levels of Ta51 binding in pre-differentiated 
N2a cells treated with both CPF and CPO for 2 h. The elevation in Ta51 levels 
was statistically significant at 3 and 10 µM concentrations of CPF (p = 0.007) 
and CPO (p ˂ 0.0001) compared to that of non OP-treated controls (Figure 
5.7C1). After 8 h incubation with 3 and 10 µM CPF and CPO, a significant 
decline (p ˂ 0.05) was observed in the levels of Ta51 binding in OP-treated cells 
in compare to controls (Figure 5.7C2). A different epitope of pNFH (recognised 
by SMI34) showed no significant changes in the levels of antibody binding to 
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pre-differentiated N2a cells exposed to all concentrations of CPF and CPO 
compared to non OP-treated controls at both time points (Figure 5.7D1 and D2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7. Effects of CPF and CPO on cytoskeletal proteins in pre-
differentiated N2a cells as determined by cell ELISA.  N2a cells were induced to 
differentiate for 20 h before being incubated without (0) or with 1, 3 and 10 µM 
concentrations of CPF or CPO for 2 and 8 h. Changes in the binding levels of 
antibodies that recognise α-tubulin (B512) (panel A), NFH (N52) (panel B) and 
pNFH (Ta51 in panel C and SMI34 in panel D) were quantified in controls and OP-
treated cells following 2 and 8 h exposure using cell ELISA. Data are presented as a 
percentage of the non OP-treated control ± SEM (from four independent 
experiments at both time points). Data were analysed using one-way ANOVA. The 
CPF effects are presented as blue solid lines with circles; the CPO effects are 
presented as red dashed lines with triangles. Asterisks indicate changes that are 
statistically different from the non OP-treated controls (p ˂ 0.05). 
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Since there dose-dependent changes were observed in the levels of binding Ta51 
antibody to pre-differentiated N2a cells treated with CPF or CPO for 2 and 8 h, it 
was of interest to investigate whether these alterations in pNFH could be 
associated with changes in ERK 1/2 MAP kinase activation.  
 
Figure 5.8A1 shows dose-dependent decreases in the binding levels of total ERK 
(tERK) to pre-differentiated N2a cells following 2 h exposure to both CPF and 
CPO. However, this reduction was only statistically significant (p ˂ 0.0001) at 
10 µM concentrations of both compounds when compared to the non OP-treated 
controls. After 8 h exposure (Figure 5.8A2), treatment of pre-differentiated N2a 
cells with up to 10 µM of both OPs showed no effects on the binding levels of 
total ERK. 
 
Figure 5.8B1 and B2 demonstrates the dose-response effects of both CPF and 
CPO on the levels of anti-phosphorylated ERK (pERK) binding to pre-
differentiated N2a cells. Exposure to both compounds for 2 h caused similar 
concentration-dependent increases in the binding levels of pERK antibody, 
which was statistically significant at 3 (p ˂ 0.001) and 10 µM (p ˂ 0.0001) 
compared to non OP-treated controls (Figure 5.8B1). By contrast, compared to 
the control, no changes were observed in anti-pERK reactivity with monolayers 
of pre-differentiated N2a cells exposed to either OP for 8 h (Figure 5.8B2). 
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Figure 5.8. Effects of CPF and CPO on the activation status of ERK1/2 MAP 
kinase on pre-differentiated N2a cells as determined by cell ELISA.  N2a cells 
were induced to differentiate for 20 h before being incubated without (0) or with 1, 3 
and 10 µM concentrations of CPF or CPO for 2 and 8 h. Changes in the binding levels 
of antibodies that recognise total ERK (K-23) (panel A) and phosphorylated ERK (K-
4) (panel B) were quantified in controls and OP-treated cells following 2 and 8 h 
exposure using cell ELISA. Data are presented as a percentage of the non OP-treated 
control ± SEM (from four independent experiments at both time points). Data were 
analysed using one-way ANOVA. The CPF effects are presented as blue solid lines 
with circles; the CPO effects are presented as red dashed lines with triangles. Asterisks 
indicate changes that are statistically different from the non OP-treated controls (p ˂ 
0.05). When SEM bars are not apparent, this means that error is smaller than the 
symbol size. 
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5.3 Discussion 
The main aim of the current chapter was to develop medium to high throughput 
assays to examine the effects of several doses of CPF and CPO on multiple 
parameters of neurite outgrowth in pre-differentiated N2a cells over two time 
points. The amount of data obtained using the high throughput assays represents 
the sensitivity and feasibility of this technique to detect and quantify OP-induced 
changes in neurite outgrowth in a pre-differentiated cell model. The use of a 
fully automated approach in this part of the current study provided rapid analysis 
for the effects of both OPs on neurite outgrowth compared to the manual 
approach of measuring neurite outgrowth (CFSE staining) used in chapter three, 
which gave robust data but was time consuming and gave information restricted 
to longer neurites only. Additionally, the instrumentation of high throughput 
analysis validated the data obtained from the use of a single sub-cytotoxic 
concentration (3 µM) of CPF and CPO at the beginning of this thesis (chapter 3) 
and in previous work (Sachana et al., 2001, Sachana et al., 2005, Flaskos et al., 
2011). 
 
In this study, both anti-α-tubulin (B512) and anti-pNFH (Ta51 and SMI34) 
staining were utilised in order to compare and evaluate the potential of each 
marker in detecting the neurotoxic effects of both OPs on neurite outgrowth. 
B512 staining was expressed in cell bodies and neurites that were both dendrite-
like and axon-like, whereas Ta51 and SMI34 staining was more specific for 
axon-like neurites. As indicated in data of neurite outgrowth parameters obtained 
by high throughput analysis (Figure 5.2), B512 staining detected more cells and 
a large cell body area compared to those quantified with Ta51 staining. 
However, Ta51 was more selective than B512 staining in detecting long neurites. 
Thus, B512 staining was more effective than Ta51 for the quantitative analysis 
of cell number and cell body area parameters, while Ta51 was more suitable for 
axon-like neurite related analysis such as neurite length and number.  
 
The high throughput quantification of pre-differentiated N2a cell number 
indicated that 1-10 µM CPF and CPO had no significant effect on the average 
cell number per field at both exposure time points. The data from the automated 
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high throughput agreed with the dose-response effects of CPF and CPO in MTT 
reduction assays both in the current study and in previous work in our laboratory 
(Sachana et al., 2001, Sachana et al., 2005, Flaskos et al., 2011). Thus, findings 
from both assays confirmed that all concentrations of CPF and CPO used in this 
study were non-cytotoxic towards pre-differentiated N2a cells after 2 and 8 h 
exposure. Similarly, measurements of the average cell body area per field, which 
indicate the circular shape of N2a cell bodies, revealed that both compounds at 1 
and 3 µM had no effect on this parameter. However, the automated system 
detected a reduction in the average cell body area in pre-differentiated N2a cells 
exposed for 8 h to the highest concentration (10 µM) of both CPF and CPO, 
which may suggest that treated cells could becoming more compact in shape at 
that time point. 
 
The quantitative assessment of the average number of neurites per field, 
maximum and average neurite length per cell, number of processes and branches 
per cell, and cells with significant outgrowth all indicate that pre-differentiated 
N2a cells respond to both CPF and CPO in a dose- and time-dependent manner. 
This suggests that the neurite length and branching decrease as the 
concentrations of both OPs and the exposure time increase. The observation that 
these parameters of neurite outgrowth were reduced at concentrations of CPF 
and CPO that have no effects on cell number and viability confirms the sub-
cytotoxic neurite inhibitory effect of both compounds towards pre-differentiated 
N2a cells.  
 
The analysis of neurite outgrowth using high throughput assays in the current 
study can provides a valuable comparison between data generated from this 
automated system and those obtained using manual approaches at the beginning 
of this thesis. In this context, high throughput measurements of maximum and 
average neurite length per each neuronal cell corresponds most closely to the 
determination of axon-like neurites previously measured with the aid of CFSE 
stain following 3 µM CPF and CPO (Chapter 3). Although automated neurite 
length measurements were performed in a rapid and more sensitive way 
compared to the manual gross assessment of long neurites by CFSE staining, 
both approaches were in a good agreement showing that there was a dose-
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dependent decrease in the neurite length and/or long neurite number in pre-
differentiated N2a cells treated with both CPF and CPO for 2 and 8 h. The 
presented data also suggest that both automated and manual assays are suitable 
for assessing neurite outgrowth number and/or neurite length. However, the 
former facilitates rapid generation of more complex datasets for multiple 
compounds, concentrations and parameter measurements.  
 
As axons extend and are guided to their synaptic targets, they form a number of 
branches, which play an essential role in connecting single neuron with multiple 
neurons (Hjorth et al., 2014). Utilisation of high throughput assays for neurite 
outgrowth was sensitive enough to support this study with additional information 
on neurite branching. Such a parameter could not be achieved previously using 
the manual measurement approach due to time constraints. In the current study, 
the data show changes in the actual branching of neurites as another sensitive 
parameter of neurite outgrowth, which was affected by both OPs in a similar 
concentration-dependent manner as other measures of neurite outgrowth in pre-
differentiated N2a cells at both time points. In humans, alterations in the 
formation of axonal branches have been reported in brains affected by 
neurodegenerative diseases (Larner, 1995, Kwon et al., 2006). The observed 
inhibition in the mean branches per cell might indicate a disruption in 
cytoskeletal proteins involved in the formation of neurite branches. For instance, 
increased MAP1B was found to be associated with decreased axonal branching 
in adult dorsal root ganglia neurons (Bouquet et al., 2004). Altered expression of 
GAP-43 in response to neurite branching has been also demonstrated in rat 
hippocampal mossy fibres (Bendotti et al., 1997). Earlier studies also linked the 
accumulation of actin filaments in axons with the formation of neurite branches 
in cultured neurons (Gallo, 2006, Ketschek and Gallo, 2010). Therefore, it would 
be of interest to extend this work to investigate the molecular basis underlying 
the observed effects of CPF and CPO on neurite branching.   
 
The current study has shown that cell-based ELISA is a rapid and simple method 
to study the molecular basis of the observed OP-induced effects on neurite 
outgrowth. Quantification of anti-tubulin and anti-NFH antibody binding in pre-
differentiated N2a cells by cell-based ELISA revealed that both CPF and CPO at 
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neurite inhibitory concentrations (3 and 10 µM) had no effects on the levels of α-
tubulin and total NFH at any time point (Figure 5.5A and B). These data 
suggested that disruption of the expression levels of these proteins was not 
responsible for the observed inhibition in multiple parameters of neurite 
outgrowth in pre-differentiated N2a cells. Although these findings are 
completely compatible with the data presented in chapter four of this thesis in 
which 3 µM concentration CPF and CPO had no effects on the reactivity of the 
same antibodies with Western blots of cell lysates, the cell-based ELISA assay 
demonstrated that even higher concentration (10 µM) of both compounds 
similarly had no effect.  
 
Inhibition of neurite outgrowth was not associated with significant alterations in 
α-tubulin, whilst further analysis using anti-pNFH suggested that there may be a 
change in NFH phosphorylation. In this high throughput part of the study, the 
employed pNFH antibodies (Ta51 and SMI34), which interact with different 
phosphorylated epitopes on the c-terminal Lys-Ser-Pro (KSP) repetitive region 
of NFH, demonstrated different results in the cell ELISA (Shaw, 1991, 
Lichtenberg-Kraag et al., 1992, Sihag et al., 2007). Using cell-based ELISA, the 
binding of anti-SMI34 antibody showed that the levels of phosphorylation at the 
epitope of NFH it recognises were unaffected in pre-differentiated N2a cells after 
CPF and CPO exposure. However, the binding levels of Ta51 antibody 
demonstrated a significant increase in NFH phosphorylation at 2 h and a 
subsequent decrease at 8 h in pre-differentiated N2a cells treated with 3 and 10 
µM CPF and CPO. The quantitative changes on cell ELISA for this antibody are 
consistent with previously observed results (chapter 4) where Western blots 
probed with Ta51 antibody were used to evaluate the effects of 3 µM 
concentration of both OPs on pNFH in pre-differentiated N2a cells. These 
findings suggest that the amount of phosphorylation at the Ta51 epitope changed 
much more than that at the SMI34 epitope. 
 
The discrepancy between the SMI34 and Ta51 antibodies demonstrated in the 
cell ELISA may be due to different effects, possibly by different kinases, at 
different phosphorylation sites on NFH. However, this finding cannot alter the 
fact that there were detectable alterations in NFH phosphorylation at both time 
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points as indicated by Ta51 antibody using two different approaches. Although 
no significant changes in NFH phosphorylation were observed with SMI34 
antibody using cell ELISA, the fact that SMI34 antibody revealed decreases in 
neurite outgrowth parameters in high throughput studies (Appendix; Figure 8.1-
8.4) in the same manner as Ta51 strongly suggests that the retraction of axon-
like neurites has occurred in OP-treated cultures.  
 
The observed alterations in pNFH together with the lack of effects on total NFH 
and α-tubulin at both time points suggest that altered phosphorylation state of 
NFH is dose dependent and represents a specific target for the inhibitory effects 
of CPF and CPO on neurite outgrowth in pre-differentiated N2a cells. The 
observed increase in the reactivity of antibody against pNFH at 2 h and the 
subsequent decline at 8 h exposure to both OPs suggest that the 
hyperphosphorylation of NFH at early time point is transient and followed by a 
reduced phosphorylation state of NFH. This disruption in NFH phosphorylation 
is similar to those found in N2a cells treated with PSP for 24 h under co-
differentiation conditions (Hargreaves et al., 2006). Moreover, the reduction in 
NFH phosphorylation at 8 h is in agreement with a previous study, which 
showed reduced levels of pNFH in N2a cells induced to differentiate for 24 h in 
the presence of TOCP (Fowler et al., 2001). These findings together indicate that 
neurite inhibitory effects of some OPs are associated with their ability to disrupt 
the NFH phosphorylation. 
 
As NF subunits accumulate in the axon, they become extensively phosphorylated 
on the c-terminal domain of NFH. Since phosphorylation of NFH has an 
important role in axon maturity and stability (Sihag et al., 2007), the changes 
observed in NFH phosphorylation at 2 and 8 h could indicate a transient 
hyperphosphorylation of NFH causing disruption in the neurofilament networks 
or a breakdown in their stability and consequently affecting axon stability. It has 
also been demonstrated that extensive phosphorylation of KSP regions in NFH 
results in the formation of sidearm projections, which subsequently affect the 
interactions of NFs with other NFs (Eyer and Leterrier, 1988) and/or other 
cytoskeletal elements such as MTs (Hisanaga and Hirokawa, 1990). 
Additionally, phosphorylation of KSP sites found to decrease the rate of slow 
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axonal transport and increase the axonal diameter (Hirokawa et al., 1984, de 
Waegh et al., 1992). Of particular interest is the fact that disruption of the 
phosphorylation status of NFH has been linked with the axonal degeneration that 
leads to the development of OPIDN following OP exposure (Suwita et al., 1986, 
Abou-Donia and Lapadula, 1990, Abou-Donia, 1993a). In this context, Suwita et 
al. (1986) detected increased phosphorylation of NFH in spinal cord 
neurofilaments isolated from chicken treated with TOCP as an early event in 
OPIDN pathogenesis (Suwita et al., 1986). Furthermore, Jortner et al. (1999) 
demonstrated reduced NFH phosphorylation using a different antibody to pNFH 
(SMI31) in spinal cords of PSP-treated chickens between 4 days of exposure and 
the appearance of OPIDN lesions such as degeneration of myelinated nerve 
fibers (Jortner et al., 1999).  The fact that altered NFH phosphorylation has also 
been described in vivo for other OP treatment underlines the capability of the 
pre-differentiated N2a cell model to predict the in vivo delayed toxicity 
following OP exposure. These findings also suggest that several OPs may be 
able to disrupt the phosphorylation status of NFH.  
 
The observed alterations in NFH phosphorylation confirmed by the data 
presented in this chapter are consistent with the possible disruption of MAPK 
signalling pathways. Thus, the effects of both CPF and CPO on the activation of 
the MAP kinase ERK1/2, one of the MAP kinase family responsible for NFH 
phosphorylation during neurite outgrowth in healthy neurons, were further 
investigated in this study. This is due to that fact that ERK1/2 is activated in N2a 
cells following induction of cell differentiation by serum withdrawal (Hargreaves 
et al., 2006) and this activation is essential for neurite outgrowth (Singleton et 
al., 2000, Lopez-Maderuelo et al., 2001). Additionally, activated ERK1/2 is 
thought to have a role in NFH phosphorylation, by phosphorylating the KSP 
repeats located in NFH protein (Veeranna et al., 1998). In the current study, 2 h 
exposure to 3 and 10 µM concentrations of both CPF and CPO was found to 
increase the levels of anti-pERK antibody with either no detectable change or a 
slight decrease in the levels of anti-total ERK antibody binding to pre-
differentiated N2a cells. These findings suggested that both OP treatments lead 
to increased activation of ERK, which may explain the observed increase in NFH 
phosphorylation at the early time point. The lack of significant changes in the 
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activation of MAP kinase ERK1/2 compared to the control in pre-differentiated 
N2a cells exposed to the same dose-range CPF and CPO for 8 h indicates that 
OP-induced activation of ERK was short-lived. The reduced levels of NFH 
phosphorylation at 8 h with a corresponding decline in the activation ERK 1/2 to 
control levels at the same time could be due at least partly to a transiently 
increased activation of ERK 1/2 at 2 h. The fact that increased levels of protein 
phosphatase activity were found to be associated with decreased NFH 
phosphorylation in pre-differentiated N2a cells treated with 3 µM concentration 
of both compounds for 8 h (chapter 4), suggests that increased phosphatase 
activity could also contribute to the reduced phosphorylation of NFH following 8 
h exposure to both CPF and CPO. However, due to a limited supply of 
phosphatase reagents, the effects of 10 µM CPF and CPO on phosphatase 
activity at 8 h exposure were not investigated and further work would be needed 
to identify the specific phosphatases involved in the modulation of NFH 
phosphorylation in OP-treated cells. 
 
In summary, this chapter demonstrates that high throughput assays can be 
successfully applied to assess the dose-response effects of CPF and CPO on 
multiple parameters of neurite outgrowth in pre-differentiated N2a cells. This 
approach shows that concentration dependent inhibitory effects of both CPF and 
CPO on neurite number and length, processes and branches occur at 
concentrations that have no effects on cell number, the latter being in good 
agreement with the lack of effect on cell viability as determined by MTT 
reduction.  The automated system not only provides rapid analysis but also 
provides other novel information on neurite outgrowth parameters, not easily 
detected manually, showing that both compounds inhibit the branching of neurite 
in a concentration-dependent manner. Consistency with data obtained from MTT 
reduction and CFSE assays in chapter three, further confirms that manual 
counting techniques were useful and reliable in detecting the neurite inhibitory 
neurotoxic effects of both OPs in pre-differentiated N2a cells. The study 
presented in this chapter also illustrates the value of B512, Ta51 and SMI34 
antibodies to detect biomarkers of neurite outgrowth via high throughput assays 
in the N2a cell model. At a molecular level, the cell-based ELISA developed in 
this chapter represents a useful alternative and sensitive approach to detect the 
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dose-response changes in cytoskeletal proteins and associated signalling 
pathways disrupted by OPs in pre-differentiated N2a cells. Findings from this 
approach correlate well with Western blot results, showing that neurite 
outgrowth inhibitory effects of both CPF and CPO are accompanied by 
significant alterations in the levels of NFH phosphorylation and disruption in the 
activation status of ERK 1/2. In order to examine whether neurite outgrowth and 
the cytoskeleton are affected in a similar manner in a more human relevant cell 
model, the effects of both CPF and CPO on a human neural progenitor cell line 
are examined in the next chapter.                        .                             
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6 Testing the effects of chlorpyrifos and chlorpyrifos 
oxon in a human neural progenitor stem cell model 
6.1 Introduction 
Although the work presented in this thesis has focused mainly on the toxic 
effects of CPF and CPO on pre-differentiated N2a cell line of mouse origin, it 
was also of interest to test the effects of these toxins on cell differentiation in a 
more human relevant cell model. The benefits of using neural progenitor stem 
cells derived from human is that measuring neurite outgrowth in a cellular model 
that more closely resembles the complexity of the human nervous system 
neurons in situ, can be more effective at predicting the chemical-related changes 
in vivo (Radio and Mundy, 2008).  
 
Neural stem cells were first isolated from different regions of embryonic human 
brain (Vescovi et al., 1999). Recent advances have also led to the isolation of 
human neural progenitor stem cells from the neocortex region in adult nervous 
system (Richardson et al., 2006). Since then the human neural progenitor stem 
cells have become valuable tools for neuroscience research. Evaluating the 
toxicity of xenobiotics on human neural cells can reduce the level of uncertainty 
associated with cells derived from animal models (Donato et al., 2007). Earlier 
research using human neural progenitor stem cells was restricted because of the 
short life span in culture and the limited capacity to maintain a stable phenotype 
and genotype across passages (Wright et al., 2006, Donato et al., 2007). 
Development of immortalised human neural progenitor stem cells using the myc 
oncogenic transcription factor was highly effective at overcoming these 
limitations (Dang et al., 1999, Kim, 2004). The ability of these cells to 
accommodate self-renewal, which generates large numbers of cells, together 
with their genomic stability is the key advantage of immortalisation using myc 
technology. These features have facilitated the utilisation of these cells for 
toxicity screening (Klemm and Schrattenholz, 2004).  
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An example of such immortalised human neural progenitor stem cell line is the 
commercially available ReNcell CX cell line (Merck Millipore), which was 
derived from a 14-week human foetal brain cortex. ReNcell CX cells can 
differentiate into a mixed population of neurons, astrocytes and oligodendrocytes 
upon mitogen withdrawal (Donato et al., 2007, Kornblum, 2007). Due to their 
immortalisation with myc oncogene transduction, these cells have the capacity 
for self-renewing as they are multipotent, as well as phenotypically and 
genetically stable (Donato et al., 2007). Thus, ReNcell CX is a useful model for 
assessing neurotoxicity in vitro (Breier et al., 2008). Using high throughput 
assays, Breier et al. (2008) used ReNcell CX cells in an undifferentiated state to 
evaluate the effects of chemicals such as lead acetate and methyl mercury 
chloride on neural stem cell proliferation and viability (Breier et al., 2008). 
However, chemical-induced changes in neurite outgrowth in differentiated 
ReNcell CX cells are yet to be investigated. Despite the large number of 
potential neurotoxicants investigated on ReNcell CX and other human neural 
progenitor stem cells, to date the effects of CPF and CPO on these cell lines have 
not been evaluated. Therefore, it was of interest to study the effects of CPF and 
CPO on a human relevant cell model. It was of further interest to determine 
whether this human neural progenitor stem cell line, which contains mixture of 
neuronal and glial cells at early differentiation stage was affected by both 
compounds in a similar manner as pre-differentiated N2a cells.  
 
To achieve these aims, ReNcell CX cells were utilised as a cell model in the 
current study. Under post differentiation exposure conditions similar to those 
applied to N2a cells, cells were exposed to multiple concentrations of CPF and 
CPO for 2 and 8 h. High throughput screening assays were used to assess the 
effects of OPs on multiple parameters of neurite outgrowth, and to confirm the 
expression of mature neural stem cell markers βIII-tubulin, pNFH and GFAP. 
MTT reduction assays were also used to assess the viability of cells following 
OP exposure. Additionally, the effects of both compounds on the enzymatic 
activity of AChE of pre-differentiated ReNcell CX cells were tested at both time 
points. Finally, cell ELISA assays were carried out to study the molecular 
mechanism underlying the neurotoxic effects of both CPF and CPO on neurite 
outgrowth in pre-differentiated ReNcell CX cells. 
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6.2 Results 
6.2.1 Characterisation of differentiated ReNcell CX cells  
ReNcell CX cells were induced to differentiate for 20 h before being treated 
without (0.5% v/v DMSO control) or with 1, 3 and 10 µM CPF or CPO for 2 and 
8 h (section 2.2.2). Upon the removal of growth factors from culture medium, 
ReNcell CX cells are capable of differentiation into a co-culture of neurons, 
astrocytes and oligodendrocytes (Donato et al., 2007, Kornblum, 2007). To 
confirm the phenotypes of differentiated ReNcell CX cells, these cells were 
immunostained with DAPI nuclear counterstain, anti-βIII- tubulin, anti-pNFH 
(clone Ta51) and anti-GFAP primary antibodies. These antibodies were chosen 
because βIII-tubulin and pNFH are neuronal-specific markers, which stain the 
neuronal cell body and neurites (axon and/or dendrites) effectively. GFAP was 
also selected as it is highly expressed by astrocytes and is considered as a useful 
marker of astroglial neurotoxicity (Harry et al., 1998). Utilising high throughput 
screening, the expression of neuronal and glial-specific markers was examined 
and viewed prior commencing the analysis of neurite outgrowth (section 2.2.16). 
 
Figure 6.1 demonstrated representative images of pre-differentiated ReNcell CX 
cells. Following 20 h of induction of cell differentiation, ReNcell CX cells were 
successfully differentiated into subpopulations of developing neuronal and glial 
cells as indicated by their ability to express neuronal markers βIII-tubulin (Figure 
6.1A) and pNFH (Figure 6.1B), and the astroglial-marker GFAP (Figure 6.1C). 
Pre-differentiated ReNcell CX cells were positive for all neural cell markers. 
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Figure 6.1. Characterisation of differentiated ReNcell CX cell line. Cells were induced 
to differentiate for 20 h by mitogen removal before being fixed and stained with 
antibodies recognising the neuronal markers βIII-tubulin (A) and pNFH (B), and the glial 
marker GFAP (C) followed by Alexa Fluor
® 
488 conjugated anti-IgG secondary 
antibodies. The representative images shown are from untreated control cells from a 
single field of view, with FITC excitation wavelength for neurites and cell bodies (green). 
Images were acquired using ImageXpress Micro Widefield High Content Screening 
system and captured using a 10x objective lens and Nikon camera system. Arrows show 
typical axon-like processes detected in neuronal cells (A and B) and astrocyte extensions 
(C) in pre-differentiated ReNcell CX cells. Scale bar represents 100 µm. 
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6.2.2 Effects of CPF and CPO on multiple parameters of neurite 
outgrowth in pre-differentiated ReNcell CX cells 
Using high throughput analysis, the effects of CPF and CPO were assessed over 
a concentration range of 1-10 µM on multi-parameters of neurite outgrowth in 
pre-differentiated ReNcell CX cells after 2 and 8 h exposure. The parameters 
used to determine the effects of both compounds on ReNcell CX cells were 
similar to those applied in N2a cells experiments, which included cell number, 
cell body area, neurite number, percentages of cells with significant outgrowth, 
maximum and average neurite length and mean processes/cell. Additionally, the 
average intensity of βIII-tubulin, pNFH and GFAP staining within neurites and 
cell bodies of each antibody-positive cell were evaluated by high throughput 
assay, as described in section 2.2.16. 
 
Figure 6.2 demonstrates the segmentation of acquired images obtained by high 
throughput assay employed in this part of the current study. All representative 
images shown are from untreated control ReNcell CX cells from a single field of 
view. Image acquisition was performed using two wavelengths; FITC to detect 
cell body and neurites (green) and DAPI to identify the nucleus of all cells in a 
field (blue). The resultant merged images showed staining distribution of FITC 
and DAPI within each cell type. Image segmentation was then performed using 
MetaXpress offline analysis software and displayed as multicoloured masks 
tracing the neurites and cell bodies in the acquired image. It can be seen that the 
staining patterns of antibodies to βIII-tubulin, pNFH and GFAP were accurately 
detected allowing for the OP-induced effects on multiple parameters of neurite 
outgrowth in pre-differentiated ReNcell CX cells to be evaluated.  
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Figure 6.2. Segmentation of stained pre-differentiated ReNcell CX cells using high 
throughput screening assay.  Cells were induced to differentiate for 20 h before being 
incubated with or without 1, 3 and 10 µM CPF or CPO for 2 and 8 h. Cells were fixed and 
stained with antibodies recognising the neuronal marker βIII-tubulin and pNFH, and the 
glial marker GFAP followed by Alexa Fluor
® 
conjugated anti-IgG secondary antibodies. 
All Images shown were from untreated controls from a single field of view. Acquired 
images were obtained using ImageXpress Micro system (10x objective) with two 
wavelengths; FITC for detecting cell bodies and neurites and DAPI for nucleus counting. 
Segmented images with multicoloured tracing masks on neurites and cell bodies were 
generated using the Neurite Outgrowth Module within the MetaXpress analysis software 
for monitoring different parameters of neurite outgrowth including cell number, cell body 
area and outgrowth length for each identified cell. 
The effects of CPF and CPO on ReNcell CX cells                                  Chapter 6 
159 
 
Figure 6.3 shows the dose-related effects of CPF and CPO following 2 and 8 h 
exposure on the average cell number/field and the average cell body area/field in 
pre-differentiated ReNcell CX cells. The presented high throughput data show 
that all concentrations of CPF and CPO had no effects on either the average 
number of both neuronal and glial cells/field or on the average area of cell 
bodies/field after 2 and 8 h exposure compared to untreated controls, as indicated 
by the analysis of anti-βIII-tubulin, anti-pNFH and anti-GFAP staining (Figure 
6.3A and B).  
 
The average number of non OP-treated neuronal cells/field after 20 h 
differentiation was between 295 and 271 cells as detected with βIII-tubulin 
marker and between 225 and 200 cells with Ta51 staining (Figure 6.3A1-A2, 
A4-A5). The average count of differentiated glial cells ranged between 303 to 
246 cells/field in controls, as indicated by anti-GFAP staining (Figure 6.3A3 and 
A6). Exposure of pre-differentiated ReNcell CX cells to CPF and CPO at all 
doses had no significant effect on the average number of neuronal or glial 
cells/field compared to the non OP-treated controls (Figure 6.3A).  
 
Figure 6.3B displays the high throughput measurement of the average cell body 
area/filed in both neuronal and glial cell populations. It can be seen that the 
average neuronal cell body area/field is greater than glial cell body area, as 
indicated by antibody staining of βIII-tubulin and GFAP markers, respectively. 
The average neuronal cell body area/field measured with Ta51 staining was 
smaller than that obtained by βIII-tubulin. This is probably due to the fact that 
Ta51 preferentially stains axons. The data also demonstrated that CPF and CPO 
at all concentrations had no effect on this parameter following 2 and 8 h 
exposure compared to non OP-treated controls. 
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Figure 6.3. Effects of CPF and CPO on cell number and cell body area of pre-
differentiated ReNcells CX cells as assessed by high throughput assay.  Cells were 
fixed and stained with antibodies recognising the neuronal markers βIII-tubulin and 
pNFH, and the glial marker GFAP followed by Alexa Fluor
® 
488 conjugated anti-IgG 
secondary antibodies. OP-induced effects on multiple parameters of neurite outgrowth 
were measured using MetaXpress imaging and analysis software. Data show the dose-
related effects of both CPF and CPO on the average cell number/field (A), and the 
average cells body area/field (B) with βIII-tubulin, pNFH and GFAP staining. The CPF 
effects are presented as blue solid lines with circles; the CPO effects are presented as red 
dashed lines with triangles. Data are represented as mean values ± SEM from four 
independent experiments. Both sets of data were analysed using two-way ANOVA. When 
SEM bars are not apparent, this means that error is smaller than the symbol size 
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Specific parameters of neurite outgrowth such as the average number of 
neurites/field and the percentage of cells with significant outgrowth (cells with 
neurites longer than 10 µm in length) were also obtained using high throughput 
assay (Figure 6.4). As demonstrated in figure 6.4A, the data of the average 
number of neurites/field (dendrites and axons-like processes) suggest that, while 
the number of neuronal and glial cells/field was unaffected, the average number 
of neurites in both cells/field was significantly (p ˂ 0.05) decreased in OP-treated 
cells after 8 h exposure compared to controls.  
 
In neuronal cells, the average number of neurites/field (dendrites and axons) in 
untreated control ranged between 40 and 25 neurites/field as obtained with βIII-
tubulin marker (Figure 6.4A1 and A4). The quantitative analysis of Ta51 showed 
that at least 18 of the detected neurites were axon-like processes in the controls 
(Figure 6.4A2 and A5). In glial cells, GFAP staining demonstrated 18 to 17 
glial-extensions in the non OP-treated controls (Figure 6.4A3 and A6).  
 
Exposure of pre-differentiated ReNcell CX cells to all concentrations of CPF and 
CPO for 2 h had no effect on the average number of neurites/field generated 
from neuronal or glial cells when compared to the untreated control (Figure 
6.4.A1, A2 and A3). After 8 h treatment, no change was observed in the average 
number of neurites/field in cells treated with 1 and 3 µM CPF and 1 µM CPO 
compared to the non OP-treated control as indicated with βIII-tubulin staining. 
However, the same staining detected a significant (p ˂ 0.005) reduction in the 
average neurite number/field by 24% and 42% in cell treated with 10 µM CPF 
and CPO, respectively compared to the untreated control (Figure 6.4A4). 
 
As indicated in figure 6.4A5, pNFH staining showed no effects on the average 
number of axon-like processes/field following 8 h treatment with 1 µM CPF and 
CPO. However, significant decreases (p ˂ 0.05) in the average number of axon-
like processes/field were detected with Ta51 staining at 3 and 10 µM 
concentrations of both compounds after 8 h exposure. The quantitative analysis 
of Ta51 staining showed that 8 h treatment with 3 µM CPF and CPO caused 
20% and 29% decline, respectively compared to the non OP-treated control. In 
addition, exposing the cells to 10 µM of both compounds for 8 h reduced the 
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number of axon-like processes/field to 35% with CPF and 52% with CPO when 
compared to non OP-treated control (Figure 6.4A5).  
 
The quantitative analysis of GFAP presented in figure 6.4A6 showed that CPF 
and CPO exposure for 8 h cause a significant (p ˂ 0.01), concentration-
dependent reduction in the number of glial-extensions/field in pre-differentiated 
ReNcell CX cells compared to the non OP-treated control. At concentrations of 3 
and 10 µM CPF, a fall in the average glial-extensions number/field was observed 
of 26% and 39%, respectively, compared to non OP-treated controls. The 
average number of glial extensions/field was further reduced compared to non 
OP-treated controls by 34% and 55% in cells treated with 3 and 10 µM CPO, 
respectively (p ˂ 0.05) (Figure 6.4A6).  
 
Quantification of cells with outgrowths greater than 10 µm in length showed that 
CPF and CPO are capable of inducing neurite retraction (Figure 6.4B). In the 
non OP-treated control, βIII-tubulin staining showed 65% to 70% of neuronal 
cells with significant outgrowth (outgrowth length ˃10 µm) including dendrites 
and axon-like processes. However, only 40% of neuronal cells contain axon-like 
processes as indicated with Ta51 staining. After 2 h exposure to both 
compounds, the percentage of βIII-tubulin-positive neuronal cells with 
outgrowth greater than 10 µm fell significantly (p ˂ 0.05) by 8% and 16% of 
control value at 3 and 10 µM, respectively (Figure 6.4B1). This percentage was 
further significantly (p ˂ 0.05) reduced by 15% and 23% of control value 
following 8 h treatment with 3 and 10 µM concentrations of both compounds, 
respectively (Figure 6.4B4). The quantitative analysis of Ta51 staining 
demonstrated that CPF and CPO induced a significant, dose-dependent decrease 
in the number of neuronal cells with axon-like processes in cultures of pre-
differentiated ReNcell CX cells, although the observed reduction after 2 h 
exposure to both compounds was similar to that detected at 8 h. As indicated in 
figure 6.4B2 and B5, no effect was observed in the percentages of cells with 
significant outgrowth after exposure to 1 µM CPF. However, CPF at 3 and 10 
µM caused significant (p ˂ 0.05) reduction by 24% and 33% of untreated control 
value, respectively. Similarly, exposure to CPO at 1, 3 and 10 µM resulted in 
12%, 25% and 39% inhibition, respectively (p ˂ 0.05)  (Figure 6.4B2 and B5).     
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The quantitative analysis of GFAP staining in figure 6.4B3 and B6 showed that 
CPO at all doses and CPF at 3 and 10µM had the ability to interfere with the 
length of glial cell extensions in cultures of pre-differentiated ReNcell CX cells. 
As indicated in figure 6.4B3, exposure to 10 µM CPF and CPO significantly (p 
˂0.0001) reduced the percentage of glial cells with extensions ˃ 10µm by 23% 
and 40%, respectively compared to the non OP-treated control at 2 h. Increasing 
the exposure time to 8 h, resulted in 44% and 50% decrease in the percentage of 
glial cells with significant extensions compared to untreated controls (Figure 
6.4B6).  
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Figure 6.4. Effects of CPF and CPO on neurite number and percentage of cells with 
significant outgrowth in pre-differentiated ReNcells CX cells as assessed by high 
throughput assay.  Cells were fixed and stained with antibodies recognising the neuronal 
markers βIII-tubulin and pNFH, and the glial marker GFAP followed by Alexa Fluor® 
488 conjugated anti-IgG secondary antibodies. OP-induced effects on multiple 
parameters of neurite outgrowth were measured using MetaXpress imaging and analysis 
software. Data show the dose-related effects of both CPF and CPO on the average neurite 
number/field (A), and the number of cells with significant outgrowth (%) (B) with βIII-
tubulin, pNFH and GFAP staining. The CPF effects are presented as blue solid lines with 
circles; the CPO effects are presented as red dashed lines with triangles. Data are 
represented as mean values ± SEM from four independent experiments. Both sets of data 
were analysed using two-way ANOVA. Asterisks demonstrate changes that are 
statistically different from the non OP-treated controls (*p ˂ 0.05). When SEM bars are 
not apparent, this means that error is smaller than the symbol size. 
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High throughput analysis further revealed the maximum length of neurites per 
each neuronal and glial cell after 20 h of differentiation. With βIII-tubulin 
staining, the maximum length of neurites in non OP-treated control ranged 
between 10 to 14 µm (Figure 6.5A1 and A4), whereas the maximum length of 
Ta51-positive-neurites was 22 µm (Figure 6.5A2 and A5). In GFAP positive 
cells, the maximum length of glial extensions ranged between 17-22 µm in 
untreated controls (Figure 6.5A3 and A6). 
 
As illustrated in figure 6.5A, there was a significant dose and time-dependent 
reduction in the maximum neurite length per cell for both neurons and glia in 
cultures of pre-differentiated ReNcell CX cells following CPF and CPO 
exposure for 2 and 8 h. The analysis of βIII-tubulin staining demonstrated that 
after 2 h treatment, the maximum length of neurites per neuronal cell was 
significantly reduced by approximately 16% and 33% at 3 and 10 µM CPF, 
respectively, and by 18% and 28% at 3 and 10 CPO, respectively (p ˂0.0001) 
(Figure 6.5A1). A greater reduction in the maximum neurite length per neuronal 
cell was observed following 8 h exposure to CPF and CPO. Treatment with 3 
and 10 µM CPF resulted in 20% and 39% decrease, respectively (p ˂ 0.0001), 
while CPO exposure at 3 and 10 µM concentrations caused 33% and 49% 
decline, respectively (p ˂ 0.0001) (Figure 6.5A4). However, both compounds at 
1 µM had no significant effects upon this parameter at either time points (Figure 
6.5A1 and A4). 
 
Similar effects of CPF and CPO on the maximum length of Ta51-positive (axon-
like) neurites was also observed. At concentrations of 1, 3 and 10 µM, CPO was 
found to induce a significant inhibitory effect on the maximum length of 
axons/neuronal cells in pre-differentiated ReNcell CX cells after both 2 and 8 h 
exposure, with 10 µM CPO causing 39% and 43% reduction, respectively (p ˂ 
0.0001) compared to the non OP-treated control (Figure 6.5A2 and A5). 
Although CPF at 1 µM had no effect on the maximum length of such neurites 
after 2 and 8 h exposure, concentrations of 3 and 10 µM caused significant 
reductions of 11% (p ˂ 0.05) and 20% (p ˂ 0.0001) compared to controls at both 
time points (Figure 6.5A2 and A5).  
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Measurements of glial cells extension length were also obtained using high 
throughput with the aid of GFAP staining. As demonstrated in figure 6.5A3 and 
A6, the maximum length of astrocyte extensions/cell ranged between 17 to 22 
µm in untreated controls. Exposure of pre-differentiated ReNcell CX cells to 
CPF and CPO for 2 and 8 h caused a significant (p ˂ 0.05), dose- and time-
dependent decrease in the maximum neurite length per glial cell compared to 
non OP-treated controls (Figure 6.5A3 and A6). The data in figure 6.5A3 
indicated that 2 h exposure to CPF at 1 and 3 µM, and CPO at 1 µM 
concentrations caused a slight but not significant reduction in the maximum 
neurite length/cell compared to the untreated controls. However, a significant (p 
˂ 0.05) decline was observed at 10 µM CPF (24% decrease), 3 and 10 µM CPO 
(28% and 36% decline, respectively) compared to the maximum neurite 
length/cell in the non OP-treated controls (Figure 6.5A3).  
 
Figure 6.5A6 show that, after 8 h treatment, the maximum neurite length/glial 
cell was further decreased compared to untreated controls, with 3 and 10 µM 
CPF causing 20% and 27% reduction, respectively. In addition, it can be seen 
that all concentrations of CPO (1, 3 and 10 µM) significantly (p ˂ 0.0001) 
reduced the length of GFAP-positive extension outgrowth by 13%, 29% and 
42%, respectively compared to the non OP-treated control (Figure 6.5A6). 
  
The data in figure 6.5B demonstrated that both compounds significantly (p ˂ 
0.05) decreased the average neurite length per cell in pre-differentiated ReNcell 
CX cells in a similar manner as the maximum neurite length per cell at both time 
points. With βIII-tubulin staining, the average length of neurites/cell in non OP-
treated control ranged between 8 to 5 µm (Figure 6.5B1 and B4). After 2 h 
treatment, this parameter was significantly reduced by approximately 12.5% and 
25% at 3 and 10 µM CPF, respectively and by 20%, 36% and 47% at 1, 3 and 10 
CPO, respectively (p ˂0.05) (Figure 6.5B1). However, no effect was observed on 
the average neurite length per cell after 2 h exposure with 1 µM CPF (Figure 
6.5B1). A greater reduction in the average neurite length per neuronal cell was 
observed following 8 h exposure to CPF and CPO. Treatment with 10 µM CPF 
resulted in 41% decrease (p ˂ 0.001), while CPO exposure at 3 and 10 µM 
concentrations caused 36% and 50% decline (p ˂ 0.0001), respectively compared 
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to the non OP-treated controls (Figure 6.5B4). However, both compounds at 1 
µM and CPF at 3 µM had no significant effects upon this parameter at 8 h 
exposure (Figure 6.5B4). 
 
The analysis of Ta51 staining demonstrated that CPF at 1 and 3 µM had no 
effects on the average length of neurites per neuronal cell after 2 h exposure 
(Figure 6.5B2). However, this parameter was significantly reduced by 
approximately 20% at 10 µM CPF (p ˂0.01), and by 14% (p ˂0.02), 24% (p 
˂0.001), and 38% (p ˂0.0001) at 1, 3 and 10 CPO, respectively compared to the 
non OP-treated control (Figure 6.5B2). After 8 h treatment, the average length of 
neurites per neuronal cell was significantly decreased by approximately 17% and 
37.5% at 3 and 10 µM CPF, respectively, and by 26%, 38% and 47% at 1, 3 and 
10 CPO, respectively (p ˂0.0001) (Figure 6.5B5). However, no significant 
change was observed on the average neurite length per cell after 8 h exposure 
with 1 µM CPF (Figure 6.5B5).  
 
Figure 6.5B3 and B6 show that the average length of astrocyte extensions/cell 
ranged between 10 to 12 µm in the non OP-treated controls. Exposure of pre-
differentiated ReNcell CX cells to CPF and CPO for 2 and 8 h caused a 
significant (p ˂ 0.05), concentration-dependent decrease in the average neurite 
length per glial cell compared to the non OP-treated controls. As indicated in 
figure 6.5B3, CPF exposure at 3 and 10 µM concentrations significantly (p 
˂0.0001) reduced this parameter by 16% and 27%, respectively compared to the 
non OP-treated control at 2 h. In addition, exposure of cells to all concentrations 
of CPO (1, 3 and 10 µM) significantly (p ˂ 0.0001) decreased the average length 
of GFAP-positive neurite by 12.5%, 25% and 35%, respectively compared to the 
non OP-treated control at the same time point (Figure 6.5B3). Similar levels of 
reduction in the average neurite length per neuronal cell were also observed 
following CPF and CPO exposure for 8 h (Figure 6.5B6). Treatment with 3 and 
10 µM CPF resulted in 11% and 29% decrease (p ˂ 0.01), respectively, while 
CPO exposure at 1, 3 and 10 µM concentrations caused 9%, 25.5%, and 40% 
decline (p ˂ 0.01), respectively compared to the non OP-treated controls (Figure 
6.5B6). However, CPF at 1 µM had no significant effects upon this parameter at 
both time points (Figure 6.5B3 and B6). 
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Figure 6.5. Effects of CPF and CPO on the maximum and average neurite length 
per cell in pre-differentiated ReNcells CX cells as assessed by high throughput 
assay.  Cells were fixed and stained with antibodies recognising the neuronal markers 
βIII-tubulin and pNFH, and the glial marker GFAP followed by Alexa Fluor® 488 
conjugated anti-IgG secondary antibodies. OP-induced effects on multiple parameters of 
neurite outgrowth were measured using MetaXpress imaging and analysis software. Data 
show dose-related effects of both CPF and CPO on maximum neurite length/cell (A), and 
average neurite length/cell (B) with βIII-tubulin, pNFH and GFAP staining. The CPF 
effects are presented as blue solid lines with circles; the CPO effects are presented as red 
dashed lines with triangles. Data are represented as mean values ± SEM from four 
independent experiments. Both sets of data were analysed using two-way ANOVA. 
Asterisks indicate changes that are statistically different from the non OP-treated controls 
(*p ˂ 0.05). When SEM bars are not apparent, this means that error is smaller than the 
symbol size. 
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The impacts of multiple concentrations of CPF and CPO on the mean number of 
processes per cell were also evaluated using high throughput analysis. As 
indicated in figure 6.6A, staining of pre-differentiated ReNcell CX cells with 
βIII-tubulin, pNFH and GFAP showed that there were no overall changes on this 
parameter of neurite outgrowth following exposure to all doses of CPF and CPO 
for 2 or 8 h. Approximately 3 processes/cell were detected with anti-βIII-tubulin.  
However, only one per cell was detected by Ta51 staining. This observation 
indicates that there were more dendrites than axons, which is a typical 
characteristic of differentiated neuronal cells. GFAP staining detected one 
extension per glial cell, which remained the same after 2 and 8 h exposure to 
both OPs. 
 
Data in figure 6.6B1 and B4 show that there was no significant change in the 
average intensity of βIII-tubulin staining within neuronal cells after CPF and 
CPO treatment for 2 and 8 h compared to untreated controls. The data in figure 
6.6B3 and B6 demonstrate that the average intensity of GFAP staining within 
glial cells was slightly but not significantly increased after both OP treatment for 
2 and 8 h compared to control. By contrast, a dose-dependent decrease in the 
average intensity of Ta51 within neuronal cells was observed in OP-treated cells 
following 2 and 8 h exposure compared to untreated control (Figure 6.6B2 and 
B5). After 2 h exposure to both compounds, this reduction was statistically 
significant (p ˂ 0.0001) at 3 and 10 µM causing 18% and 28% decline, 
respectively compared to untreated control (Figure 6.6B2). Further reduction was 
also observed in the average intensity of Ta51 staining after 8 h, which was 
significant (p ˂ 0.0001) at 3 and 10 µM CPF (11% and 19.5%, respectively) and 
1, 3, 10 µM CPO causing 8.5%, 19% and 28% decrease, respectively (Figure 
6.6B5).  
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Figure 6.6. Effects of CPF and CPO on the mean number of processes per cell and 
staining intensity in pre-differentiated ReNcells CX cells as assessed by high 
throughput assay.  Cells were fixed and stained with antibodies recognising the neuronal 
markers βIII-tubulin and pNFH, and the glial marker GFAP followed by Alexa Fluor® 
488 conjugated anti-IgG secondary antibodies. OP-induced effects on multiple 
parameters of neurite outgrowth were measured using MetaXpress imaging and analysis 
software. Data show dose-related effects of both CPF and CPO on mean processes/cell 
(A), and average staining intensity (B) with βIII-tubulin, pNFH and GFAP staining. The 
CPF effects are presented as blue solid lines with circles; the CPO effects are presented as 
red dashed lines with triangles. Data are represented as mean values ± SEM from four 
independent experiments. Both sets of data were analysed using two-way ANOVA. 
Asterisks indicate changes that are statistically different from the non OP-treated controls 
(*p ˂ 0.0001). When SEM bars are not apparent; it means that the error is smaller than 
the symbol size. 
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6.2.3 Effects of CPF and CPO on the viability of pre-
differentiated ReNcell CX cells 
To examine the viability of pre-differentiated ReNcell CX cells after being 
exposed to both OPs, MTT reduction assays were performed, as described in 
section 2.2.7. Figure 6.7 shows the concentration-related effects of CPF and CPO 
after 2 and 8 h exposure in pre-differentiated ReNcell CX cells. The data 
indicated that all concentrations of CPF and CPO tested had no significant effect 
on MTT reduction in pre-differentiated ReNcell CX cells when compared to the 
untreated controls at both time points (Figure 6.7A and B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7. Effects of CPF and CPO on MTT reduction in pre-differentiated 
ReNcell CX cell. After 20 h of differentiation, ReNcell CX cells were treated without 
(0.5% v/v DMSO control) or with 1, 3 and 10 µM CPF or CPO for 2 and 8 h. The 
effects of both compounds on MTT reduction were measured to evaluate cell viability 
after 2 h (A) and 8 h (B) exposure. Data are expressed as a percentage of the non-OP 
treated control ± SEM from four separate experiments. Data were analysed using one 
way ANOVA. The CPF effects are presented as blue solid lines with circles; the CPO 
effects are presented as red dashed lines with triangles. The lack of asterisks reflect the 
fact that no statistically significant changes were found in MTT reduction in OP-treated 
cells compared to the untreated controls at both time points. When SEM bars are not 
apparent, this means that the error is smaller than the symbol size. 
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6.2.4 Effects of CPF and CPO exposure on AChE activity in pre-
differentiated ReNcell CX cells 
 
To determine whether the observed morphological changes in pre-differentiated 
ReNcell CX cells could be related to an effect on the acute toxicity target AChE, 
the impact of CPF and CPO on the activity of AChE was assessed, as explained 
in section 2.2.9.  
 
After 2 and 8 h exposure, it can be seen that CPF at 1 and 3 µM had no 
significant effect on AChE activity of pre-differentiated ReNcell CX cells 
compared to non OP-treated controls (Figure 6.8A and B). In contrast, CPF at 
higher concentration (10 µM) significantly decreased the specific activity of 
AChE of pre-differentiated RenCell CX cells by 24% and 20% following 2 and 8 
h exposure, respectively compared to the control value (p = 0.01). Exposure of 
pre-differentiated ReNcell CX cells to CPO was also found to cause a 
considerable dose-dependent inhibition in the AChE activity, with 1, 3, and 10 
µM causing 47%, 58.5%, and 67% reduction after 2 h and 35.5%, 50%, and 
62.5% inhibition after 8 h exposure compared to the untreated controls (p ˂ 
0.0001). As expected, CPO was found to be more potent in inhibiting the AChE 
activity compared to CPF, with an IC50 value (concentration that caused 50% 
inhibition in AChE) of approximately 1-2 µM at 2 and 8 h exposure.  
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Figure 6.8. Effects of CPF and CPO on AChE activity in pre-differentiated ReNcell 
CX cells. Cells were induced to differentiate for 20 h before being incubated without (0) 
or with or 1, 3 and 10 µM concentration of CPF and CPO for 2 and 8 h, after which, 
AChE activity was measured. Enzyme specific activity is expressed as a percentage of 
the absorbance change/mg protein/min value of the corresponding control ± SEM from 
four separate experiments. The CPF effects are presented as blue solid lines with circles; 
the CPO effects are presented as red dashed lines with triangle. Asterisks indicate 
statistically significant changes compared to the corresponding non OP-treated controls 
(*p = 0.01 with CPF) (*p ˂ 0.0001 with CPO). 
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6.2.5 Effects of CPF and CPO on cytoskeletal proteins and 
associated cell signaling pathways in pre-differentiated 
ReNcell CX cells 
 
The neurotoxic effects of CPF and CPO on neurite outgrowth parameters in pre-
differentiated ReNcell CX were further studied by evaluating the molecular 
changes in cytoskeletal proteins and developmentally related cell signalling 
pathways. Cell ELISAs were employed to determine and quantify OP-induced 
changes in the binding of antibodies recognising total βIII-tubulin (clone 2G10), 
GFAP (clone GA5), pNFH (clone Ta51), total NFH (clone N52), total ERK (K-
23) and pERK (clone E-4) after 2 and 8 h exposure, as described in section 
2.2.15. Results with anti-GFAP antibody were omitted from this study as poor 
absorbance values were detected in untreated controls. The very low values were 
considered unreliable to perform accurate qualitative analysis for the effects of 
CPF and CPO on GFAP protein. 
 
As demonstrated in figure 6.9A and C, there were no significant changes in 
antibody binding to βIII-tubulin and total NFH in pre-differentiated ReNcell CX 
cells treated with all three concentrations of CPF or CPO at 2 and 8 h compared 
to the non OP-treated controls. In contrast to the unchanged levels of total NFH 
reactivity, the binding level of pNFH was significantly decreased in OP-treated 
cells compared to the untreated control (Figure 6.9B1 and B2; p ˂ 0.05). After 2 
h treatment, it was demonstrated that 1 µM CPF and CPO had no effect on the 
binding level of pNFH compared to the level in the non OP-treated control. 
However, both compounds at 3 and 10 µM caused a significant decline in NFH 
phosphorylation levels compared to the non OP-treated control at 2 h exposure 
(Figure 6.9B1). The 8 h exposure of pre-differentiated ReNcell CX cells to all 
concentrations of CPO and 3 and 10 µM CPF was also found to cause a 
significant reduction in pNFH levels compared to the level in untreated control 
(Figure 6.9B2). However, no significant change was observed on the levels of 
pNFH compared to non OP-treated control after 8 h exposure with 1 µM CPF 
(Figure 6.9B2). 
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Figure 6.9. Effects of CPF and CPO on cytoskeletal proteins in pre-differentiated 
ReNcell CX cells as determined by cell ELISA.  Cells were induced to differentiate 
for 20 h before being incubated without (0) or with 1, 3 and 10 µM concentrations of 
CPF or CPO for 2 and 8 h. Changes in the binding levels of antibodies recognising 
βIII-tubulin (panel A), pNFH (panel B) and total NFH (panel C) were quantified in 
fixed monolayers using cell ELISA. Data are presented as a percentage of the non OP-
treated control ± SEM from four independent experiments at both time points. Data 
were analysed using one way ANOVA. The CPF effects are presented as blue solid 
lines with circles; the CPO effects are presented as red dashed lines with triangles. 
Asterisks indicate changes that are statistically different from the non OP-treated 
controls (p ˂ 0.05). When SEM bars are not apparent, this means that the error is 
smaller than the symbol size. 
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With regard to the effects of OPs on the ERK1/2 MAP kinase signalling 
transduction pathway, it can be seen that dose-range CPF and CPO had no effect 
on the binding of antibodies recognising total ERK nor pERK in pre-
differentiated ReNcell CX cells treated for 2 or 8 h (Figure 6.10A and B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10. Effects of CPF and CPO on the activation status of ERK1/2 MAP 
kinase in pre-differentiated ReNcell CX cells as determined by cell ELISA.  
Cells were induced to differentiate for 20 h before being incubated without (0) or 
with 1, 3 and 10 µM concentrations of CPF or CPO for 2 and 8 h. Changes in the 
binding levels of antibodies recognising total ERK (K-23) (panel A) and 
phosphorylated ERK (K-4) (panel B) were quantified in controls and OP-treated 
cells using cell ELISA. Data are presented as a percentage of the non OP-treated 
control ± SEM from four independent experiments at both time points. Data were 
analysed using one way ANOVA. The CPF effects are presented as blue solid lines 
with circles; the CPO effects are presented as red dashed lines with triangles.When 
SEM bars are not apparent, this means that the error is smaller than the symbol size. 
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6.3 Discussion 
The utilisation of human neural stem cells for neurotoxicity screening has been 
demonstrated in a number of earlier studies (Breier et al., 2008, Mundy et al., 
2010, Krug et al., 2013, Wilson et al., 2014). The majority of these reports used 
undifferentiated human-derived neural progenitor cells (Breier et al., 2008) or 
differentiated human-derived neuronal cells only (Wilson et al., 2014). In 
contrast, the current study utilised human ReNcell CX cells, which differentiate 
into a co-culture of neuronal and glial cells providing a more relevant model of 
the central nervous system. Simulating the same differentiation conditions and 
OP exposure as the N2a cell model (Chapters 3, 4 and 5), the current work 
provided novel information to the literature in terms of the effects of CPF and 
CPO on pre-formed neurites in ReNcell CX cells.  
 
The current study indicated that ReNcell CX cells were successfully 
differentiated into a mixed population of neuronal and glial cells, which 
exhibited extensive developing neurite network upon 20 h of growth factor 
removal. The characterisation of pre-differentiated ReNcell CX cell morphology 
was confirmed by the expression of βIII-tubulin, pNFH and GFAP neural cell 
markers using high throughput assay. Induction of ReNcell CX cells 
differentiation by mitogen withdrawal is in agreement with previous studies, 
which identified the neuronal and glial cell population using βIII-tubulin and 
GFAP as biomarkers (Donato et al., 2007). 
 
The high throughput data presented in this study showed that both CPF and CPO 
at all concentrations had no effect on the average cell number or cell body area 
of neuronal and glial cells per field following 2 and 8 h of exposure. This result 
was further supported by MTT reduction assay, which clearly showed that the 
dose-range used of both compounds had no effect on pre-differentiated ReNcell 
CX cell viability at both time points. The observed lack of both compounds on 
cell number, cell body area and viability suggested that the range of CPF and 
CPO concentrations employed, as for N2a experiments, was sub-cytotoxic 
towards pre-differentiated ReNcell CX cells and that impacts on neurite 
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outgrowth was a direct response to their neurotoxicity rather than a consequence 
of cytotoxicity.  
 
The concentration-dependent reduction in neurite length in pre-differentiated 
ReNcell CX cells induced by treatment with sub-cytotoxic concentrations of 
both CPF and CPO was seen as early as 2 and 8 h after exposure. The observed 
changes in maximum and average neurite length, and number of neurites via 
analysis of antibody reactivity with βIII-tubulin, pNFH and GFAP suggested that 
both compounds caused a significant and rapid retraction of dendrites, axon-like 
processes and extensions in neuronal and glial cells in this co-culture system. 
This possibility was further confirmed by the observation that there were fewer 
cells with significant outgrowth under the same conditions. Collectively, high-
throughput analysis indicated that exposure to sub-cytotoxic concentrations of 
both compounds has the ability to induce a retraction of neurites in both neuronal 
and glial cells.  
 
The observed reduction in neurite outgrowth in pre-differentiated ReNcell CX 
cells is consistent with those reported earlier in pre-differentiated N2a cells 
(Chapter 5) using similar experimental conditions and data analysis techniques. 
The current finding is also in agreement with the study of Sachana et al. (2001), 
who found a 50% impairment in the outgrowth of axon-like processes in pre-
differentiated N2a cell model following 4 and 8 h exposure to 3 µM CPF 
(Sachana et al., 2001, Sachana et al., 2005). Additionally, Flaskos et al. (2011) 
used similar CPO concentrations to those applied in the current study and found 
that, when added at the point of induction of N2a cell differentiation, CPO 
reduced the outgrowth of axon-like processes in a dose-dependent manner after 
24 h exposure (Flaskos et al., 2011). The demonstrated inhibitory effect of CPF 
and CPO in glial-extensions were also determined in a previous study by 
Sachana et al. (2008), in which a similar concentration range of both compounds 
(1-10 µM) was able to inhibit the extension outgrowth produced from 
differentiating rat C6 glioma cells after 24 h exposure (Sachana et al., 2008). 
However, this is the first time that the effect of CPF and CPO towards neurite 
outgrowth was investigated in a human neural stem cell based model that 
contains a mixed population of neuronal and glial cells.    
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The high throughput data analysis also showed that 2 and 8 h exposure to both 
compounds had no effect on the staining intensity of anti-βIII-tubulin and anti-
GFAP, which is consistent with the lack of effect observed on neuronal and glial 
cell numbers and cell body area. This suggests that there was no change in the 
synthesis of these antigens or in the way they were distributed in their 
corresponding cell types. However, the staining intensity with Ta51, which 
recognises pNFH was reduced in OP-treated cells. Since neuronal cell count and 
cell body area were unaffected, the reduced intensity of Ta51 staining may have 
reflected a decrease in pNFH localisation in neurites, which is consistent with the 
observed reduction in neurite length following CPF and CPO treatment at both 
time points.  
 
Quantification of OP-induced changes in cytoskeletal proteins obtained by cell 
ELISA showed unchanged levels of βIII-tubulin in pre-differentiated ReNcell 
CX cells after CPF and CPO exposure for 2 and 8 h. The lack of an effect on 
βIII-tubulin level again suggested no overall changes in the synthesis of this 
neuron specific tubulin isoform. This finding was consistent with high 
throughput screening data using anti-βIII-tubulin staining which showed no 
change in neuronal cell number, cell body area or staining intensity in cells 
incubated with antibody to this isoform. In pre-differentiated N2a cells, the 
levels of both α and β-tubulin were also found to be unaltered after 2 and 8 h 
treatment with similar concentrations of CPF and CPO (Chapter 4 and 5). 
Evidence of unchanged level of α and β-tubulin subunits in pre-differentiated 
N2a cells and C6 glial cell lines following similar exposure time with CPF and 
CPO was also demonstrated in a number of previous studies (Sachana et al., 
2001, Sachana et al., 2005, Sachana et al., 2008). Moreover, exposure of cells to 
other OPs such as PSP, diazinon and to the pyrethroid cypermethrin under both 
co- and post-differentiation exposure conditions were found to have no effect on 
tubulin levels (Hargreaves et al., 2006, Flaskos et al., 2007). 
 
During neuronal development, α and β-tubulin are the main constituents of MT 
structure, which have an essential role in cell differentiation and neurite 
outgrowth (Easter et al., 1993). Reduction in the levels of tubulin subunits after 
CPF and CPO exposure could indicate a disruption in the MT network due to 
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reduced subunit and/or polymer levels. Thus, the unchanged levels of α and β-
tubulin found in this study together with previous data suggested that CPF and 
CPO exposure were not associated with tubulin synthesis alterations or MT 
network disruption.    
 
With regard to NFs, data from cell ELISA’s suggest that CPF and CPO exposure 
reduced the level of pNFH (Ta51 reactivity) with no overall effect on the level of 
total NFH (N52) after 2 and 8 h exposure. The reduction in the level of Ta51 
presumably reflects a decreased phosphorylation status of NFH protein, which is 
in accordance with the observed retraction of axon-like processes and the lower 
staining intensity detected with Ta51 staining via high throughput analysis. The 
observed decline in pNFH together with the lack of effects on total NFH and 
βIII-tubulin at both time points suggested that decreased phosphorylation state of 
NFH is a specific target for the inhibitory effects of CPF and CPO on neurite 
outgrowth in pre-differentiated ReNcell CX cells. This finding is also consistent 
with previous studies, which showed reduced levels of pNFH in N2a cells 
induced to differentiate for 24 h in the presence of TOCP (Fowler et al., 2001) or 
PSP (Hargreaves et al., 2006). The fact that CPF and CPO decreased the level of 
NFH phosphorylation in a similar manner as other OPs suggests that several OPs 
are able to induce a neurite retraction and this effect is associated with reduced 
levels of pNFH as an early neurotoxic marker.  
 
The observation of decreased levels of NFH phosphorylation in pre-
differentiated ReNcell CX cells treated with CPF and CPO is also in agreement 
with the significant decrease in the reactivity of SMI31 antibody with spinal cord 
NFH phosphorylation in chickens treated with PSP (Jortner et al., 1999).  The 
altered NFH phosphorylation described in vivo for PSP and the subsequent 
observed degeneration of myelinated nerve fibre indicated early effects in the 
clinical lesions of OPIDN (Jortner et al., 1999). The fact that altered NFH 
phosphorylation has also been found in vivo for other OP treatments highlights 
the potential ability of pre-differentiated ReNcell CX cells to predict the in vivo 
delayed toxicity following OP exposure.  
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 As NFs accumulate in the axon, they become extensively phosphorylated on the 
C-terminal domain of NFH. This phosphorylation of NFH has an important role 
in axon maturity and stability (Shaw, 1991, Sihag et al., 2007). Thus, the 
observed sustained reduction in NFH phosphorylation could indicate a change in 
the NF networks or a breakdown in NF subunit stability and a consequent 
decrease in axon stability. In addition, the imbalance in the phosphorylation 
status of NFH could cause disruption in the interactions of NFH side arms with 
other macromolecules in axons (Nixon and Marotta, 1984, Eyer and Leterrier, 
1988, Hisanaga and Hirokawa, 1990). 
 
The lack of CPF and CPO effects on the levels of NFH in pre-differentiated 
ReNcell CX cells is in agreement with the earlier works on pre-differentiated 
N2a cells (Chapter 5), which revealed no effect on the levels of NFH in OP-
treated cells compared to control at both time points under similar post 
differentiation exposure conditions. However, treatment of pre-differentiated 
ReNcell CX cells with CPF and CPO led to a reduction in pNFH at both time 
points which was not the case in pre-differentiated N2a cells where a rise in 
pNFH level was initially observed at 2 h followed by a significant decline at 8 h. 
This could be explained by the fact that N2a cells is a mono-culture cell model 
while ReNcell CX cells is a co-culture of mixed neuronal and glial cell types 
which could influence the outcome. For example, glial cells produce and secrete 
neurotrophins such as glial derived neurotrophic factor (Lin, 1996). In a study by 
the host laboratory, it was found that conditioned medium from glial cells 
protected differentiating N2a cells from the neurite inhibitory effects of OPs 
(Harris et al., 2009a). They also play a role in guiding neurite growth during 
neural development (Deumens et al., 2004). Another reason that could clarify the 
observed diversity is the origin of both cells where N2a cells are derived from 
the mouse C1300 tumour (neuroblastoma) (Klebe and Ruddle, 1969) whereas 
ReNcell CXs were produced from human foetal cortex (Donato et al., 2007). 
Different neuronal cell types from distinct species may respond differently to OP 
exposure due to differences in maturation times and/or activities of signalling 
pathways and receptors during development. It could also be that a small sub-
population of neurons in RenCell CX cultures does actually respond in the same 
manner as N2a cells with respect to hyperphosphorylation of NFH. 
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The observed reductions in NFH phosphorylation in both cell models indicated 
that disruption of signalling pathways could arise following CPF and CPO 
exposure. However, in the current study on ReNcell CX cells, both OPs had no 
detectable effects on the levels of ERK1/2 phosphorylation using the specified 
concentrations and exposure time. This could be due to the fact that ReNcell CX 
cells differentiate into mixed populations of neuronal and glial cells with each 
having a different response with respect to ERK1/2 activation during neural cell 
differentiation. The different rate of neuronal and glial cell maturation could also 
correspond to different level of expression of signalling pathway and receptors 
that activate these pathways. Thus, it may be that this system is not fully in place 
in ReNcell CX cells at this early stage of differentiation. It may also be that the 
changes in ERK1/2 activation are occurring in this co-culture model but in a very 
small population of neurons, and thus, the increased ERK1/2 using cell ELISA 
could not be observed. Furthermore, regulatory phosphatases could have a key 
role in the observed reduction in NFH phosphorylation. Therefore, an extension 
of this work could be conducted to measure phosphatase activity and, if altered, 
identify specific phosphatases involved in the regulation of NFH 
phosphorylation following CPF and CPO exposure. Additionally, future work 
could investigate whether the OP-associated reduction in NFH phosphorylation 
is a result of the influence of other protein kinases such as cyclin dependent 
kinase 5 (Cdk5) and p38 MAP kinase.  
 
Exposure of pre-differentiated ReNcell CX cells to CPF and CPO induced 
concentration-dependent decrease in the activity of AChE. Despite being classed 
as a weak inhibitor of AChE, the highest concentration of CPF resulted in a 
significant reduction in AChE activity. This suggests that CPF may partially bio-
activated to CPO by some metabolic activity of pre-differentiated ReNcell CX 
cells. However, the observed inhibition in AChE following CPF treatment would 
not reflect acute toxicity in vivo, since AChE inhibition did not reach the levels 
(70% AChE inhibition) that have been shown to induce acute cholinergic 
syndrome (Clegg and van Gemert, 1999b). In this study, it was also apparent that 
the extent of inhibition of AChE following the exposure of pre-differentiated 
ReNcell CX cells to CPO was lower than the sustained reductions of AChE 
observed in pre-differentiated N2a cells (Chapter 3). However, exposure of pre-
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differentiated ReNcell CX cells to CPO at higher concentration caused 60-70% 
AChE inhibition, which is bordering on acute toxicity. The data also showed that 
there is a sign of less inhibition at 8 h than at 2 h, which may suggest acute 
toxicity at early time and a recovery of AChE at the later time. This finding 
indicates that co-culture of neuronal and glial cells could be more resistant to 
acute toxicity than neuronal cells alone. This could be due to the possibility that 
CPO is detoxified by the populations of glial cells or undifferentiated stem cells 
in ReNcell CX model. The ability of glial cells to hydrolyse CPO was previously 
demonstrated in the study of Sachana et al. (2008), who found lack of significant 
AChE inhibition in rat C6 glioma cells following 4 h exposure to CPO at similar 
concentrations to those employed in the current study (Sachana et al., 2008). It is 
well known that xenobiotic metabolism is mainly located in the liver. However, 
there is evidence suggesting the presence of some CYP450 isoforms, which are 
involved in the metabolism of oxons in different brain region in humans (Dutheil 
et al., 2008). For example, CYP2B6 was present in neuronal and astrocyte cells 
of the cerebral cortex as identified by Western blot and immunoblot techniques 
(Miksys et al., 2003, Miksys and Tyndale, 2004). In addition, CYP3A4 and 
CYP1A2 mRNA has been detected in both neuronal and glial cell types in the 
cortical tissue of the brain using real time polymerase chain reaction (RT-PCR) 
(Farin and Omiecinski, 1993). Human CYP2D6 associated with neurological 
disorders such as Parkinson`s disease was also mainly present in cortical 
neurons, glial cells of the cortex, and other brain regions (Gilham et al., 1997, 
Riedl et al., 1998). The presence of such CYP450s in the glial cells demonstrated 
in the previous studies might explain the discrepancies found between pre-
differentiated N2a and ReNcells CX cells in their potential ability for CPO 
detoxification. Future work on the identification of these CYP450 isoforms in 
human pre-differentiated ReNcell CX cells would be worthwhile. 
 
The current observation that CPO induced significant reduction in the enzymatic 
activity of AChE in pre-differentiated ReNcell CX cells at both time points has 
been demonstrated in a number of previous studies. For example, sustained 
inhibition of AChE was detected in N2a cells induced to differentiate for 4 and 
24 h in the presence of CPO (Flaskos et al., 2011). More than 70% AChE 
inhibition was also noted in aggregating culture of rat brain cells (Monnet-
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Tschudi et al., 2000) and PC12 cells (Das and Barone, 1999) treated with CPO. 
The finding of this study together with the previous data indicate that the 
significant reduction in the specific activity of AChE observed following CPO 
exposure could possibly contribute to the observed neurite retraction and the 
underlying molecular effects on cytoskeletal proteins. However, it is unlikely 
that inhibition of AChE alone could be related to the observed changes in the 
outgrowth of neurites in pre-differentiated ReNcell CX cells, as other studies 
suggest that lower concentration of CPO that had no effect on AChE can also 
induce marked impairment in the development of neurites. Indeed, the fall in 
AChE activity could simply accompany rather than cause the retraction of 
neurites. In this respect, CPO was found to cause significant inhibition in neurite 
outgrowth in cultures of embryonic sympathetic (Howard et al., 2005) and 
sensory neurons (Yang et al., 2008) without affecting the enzymatic activity of 
AChE. The notion that the neurodevelopmental effects of CPO is not directly 
caused by AChE inhibition could be explained by the fact that CPO can directly 
interfere with the morphogenic activity of AChE, which is known to be 
displayed during the normal process of neurodevelopment, rather than enzymatic 
activity of AChE protein (Howard et al., 2005, Yang et al., 2008). For example, 
many types of neurons have been found to transiently express AChE along axons 
and in growth cones during the period of axonal outgrowth (Robertson, 1987, 
Bigbee et al., 1999). This expression of AChE has been linked to its 
morphogenic role during neural development (Yang et al., 2008). 
 
Thus, AChE inhibition may not be the main cause for the CPO-induced 
morphological and biochemical effects in pre-differentiated ReNcell CX. 
However, the fact that CPO caused a more severe effect on several parameters 
suggests that AChE inhibition has at least some influence in the severity of its 
effect. 
 
In conclusion, this part of the current study investigated the effects of CPF and 
CPO in a differentiating human neural ReNcell CX stem cell model at an early 
stage of neuronal differentiation. At sub-cytotoxic concentrations, CPF and CPO 
were found to cause retraction of neurites in both neuronal and glial cell 
population, and in neuronal cells these alterations were associated with reduced 
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level of NFH phosphorylation without affecting the levels of total NFH, βIII-
tubulin or MAP kinase ERK1/2. The obtained data also suggested that AChE 
inhibition may not be directly involved in the process by which CPF induces 
developmental toxicity in pre-differentiated ReNcell CX cells. However, slightly 
stronger CPO-induced changes were related to concentrations that inhibit the 
acute toxicity target by 60-70% of control levels.                              
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7 General discussion 
7.1 Summary of findings 
In this thesis, I aimed to evaluate the ability of CPF and CPO to induce neurite 
retraction and cytoskeletal disruption in pre-differentiated mouse N2a cells and 
the human neural progenitor ReNcell CX stem cell line. Initially, the ability of 
both compounds to interfere with the outgrowth of pre-formed neurites produced 
by differentiating N2a cells following 2, 4 and 8 h exposure was evaluated using 
single concentration (3 µM). MTT reduction assays showed that the specified 
concentration of CPF and CPO was non-cytotoxic towards pre-differentiated 
N2a cells. Morphometric analysis of fixed monolayers of OP-treated cells 
labelled with CFSE showed reduced numbers of axon-like processes compared 
to the untreated control. Additionally, retraction of neurites was observed within 
2 h of exposure by live cell imaging.  The enzymatic activity of AChE assay data 
suggested that the morphological effects on axon-like neurites were not 
dependent on the inhibition of AChE in case of CPF. However, greater CPO-
induced effects were seen at doses that caused severe inhibition of AChE and, 
thus, may influence the severity of its effects compared to CPF. 
 
The next part of this thesis focused on relating the observed morphological 
alterations on neurite outgrowth to the levels of expression and activities of 
cytoskeletal and associated regulatory proteins in pre-differentiated N2a cells. 
Using indirect immunofluorescence, neurofilament disruption was observed in 
OP-treated cells stained with anti-pNFH monoclonal antibody SMI34, while the 
microtubule network was apparently unaffected, suggesting that neurofilaments 
were specifically targeted by these agents. The lack of effect on microtubules 
was further confirmed by western blotting analysis with anti-tubulin antibodies, 
which showed no changes in reactivity. The transiently increased levels of 
reactivity of Ta51 after 2 h exposure and reduced levels of reactivity of the same 
antibody following 8 h treatment with both compounds, in the absence of altered 
reactivity with antibodies to total NFH, suggested that there was a transient 
hyperphosphorylation of NFH leading to subsequent hypophoshporylation of 
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NFH in OP-treated cells. The fact that the observed increase in anti-pNFH 
reactivity at 2 h exposure was associated with increased activation of ERK1/2, 
suggest that this MAPK was disrupted by OP exposure. The observation of 
increased levels of phosphatase activity following 8 h OP treatment, could 
account for the reduction in NFH phosphorylation at the later time point. These 
findings suggest that OP-induced neurite retraction in N2a cells is associated 
with early transient increase in NFH phosphorylation and ERK1/2 activation 
followed by protein phosphatase mediated dephosphorylation. Moreover, the 
immunoblot analysis using monoclonal antibody GAP7B10 that recognises 
GAP-43 suggested that CPF and CPO induced a transient reduction in GAP-43 
after 4 h exposure. The transiently reduced expression level of GAP-43 could 
account for the collapse in axon outgrowth observed by live cell imaging 
following exposure of pre-differentiated N2a cells to both compounds. It will be 
interesting in future work to determine whether these alterations in cell signalling 
and reduced levels of GAP-43 are directly related. The precise nature of the 
phosphatase activities involved in NFH dephosphorylation would also be worth 
investigating. 
 
The development of high throughput platforms has enabled researchers to 
evaluate and quantify the neurotoxin exposure effects in a variety of neural cell 
lines. In this study, a high throughput assay was developed to investigate the 
effects of several CPF and CPO concentrations on multiple parameters of neurite 
outgrowth in pre-differentiated N2a cells after 2 and 8 h exposure. Utilising the 
fully automated approach, measurements of neurite outgrowth were provided 
based on staining with three different cytoskeleton-specific antibodies used in 
earlier work (B512, Ta51 and SMI34). The high throughput data indicated that 
CPF and CPO at sub-cytotoxic doses (1-10 µM) reduced the number of 
outgrowth, neurite length/cell, number of processes and branches/cell in a 
concentration-dependent manner, without affecting the cell count or cell body 
area in pre-differentiated N2a cells at both time points. The data obtained using 
this technique provide further confirmation for the effects observed for both OPs 
on neurite outgrowth monitored by manual approaches (e.g. CFSE staining) in 
previous chapters. Additionally, a cell ELISA approach was conducted to 
determine the dose-response changes of both compounds on the binding levels of 
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cytoskeletal proteins and the relevant ERK1/2 MAP kinase signalling pathway. 
The data showed that treatment of pre-differentiated N2a cells with 3 and 10 µM 
CPF and CPO resulted in significant increases in NFH phosphorylation at 2 h 
and a subsequent decrease after 8 h with lack of effects on total NFH and α-
tubulin levels at both time points. This observed alteration in NFH 
phosphorylation at early time point was found to be associated with an increase 
level of anti-pERK antibody. However, the levels anti-total ERK were 
unaffected.  
Using the same experimental protocol used on N2a cells, the last part of this 
thesis evaluated the effects of both CPF and CPO in ReNcell CX cells, which is 
more relevant to the complexities of the developing human nervous system. The 
neuronal and glial subpopulations of ReNcell CX cells were characterised using 
the neuronal-specific marker (βIII-tubulin and pNFH) and the astrocyte-specific 
marker GFAP. Data generated using high throughput assay showed that CPF at 3 
and 10 µM and CPO at 1, 3 and 10 µM concentrations were able to reduce the 
outgrowth of neurites in both cell types following 2 and 8 h exposure. However, 
the doses used of both OPs had no effects on cell number or cell body area. 
Moreover, viability of ReNcell CX cells was found not to be affected following 
treatment with all concentrations of CPF and CPO, as indicated by MTT 
reduction assay. The molecular changes underlying the neurite inhibitory effects 
of CPF and CPO in differentiating human neuronal and glial cells were further 
investigated using cell ELISA. The results obtained suggested a selective 
inhibition in the levels of NFH phosphorylation with no detectable effects on 
total NFH, βIII-tubulin and ERK1/2 MAPK transduction pathway after 2 and 8 h 
exposure to both compounds. Unfortunately, it was unable to assess the effect of 
both OPs on the binding level of GFAP, as the anti-GFAP antibody reactivity 
was too weak. This very low expression of GFAP may reflect the early 
differentiation stage of astro-glial cells at this time point. 
In this study, it is also important to mention that the neurotoxic actions of CPF 
towards pre-differentiated ReNcell CX cells was not related to significant levels 
of AChE inhibition. However, the fact that, as for N2a cells, CPO-induced 
morphological and biochemical alterations were greater than those of CPF 
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suggests that the level of AChE inhibition may affect the severity of the 
morphological effects.  
 
Figure 7.1 illustrates the common neurotoxic impact of CPF and CPO on pre-
differentiated N2a and ReNcell CX-derived neuronal cells. At sub-cytotoxic 
concentrations, both compounds were able to induce a retraction of neurite 
outgrowth in both cell models without affecting the microtubule network. The 
neurite inhibitory effect was associated with decreased level of NFH 
phosphorylation, which mediated by increased phosphatase activity in pre-
differentiated N2a cells. However, further work need to be carried to know if 
increased phosphatase activity could account for the NFH hypophosphorylation 
observed in pre-differentiated ReNcell CX cells following CPF and CPO 
exposure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1. Schematic diagram of common CPF and CPO effects in pre-
differentiated N2a cells and and ReNcell CX-derived neuronal cells. 
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The findings obtained in this study may also reflect the potential impacts of both 
CPF and CPO on memory, since information acquisition and memory storage in 
the mammalian nervous system are mainly dependent on changes in the synapses 
and their protein contents. For example, increased levels of GAP43 are important 
for axonal outgrowth and neuronal connectivity by facilitating the formation of 
new synapses. GAP43 also plays an essential role in synaptic transmission and 
plasticity (Holtmaat et al., 1995). Previously, it has been demonstrated that 
decreased levels of GAP43 were associated with memory impairment in animals 
(Rekart et al., 2005). Thus, the protein changes observed in the current work 
could have induced functional and structural alterations in synaptic plasticity, 
which represents a cellular mechanism of learning and memory processes 
(Mansuy and Shenolikar, 2006). Therefore, the cytoskeletal disruption observed 
in both N2a cells and human neural progenitor stem cells following CPF and 
CPO exposure in this study could reflect a potential to induce memory disorders 
and cognitive deficits associated with aging, dementias or neurodegenerative 
disease. 
 
 
7.2 Correlations between in vitro concentrations and in vivo 
exposure 
 
It is difficult to estimate the correlation between in vivo exposure and the 
experimental concentrations used in the current work. However, CPF-induced 
neurite retraction and cytoskeletal disruption were observed at concentrations 
similar to those detected in vivo in the developing humans. For instance, using 
meconium analysis (used to estimate the foetal exposure to environmental 
toxicants), about 22.8 µM of CPF has been detected in samples taken from new-
born children (Ostrea et al., 2002). It is important to mention that this cohort 
study was based on 200 pregnant women who were continuously exposed to 
CPF via inhalation and dermal absorption. Exposure to CPF via these routes 
reduced the chance of bio-activating CPF to CPO in the mother`s liver. 
However, it allowed high concentrations of CPF to reach the foetus without 
causing maternal toxicity symptoms (Ostrea et al., 2002). In a further study, 
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Estevan et al. (2013) suggested that CPF at non-cytotoxic concentrations of 10 
and 20 µM can cause developmental neurotoxicity in vivo if the exposure occurs 
via skin, which allowed low transformation of CPF to CPO (Estevan et al., 
2013). Therefore, the applied CPF concentrations in this study have clinical 
relevance to human developmental neurotoxicity only if it occurs under similar 
exposure scenarios to those mentioned above.    
 
With regard to CPO, a previous study indicated that CPO-induced effects on 
neurite outgrowth and cytoskeletal proteins at similar concentrations (1-10 µM) 
to those used in this study are clinically relevant to human developmental 
neurotoxicity (Flaskos et al., 2011). The research group suggested that low 
micromolar concentrations of CPO were attainable in developing organisms 
since micromolar levels of CPF (22.8 µM) were detectable in the above-
mentioned meconium samples of new-born children (Ostrea et al., 2002). It is 
well established that CPO has high water solubility compared to CPF, which 
might reduce its ability to enter the foetus through the lipid membrane of the 
placenta (Sogorb and Vilanova, 2010). However, the detection of significant 
cholinesterase inhibition in the mammalian foetus following in vivo exposure of 
pregnant animals to CPF and other OPs (Gupta, 1995) provide further support to 
the suggestion of Flaskos et al. (2011) findings that foetal exposure to CPO can 
occur .  
 
Moreover, the foetus is likely to be exposed mainly to the parent compound but 
possibly also to the oxon metabolite in the maternal tissues. The main enzyme 
responsible for oxon formation in humans (CYP2B6) is present at relatively low 
levels in human placenta, suggesting that the placenta does not make a major 
contribution to oxon formation (Pelkonen et al., 2006, Foxenberg et al., 2007, 
Croom et al., 2010). However, although CYP2B6 is expressed at low levels in 
the human foetus compared to later stages of development (Croom et al., 2009, 
Croom et al., 2010), the level of PON 1, which is responsible for hydrolysing 
and detoxifying the oxon forms of certain OPs such as CPO, is also relatively 
low at this stage (Costa et al., 2005). This could allow some oxon formation 
and/or accumulation in foetal tissue. Additionally, reduced levels of serum PON 
1 due to genetic polymorphisms in the PON1 gene is associated with increased 
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susceptibility to the toxic effect of the oxon metabolite (Costa et al., 2005). 
Therefore, the presence of CPO at low micromolar concentrations in developing 
animals is clinically relevant to developmental neurotoxicity.  
 
There is another possible scenario regarding the potential clinical relevance of 
CPO concentrations employed in this study. This scenario can be related to 
OPIDN since the pre-differentiated cell system could also simulate what might 
occur following OP toxicity in adults. The observed dying back of axons in pre-
differentiated N2a and ReNcell CX cells could reflect events following OP acute 
toxicity in adults. It is highly likely that such a concentration of CPO (1-10 µM), 
which caused severe inhibition in AChE levels to more than 70% would be lethal 
to the foetus (Solomon and Moodley, 2007, Heilmair et al., 2008). However, 
there are numerous case studies of patients who have survived such levels of 
cholinesterase inhibition with the help of pharmacological intervention, such as 
adrenaline and/or oximes administration, which develop delayed neuropathy. For 
example, 19 year old male who ingested a large dose of CPF, was hospitalised 
suffering from cholinergic crisis. After he was treated with atropine and 
pralidoxime, he developed respiratory paralysis and required mechanical 
ventilation for 16 days. Weeks later, he had progressive signs of OPIDN, such as 
deficits in the lower limbs and muscular atrophy (Nand et al., 2007). Thus, 
survivors of acute cholinergic crisis can be affected by a delayed neuropathy 
involving dying back of axons in peripheral/central neurons (Clegg and van 
Gemert, 1999a, Nand et al., 2007, Thivakaran et al., 2012). Indeed, it has been 
shown that CPF administered at acute levels in animal models can lead to 
OPIDN (Gupta, 2006). Therefore the morphological changes in neurite 
outgrowth following CPO exposure may have potential clinical relevance in 
terms of delayed neuropathy. 
 
It is important to mention that previous studies by other researchers reported 
significant AChE inhibition following exposure to CPO at nanomolar levels. For 
instance, CPO at 2 and 4 nM was reported to cause 50% AChE inhibition (IC50) 
after 30 min exposure in chicken brain homogenate and SH-SY5Y human 
neuroblastoma cells, respectively (Sogorb et al., 2010). In vivo, Eyer et al. (2009) 
demonstrated that the ratio of CPO/CPF in blood samples of self-intoxicated 
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patients was in the range of 0.004-0.025. In this context, cases with 0.3-5 µM 
CPF were causing 7-200 nM concentration of CPO with about 100% AChE 
inhibition and very severe toxicity (Eyer et al., 2009). Therefore, if we take the 
CPO/CPF ratio into consideration, the CPO doses used in the current study may 
not be easily compatible with life or physiologically relevant. However, it is not 
known exactly how much of the CPO applied in the current study actually 
entered the cells, nor the rate at which it was destabilised or degraded in vitro. 
 
 
7.3 Limitations and future work 
This study evaluated the effects of pure CPF and CPO compounds (97.6% 
purity) at similar concentration ranges on neurite outgrowth, cytoskeletal and 
associated regulatory proteins in two pre-differentiated cellular models. 
However, exposure of the foetus to levels of CPO causing severe AChE 
inhibition would be lethal. Therefore, it would be of interest for future work to 
investigate the ability of CPO at lower concentrations to cause dying back of 
axon-like process without affecting AChE activity. Additionally, the effects of 
combined exposure to a mixture of a similar concentration of CPF and a much 
smaller amount of CPO, together with longer exposure times on neurite 
outgrowth are merit investigation. This could be carried out using a ratio of 1:20 
CPO:CPF because it has been estimated that about 5% of CPF is converting to 
CPO in humans (Eyer et al., 2009).  
 
In the current study, cells were induced to differentiate for 20 h to reflect the 
early stages of neurite outgrowth in neural development or nerve regeneration. 
Longer differentiation times could be applied to obtain a more representative 
model of OPIDN. Extending the exposure time or using repeat exposures could 
also have an impact on the extent of neurotoxicity both in vitro and in vivo.  
 
Cytoskeletal related molecular studies were conducted using Western blotting 
and cell ELISA approaches. For the most part, data generated from both assays 
were comparable. However, with the cell ELISA approach, it was not possible to 
determine the effects of CPF and CPO on the binding level of GFAP in pre-
differentiated ReNcell CX cells, due to poor reactivity of GFAP antibody with 
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fixed cell monolayers. Thus, a more sensitive method is required to repeat to 
quantify the protein, such as Western blotting. One approach could be to use 
other anti-GFAP antibodies to determine whether they are more suited to the 
ELISA approach. Alternatively, the same primary antibody used in the current 
work could be detected by biotin-labelled secondary antibodies followed by 
HRP-Extravidin to amplify the signal further. 
 
Cell signalling studies indicated that ERK1/2 MAP kinase activation was 
increased in pre-differentiated N2a cells treated with both CPF and CPO for 2 h. 
As NFH is a known substrate for ERK1/2 (Veeranna et al., 1998), the activation 
status of this MAP kinase could account for the increased levels of NFH 
phosphorylation. The detrimental effect on this signaling pathway could be 
further expanded by using ERK 1/2 inhibitors prior to OP exposure. Additional 
work could also examine the effects of CPF and CPO on upstream regulators of 
ERK1/2 by using specific MEK1/2 antibodies. Moreover, the exact mechanism 
underlying the impact of CPF and CPO on pre-differentiated ReNcell CX cells 
would also be of interest. 
 
In pre-differentiated N2a cells, the increased phosphatase activity could account 
for the observed reduction in NFH phosphorylation at 8 h. However, this 
observation was seen using single concentration (3 µM) of CPF and CPO. 
Therefore, it would be of value to re-evaluate the effect of both OPs on 
phosphatase activity using the dose range of each toxin. Additionally, an 
extension of this work could include the assessment of phosphatase activity in 
ReNcell CX cells following CPF and CPO exposure. Furthermore, future work 
will also aim to identify specific phosphatases associated with NFH 
phosphorylation in OP treated cells. For example, protein phosphatase 2A was 
previously found to reduce NFH phosphorylation following hyper-
phosphorylation by cyclin-dependent kinase-5 (cdk5) in animal models 
(Veeranna et al., 1995). In addition, protein aggregation studies in Alzheimer’s 
disease patients highlighted the association of increased NFH phosphorylation 
with a decrease in protein phosphatases 2A activity (Vogelsberg-Ragaglia et al., 
2001). 
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High throughput analysis of ReNcell CX cells could be extended to study the 
effects of OP exposure on individual neuronal and glial cell types in more detail. 
This would involve the use of additional image analysis software packages to 
determine the effects of exposure on the proportions of cell expressing specific 
biomarkers (e.g. myelin basic proteins for oligodendrocytes, choline acetyl 
transferase for cholinergic neurons, tyrosine hydroxylase for dopaminergic 
neurons, etc) above the levels found in non-differentiated neural stem cells, 
which could be further identified by counter-staining monolayers with antibodies 
to nestin.    
                                                       
 
7.4 Conclusion 
In conclusion, the present study used several morphological and biochemical 
approaches to study the effects of sub-cytotoxic concentration of CPF and CPO 
on neurite outgrowth and cytoskeletal proteins in differentiating neural cellular 
models. Indeed the findings show that pre-differentiated N2a cells represent a 
useful cellular system for neurotoxicity screening. However, the fact that N2a 
cells provide a mono-culture cell model, and are derived from a rodent tumour, 
they may not give a true reflection of the complexity of the human nervous 
system and its response to OP exposure. The current study also highlights that 
evaluating the toxicity on human neural progenitor ReNcell CX stem cells 
reduced the level of uncertainty associated with cells derived from animal 
models. A further advantage of using such human-derived neural progenitor stem 
cells is that they differentiate into a co-culture incorporating both neuronal and 
glial cell types. As such, with further development, it should be more effective at 
predicting the toxin-related changes in vivo.  
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Figure 8.1. Effects of CPF and CPO on cell number and cell body area in pre-differentiated N2a cells as assessed by high throughput 
assays.  Cell were then fixed and stained with SMI34 and Ta51, after which data were acquired using the ImageXpress Micro system and the 
average cell number/field and the average cell body area/field were measured using MetaXpress imaging and analysis software. Data show dose-
related effects of both CPF and CPO on cell number (A) and cell body area (µm) (B) with SMI34 and Ta51 staining at 2 h and 8 h. High throughput 
data are represented as mean values ± SEM from four independent experiments. Data were analysed using two-way ANOVA. The CPF effects are 
presented as blue solid lines with circles; the CPO effects are presented as red dashed lines with triangles. Asterisks indicate changes that are 
statistically different from the non OP-treated controls (*p ˂ 0.05). When SEM bars are not apparent, this means that error is smaller than the 
symbol size.   
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Figure 8.2. Effects of CPF and CPO on neurite number and percentage of cells with significant outgrowth in pre-differentiated N2a 
cells as assessed by high throughput analysis. Cells were stained with SMI34 and Ta51, after which data were acquired using ImageXpress 
Micro system and measured using MetaXpress imaging and analysis software. Data show dose-related effects of both CPF and CPO on the 
average neurite number/field (A) and the percentage of cells with significant outgrowth (B) at 2 and 8 h with SMI34 and Ta51 staining. Data are 
presented as mean values ± SEM from four independent experiments for both time points. Data were analysed using two-way ANOVA. The 
CPF effects are presented as blue solid lines with circles; the CPO effects are presented as red dashed lines with triangles. Asterisks indicate 
changes that are statistically different from the non OP-treated controls (p ˂ 0.05). When SEM bars are not apparent, this means that error is 
smaller than the symbol size. 
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Figure 8.3. Effects of CPF and CPO on maximum and average neurite length/cell in pre-differentiated N2a cells as assessed by high 
throughput analysis. Cells were stained with SMI34 and Ta51, after which data were acquired using ImageXpress Micro system and measured 
using MetaXpress imaging and analysis software. Data show dose-related effects of both CPF and CPO on the maximum neurite length/cell (A) 
and the average neurite length/cell (B) at 2 and 8 h with SMI34 and Ta51 staining. Data are presented as mean values ± SEM from four 
independent experiments for both time points. Data were analysed using two-way ANOVA. The CPF effects are presented as blue solid lines with 
circles; the CPO effects are presented as red dashed lines with triangles. Asterisks indicate changes that are statistically different from the non 
OP-treated controls (*p ˂ 0.05). When SEM bars are not apparent, this means that error is smaller than the symbol size. 
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Figure 8.4. Effects of CPF and CPO on the mean number of processes and branches/cell in pre-differentiated N2a cells as assessed by 
high throughput analysis.  Cells were stained with SMI34 and Ta51, after which data were acquired using ImageXpress Micro system and 
measured using MetaXpress imaging and analysis software. Data show dose-related effects of both CPF and CPO on the mean processes/cell (A) 
and the mean branches/cell (B) at 2 and 8 h with SMI342 and Ta51 staining. Data are presented as mean values ± SEM from four independent 
experiments for both time points. Data were analysed using two-way ANOVA. The CPF effects are presented as blue solid lines with circles; the 
CPO effects are presented as red dashed lines with triangles. Asterisks indicate changes that are statistically different from the non OP-treated 
controls (*p ˂ 0.05). When SEM bars are not apparent, this means that error is smaller than the symbol size. 
 
